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SUMMARY 
Idiopathic pulmonary fibrosis (IPF) is an irreversible and progressive disease of the lungs, which 
is characterized by aberrant tissue remodeling and massive deposition of extracellular matrix 
proteins. This process is mainly conducted by myofibroblasts, an activated fibroblast phenotype. 
During the pathogenesis of IPF, the fine alveolar structure is destroyed and gas exchange 
declines, finally resulting in organ failure. So far, pharmacological treatment options are very 
limited and lung transplantation still remains the only curative therapy. 
Pathologic tissue remodeling in IPF is closely connected to altered cell and protein 
homeostasis. The ubiquitin-proteasome system is critical for degradation of polyubiquitinated 
proteins in a spatially and timely controlled manner, thereby regulating protein levels. The 
proteasome is a multicatalytic enzyme complex consisting of a barrel shaped 20S catalytic core 
particle (CP) and one or two 19S regulatory particles (RP), thus forming active 26S/30S 
proteasomes. Dysregulation of the proteasome has been reported for several chronic diseases 
of the heart, brain, and also lung. Furthermore, inhibition of the proteasome has been shown to 
provide antifibrotic effects in different organs, including the lung.  
As nothing is known about proteasome function in the pathogenesis of IPF, the first aim of the 
present study was to analyze proteasomal regulation during tissue remodeling and 
myofibroblast differentiation. 
For that, lung fibroblasts were treated with transforming growth factor-β (TGF-β) and 
proteasome activity as well as composition was examined. For in vivo testing, the bleomycin 
mouse model of lung fibrosis was used and human lung tissue of IPF patients was analyzed. It 
was found that induction of myofibroblast differentiation by TGF-β mediated assembly of 19S 
RPs with 20S CPs, thereby forming 26S/30S complexes, which was critically dependent on the 
regulatory particle non-ATPase 6 subunit (Rpn6). In addition, silencing of Rpn6 in primary 
human lung fibroblasts counteracted TGF-β-induced myofibroblast differentiation. During 
bleomycin-induced fibrotic remodeling of mouse lungs, increased formation of 26S/30S 
proteasomes was accompanied by augmented expression of Rpn6 in fibrotic lungs. Here, Rpn6 
was highly expressed in hyperplastic alveolar epithelial cells and Clara cells. Overexpression of 
Rpn6 was also observed in myofibroblasts and hyperplastic bronchiolar basal cells of fibrotic 
lung tissue of IPF patients and accompanied by enhanced polyubiquitination of proteins.  
As therapeutic application of proteasome inhibitors in pulmonary fibrosis showed controversial 
results including beneficial antifibrotic effects but also toxicity, the second aim of this study was 
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to test whether site-specific inhibition of the proteasome, using the novel second generation 
inhibitor oprozomib, provides antifibrotic effects in the absence of systemic side effects after 
local pulmonary application. 
Oprozomib was compared to the FDA-approved proteasome inhibitor bortezomib and tested on 
the human alveolar epithelial cancer cell line A549 and on primary mouse alveolar epithelial 
type II cells regarding its cytotoxic effects. Oprozomib was less toxic than bortezomib and 
provided high selectivity for the chymotrypsin-like active site of the proteasome. In primary 
mouse lung fibroblasts, oprozomib showed significant antifibrotic effects like reduction of 
collagen I and α-smooth muscle actin expression at non-toxic doses. When applied locally into 
the lungs of healthy mice via instillation, oprozomib was well tolerated and effectively reduced 
pulmonary proteasome activity. In bleomycin-challenged mice, however, locally applied 
oprozomib resulted in accelerated weight loss and increased mortality. Furthermore, oprozomib 
failed to reduce fibrosis in these mice, but rather augmented fibrotic lung remodeling in 
bleomycin-challenged animals. 
To conclude, this study identified a novel mechanism for fibrotic remodeling of the lungs 
involving 26S/30S proteasome activation via Rpn6 upon TGF-β-mediated myofibroblast 
differentiation. Increased levels of Rpn6 and polyubiquitinated proteins in IPF lungs further 
suggest an important contribution of the ubiquitin-proteasome system to the pathogenesis of 
this disease. Inhibition of the proteasome with the novel site-specific proteasome inhibitor 
oprozomib provided low toxicity and antifibrotic effects in alveolar epithelial cells and pulmonary 
fibroblasts. These results could not be confirmed in pulmonary fibrosis of bleomycin-treated 
mice, as oprozomib treatment showed high toxicity in fibrotic animals. 
In light of these data, current proteasome inhibitors, which block the catalytic core, might be too 
toxic as therapeutic agents for the treatment of fibrotic lung diseases. However, interference 
with the formation of 26S/30S proteasomes, as shown by Rpn6 knockdown, might provide a 
novel concept for therapeutic regulation of proteasome activity in lung fibrosis. 
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1 INTRODUCTION 
1.1 Idiopathic Pulmonary Fibrosis 
“IPF is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of 
unknown cause, occurring primarily in older adults, limited to the lungs, and associated with the 
histopathologic and/or radiologic pattern of UIP.” 
Definition by the Official ATS/ERS/JRS/ALAT Statement on Idiopathic Pulmonary Fibrosis 
(Raghu et al., 2011). 
1.1.1 Clinical phenotypes, prognosis, and risk factors of IPF 
Idiopathic pulmonary fibrosis (IPF), a form of usual interstitial pneumonia (UIP), is a devastating, 
irreversible, and chronic pulmonary disease, which is characterized by a progressive destruction 
of the fine alveolar architecture and loss of lung function. So far, treatment options in IPF are 
very limited resulting in a poor prognosis for affected patients. As IPF mainly occurs in 
middle-aged to elderly adults (50 years and onwards), it is regarded as an age-related disease 
(Raghu et al., 2011). Even though IPF is not a very common disease, its incidence is rising and 
is currently estimated to be between 4.6 and 16.3 per 100,000 people, and seems to be more 
frequent in men than women (King et al., 2011). The aggressive nature of IPF is also reflected 
by a poor median survival of only up to 2-3 years after initial diagnosis (Raghu et al., 2011). A 
long asymptomatic period in the beginning of the disease often leads to late diagnosis, as most 
IPF patients consult a medical doctor for the first time at an already advanced stage of the 
disease (Figure 1.1). At the onset of symptoms, three major progression types can be 
distinguished. Most patients experience a slow but progressive clinical and functional decline. 
This can be accompanied by acute exacerbations, which, in IPF, often occur in the absence of 
specific reasons such as infection, heart failure, or pulmonary embolism. Acute exacerbations 
often indicate the beginning of the final phase of the disease. Few patients face a fast 
progressive course with a short time of survival. These patients are predominantly male 
smokers, and activation of cigarette smoke-induced inflammatory pathways has been reported. 
In addition, heavy smokers are also likely to show a combination of pulmonary fibrosis and 
emphysema, leading to a faster progression of the disease than in patients with IPF alone (King 
et al., 2011). 
Even though IPF is defined as a disease of unknown etiology, various potential risk factors have 
been reported. Cigarette smoking (Baumgartner et al., 1997) and environmental exposure to 
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dust, especially from metal or wood, have been strongly associated with IPF. But also chronic 
viral infection or gastroesophageal reflux linked to a presumed microaspiration of gastric acid 
have been assumed to contribute to the pathogenesis of the disease (Raghu et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Several studies provide evidence for genetic predisposition of pulmonary fibrosis and account 
for about 5% of IPF cases. Most common disease-linked mutations in familial forms of IPF have 
been identified in the surfactant protein C gene (SFTPC) (Thomas et al., 2002), in the promotor 
region of the mucin 5B gene (MUC5B) (Seibold et al., 2011), and in genes encoding telomerase 
(TERT and TERC) (Armanios et al., 2007). 
Figure 1.1. Clinical phenotypes of IPF 
A long asymptotic period is followed by an acute onset of symptoms, which usually is also the time of 
diagnosis. Three main phenotypes are distinguished: A slow progressive phenotype, experienced by 10% of 
patients, exhibits a slow, clinical and functional decrease, which can be worsened by episodes of acute 
exacerbations. In contrast, patients with a rapid progressive course have a very short duration of illness. 
Heavy smokers might also develop an intermediate phenotype which is characterized by additional presence 
of emphysema. (Taken from King et al., 2011) 
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1.1.2 Pathological characteristics of IPF 
A final diagnosis of IPF can be obtained by histological analysis of lung biopsies and 
non-invasive diagnostic procedures, such as lung function testing and high resolution computed 
tomography (HRCT).  
A common histological feature of IPF at low magnification is the proximity of alternating normal 
and scarred lung areas, resulting in a patchy distribution (Figure 1.2A). Hereby, scarred areas 
predominate in subpleural/paraseptal regions, whereas the centrolobule may show regions with 
normal lung structure (Figure 1.2B). The lung architecture, normally presented by fine alveolar 
structures, is distorted and large airspaces, so called honeycombs, which are encompassed by 
bronchial epithelium and often filled by inflammatory cells or mucus, are present. In contrast to 
emphysema, the background of honeycombs consists of destroyed lung tissue (Figure 1.2C) 
(Cavazza et al., 2010). A typical feature in the histology of IPF is the presence of so called 
fibroblast foci, which consist of proliferating, extracellular matrix (ECM) deposing, 
spindle-shaped myofibroblasts embedded in a myxoid matrix (Figure 1.2D). Fibroblast foci 
indicate areas of acute fibrotic remodeling, whereas honeycombing and fibrotic scars prevail in 
areas of past fibrotic injury (Cavazza et al., 2010; Raghu et al., 2011; Wolters et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Histopathology of IPF (H&E) 
(A) Patchwork pattern of scarred and normal lung areas (20x magnification). (B) Arrows indicate fibrosis in the 
peripheral, subpleural, and paraseptal area (20x magnification). (C) Honeycombing (20x magnification) and 
(D) fibroblast focus consisting of proliferating myofibroblasts (20x magnification). (Taken from Cavazza et al., 
2010) 
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Honeycombing is also a typical criterion for a definite diagnosis of IPF by HRCT. Here, it is 
manifested as reticular opacities mainly in the subpleural region with well-defined walls (Figure 
1.3) (King et al., 2011; Raghu et al., 2011). 
 
 
 
 
 
 
 
 
 
1.1.3 Pathomechanisms in IPF 
Despite the identification of a variety of risk factors, which are discussed to trigger the initiation 
of lung fibrosis, the origin of IPF and its underlying pathomechanism is not completely 
understood yet.  
Most of these risk factors such as smoking, exposure to air pollutants or viral infection might 
lead to perpetuated microinjuries of the alveolar epithelium and might trigger a dysregulation 
within the wound healing process. This finally results in excessive and ongoing deposition of 
extracellular matrix proteins, thereby causing distortion of the fine alveolar structure and finally  
organ failure (Wynn, 2011). Therefore, IPF is also widely regarded as unrestrained wound 
healing response (Fernandez & Eickelberg, 2012b). 
Normal wound healing consists of four distinct phases including clotting and coagulation, 
migration of inflammatory cells, fibroblast activation and finally tissue remodeling and resolution. 
In the lung, epithelial cells release inflammatory mediators after disruption to start an 
antifibrinolytic-coagolation cascade and to recruit inflammatory cells like neutrophils, 
lymphocytes, eosinophils and macrophages to the site of injury. These leukocytes further 
release profibrotic cytokines such as interleukin-1β (IL-1β), tumor necrosis factor (TNF), 
interleukin-13 (IL-13) and transforming growth factor-β (TGF-β) to induce fibroblast migration, 
proliferation, and activation (Wynn, 2011). Further, activated macrophages and neutrophils 
Figure 1.3. HRCT of a typical pattern of UIP 
Axial HRCT image shows a typical UIP pattern with multiple layers of extensive honeycombing in basal 
regions, indicated by arrows. (Taken from Raghu et al., 2011) 
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remove dead cells and attack invading organisms. Activated fibroblasts, so-called 
myofibroblasts, express α-smooth muscle actin (αSMA) and secrete ECM proteins. During the 
tissue remodeling step, myofibroblasts mediate wound contraction to finally facilitate migration 
of dividing epithelial cells over the present matrix to regenerate the damaged tissue. However, 
in IPF the wound healing process is dysregulated, myofibroblasts remain activated and 
excessively dispose ECM, leading to scar formation and finally tissue destruction (Figure 1.4) 
(King et al., 2011; Wynn, 2011). 
 
 
 
 
 
 
 
 
 
 
 
1.1.3.1 The alveolar epithelium 
IPF primarily occurs in the alveolar region of the lung. The alveolar epithelium consists of type I 
epithelial cells (AECI or ATI), responsible for the gas exchange, and type II epithelial cells 
(AECII or ATII) that produce large amounts of surfactant proteins and are discussed to be 
progenitor cells of AECI (Barkauskas & Noble, 2014). A typical histological feature in IPF is the 
presence of abnormal hyperplastic and hypertrophic AECII, which overlay fibroblastic foci 
(Katzenstein & Myers, 1998). These cells are highly active, showing both apoptosis and 
proliferation, and indicate ongoing dysregulated repair processes without persistent stimulus 
(King et al., 2011; Korfei et al., 2011). In IPF it is hypothesized that the alveolar epithelium is 
unable to mediate normal tissue regeneration. This is supported by human genetic studies in 
familial cases of pulmonary fibrosis, reporting gene mutations that effect proteins, which are 
mainly expressed in alveolar epithelial cells (Wolters et al., 2014). For example gene mutations 
Figure 1.4. Wound healing process in normal and fibrotic lungs 
Lung regeneration after injury can be divided into four phases: During the clotting and coagulation phase 
affected epithelial cells release inflammatory mediators and initiate an antifibrinolytic-coagolation cascade. 
Inflammatory cells migrate and secrete profibrotic cytokines to induce myofibroblast activation. Myofibroblasts 
then release ECM components and mediate the final tissue remodeling phase. In healthy lungs, the epithelium 
integrity is restored whereas in IPF myofibroblasts stay activated and continue the remodeling process, 
leading to an excessive deposition of ECM. (Taken from Wynn, 2011) 
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in surfactant proteins C and A2, which are expressed exclusively in AECIIs, might activate the 
unfolded protein response (UPR) (Noble et al., 2012; Wolters et al., 2014). The UPR involves a 
variety of conserved signaling pathways and monitors the chaperone-mediated folding capacity 
of the endoplasmic reticulum (ER). ER-stress occurs when the ER is unable to restore proper 
protein folding, as shown for the mentioned mutant surfactant proteins, leading to accumulation 
of misfolded proteins (Meiners et al., 2015; Walter & Ron, 2011). As a consequence, the UPR is 
activated via three ER transmembrane transducers: Inositol requiring enzyme 1 (IRE1) induces 
expression of chaperones and proteins involved in ER-associated protein degradation (ERAD) 
to enhance degradation of misfolded proteins by the ubiquitin-proteasome system (UPS). Next 
to proteasomal protein degradation, autophagy is activated during UPR to dispose aggregates 
of misfolded proteins via lysosomes (Senft & Ronai, 2015). Activating transcription factor 6 
(ATF6) also elevates expression of chaperones and protein kinase RNA-like ER kinase (PERK) 
activation reduces overall protein translation (Christianson & Ye, 2014; Walter & Ron, 2011; Wei 
et al., 2013). Further, the UPR can increase ER abundance, thereby enhancing its capacity for 
protein folding and processing to prevent accumulation of misfolded proteins and to restore 
homeostasis (Wei et al., 2013). Successful UPR results in UPR-attenuation, but in case 
ER-stress remains the UPR promotes apoptosis (Shore et al., 2011) as proposed for AECIIs in 
sporadic cases of IPF (Tanjore et al., 2012). Impaired autophagy has also been proposed to 
contribute to accelerated senescence in epithelial cells with ER-stress responses (Araya et al., 
2012) and to be involved in TGF-β-mediated myofibroblast activation (Araya et al., 2012; Patel 
et al., 2012).  
Furthermore, pulmonary surfactant is crucial to maintain alveolar stability during respiration and 
insufficient production might lead to alveolar damage (Hardie et al., 2010). Seibold et al. 
identified a common polymorphism in the promoter region of MUC5B leading to an 
overexpression of the gel-forming mucin in bronchial epithelial cells. Excessive concentrations 
of mucin are discussed to impair the mucosal host defence and to reduce lung clearance of 
microorganisms, inhaled particles or dissolved chemicals. This might cause an persistent 
exaggerated lung injury and trigger development of IPF (Seibold et al., 2011). 
Short dysfunctional telomeres are associated with premature aging as seen in patients with 
dyskeratosis congenital. Armanios et al. could identify mutations in the genes hTERT and hTR 
encoding telomerase reverse transcriptase and telomerase RNA in familial IPF. Impaired 
telomerase function, resulting in short dysfunctional telomeres, are known to activate a DNA 
damage response which results in apoptosis or senescence. This might lead to a reduced 
regenerative capacity of the alveolar epithelium in the lung and a progressive loss of alveolar 
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cells, leading to damage of the epithelium and development of fibrotic lesions (Armanios et al., 
2007; Wolters et al., 2014). 
The interplay of several factors like age, environmental exposure to smoke or dust, genetic 
factors, gastroesophageal reflux, viral infections or unknown endogenous factors might finally 
contribute to the diseases pathogenesis (Raghu et al., 2011). Thereby, loss of proteostasis, as 
indicated by persistent ER-stress, UPR, and impaired autophagy may play a crucial role to 
promote an alveolar epithelium which is susceptible to an abnormal tissue repair, finally leading 
to IPF (Balch et al., 2014). 
1.1.3.2 Myofibroblast activation 
Fibroblast foci are histological hallmarks of IPF and ECM releasing myofibroblasts strongly 
contribute to the scarring process and the destruction of the fine alveolar structure. 
Myofibroblasts are key effector cells in IPF, which are discussed to originate from various 
sources including bone marrow derived, circulating fibrocytes, resident fibroblasts or epithelial-
to-mesenchymal transition (EMT) (Fernandez & Eickelberg, 2012b; Phan, 2012). They are 
highly contractile due to expression of αSMA in stress fibres, which is also a common marker for 
this cell type. Myofibroblast differentiation in the lung is mainly induced by mediators, released 
by alveolar epithelial cells in response to lung injury as described in chapter 1.1.3.1 (King et al., 
2011; Klingberg et al., 2013). 
The presence of high local concentrations of biologically active TGF-β, high mechanical stress, 
and specialized ECM-components such as the extra domain A (ED-A) splice variant of 
fibronectin (Fn) are discussed to act as main drivers of myofibroblast differentiation (Hinz et al., 
2007). High levels of TGF-β are a characteristic feature of IPF lungs and are proposed to be 
mainly released by macrophages and epithelial cells in response to epithelial injury or by 
activated myofibroblasts within the remodeling process. TGF-β is commonly regarded as key 
initiator of fibroblast differentiation into ECM-secreting myofibroblasts (Duffield et al., 2013; 
Fernandez & Eickelberg, 2012a; Wynn & Ramalingam, 2012).  
When TGF-β is activated from its latent complex, it binds to TGF-β transmembrane type I (TβRI) 
and type II (TβRII) serine/threonine kinase receptors and induces their heterodimerization. 
Subsequently, TβRII transphosphorylates TβRI, which finally phosphorylates receptor-specific 
transcription factors (R-SMADs: SMAD2 and SMAD3) (Massagué, 2012) (Figure 1.5). 
Translocation of phosphorylated SMADs into the nucleus is then mediated by SMAD4, and 
transcription of profibrotic genes, including ECM components such as collagens, αSMA, and 
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fibronectin, is activated after association of the R-SMAD/SMAD4 complex with the genomic 
SMAD-binding element (SBE). Transcriptional regulation by SMADs can be antagonized by 
nuclear proteins SKI and SNO (also SnoN). Furthermore, SMAD7, an inhibitory SMAD 
(I-SMAD), counteracts TGF-β signaling through various mechanisms. R-SMADs can also 
regulate TGF-β-mediated transcription via SMAD-induced miRNA processing (Akhurst & Hata, 
2012; Massagué, 2012). 
Resident fibroblasts are regarded as the main source of myofibroblasts in lungs of IPF patients. 
Under normal conditions, they regulate ECM homeostasis by expression and secretion of ECM 
proteins to build up matrix and by release of matrix metalloproteinases and tissue inhibitors of 
matrixmetalloproteinases to degrade or remodel ECM. Residing in the subepithelial region, they 
show little actin-associated cell-cell or cell-matrix interactions (Bagnato & Harari, 2015; Hinz et 
al., 2007). After injury of the epithelium, the release of profibrotic markers, mainly TGF-β, 
induces fibroblast differentiation in highly contractile, proliferating myofibroblasts which then 
migrate to the area of epithelial disruption to deposit ECM, thereby mediating initial wound 
contraction and closure (Phan, 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. SMAD-dependent TGF-β signaling 
TGF-β mediates phospholyation of TβRII and TβRI, which then phosphorylates R-SMADs, thereby activating 
their translocation into the nucleus. R-SMADs may also regulate gene expression via SMAD-mediated miRNA 
processing. I-SMAD, SKI and SNO act as inhibitory factors of the TGF-β pathway. (Taken from Akhurst & 
Hata, 2012) 
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Fibrocytes are a special subpopulation of leukocytes and have been shown to infiltrate into IPF 
lungs from the blood. They have been described in areas of active fibrotic remodeling in 
proximity of newly formed scar tissue. Fibrocytes combine features of hematopoietic and 
mesenchymal cells like expression of CD45 and CD34 together with expression of collagen I 
and fibronectin. Alveolar epithelial cells in IPF lungs express the chemokine CXCL12, thereby 
inducing chemotaxis of fibrocytes towards the injured epithelium. Subsequent TGF-β mediated 
differentiation at the site of injury might add to the excessive accumulation of myofibroblasts in 
IPF (King et al., 2011; Maharaj et al., 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Another proposed source of myofibroblasts is the alveolar epithelium itself. Within the process 
of EMT, AECs loose epithelial cell markers and polarity and acquire a mesenchymal phenotype 
indicated by single cell motility and synthesis of ECM (Fernandez & Eickelberg, 2012a). There is 
strong evidence for TGF-β as main driver of EMT in lungs of IPF patients. AECs in IPF lungs 
show high levels of SNAI1 and SNAI2 transcription factors, which have been shown to be main 
effectors of TGF-β mediated EMT in the lung (Jayachandran et al., 2009). 
Figure 1.6. Proposed sources of myofibroblasts in IPF 
TGF-β is released by AECs, macrophages or activated myofibroblasts in response to epithelial injury. Bone 
marrow-derived fibrocytes and resident fibroblasts are recruited and differentiate into highly contractile, 
ECM-releasing myofibroblasts. AECs undergo EMT and contribute to the myofibroblast pool. In IPF the aberrant  
wound healing process persists and myofibroblasts stay activated. (Taken from Fernandez & Eickelberg, 2012a) 
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Within normal tissue repair, myofibroblasts undergo apoptosis once the healing process is 
finished. In IPF, this does not happen in fibroblast foci and myofibroblasts stay activated 
resulting in an ongoing remodeling process and excessive deposition of ECM (Figure 1.6). The 
underlying mechanism is not completely understood yet but might involve persistent profibrotic 
TGF-β signaling by AECs, macrophages and myofibroblasts (Fernandez & Eickelberg, 2012a, 
2012b). 
1.1.4 Treatment strategies in IPF 
Due to the devastating character of IPF, its fast progression and a general late diagnosis, 
therapeutic interventions are very limited. Despite extensive research efforts during the past 
decades medical science was not able to establish an effective curative pharmacological 
therapy for the treatment of IPF. Although pirfenidone was approved for the treatment of IPF in 
Japan (2008), Europe (2011) and USA (2014), the official guidelines for diagnosis and 
management of IPF of the American Thoracic Society (ATS), the European Respiratory Society 
(ERS), the Japanese Respiratory Society (JRS) and the Latin America Thoracic Society (ALAT) 
do not in general recommend any specific pharmacologic therapy but rather suggest to apply 
non-pharmacological interventions (Raghu et al., 2011). 
1.1.4.1 Pharmacological therapies and drug candidates 
Just recently, a phase III trial to study therapeutic effects of pirfenidone, an orally available 
pyridine derivative, was completed successfully. Compared to placebo, treatment with 
pirfenidone significantly reduced disease progression in IPF patients and was associated with 
decreased mortality (King et al., 2014). Pirfenidone provides pleiotropic antifibrotic, anti-
inflammatory, and antioxidative effects, but the underlying mechanism of action is not well 
understood. In vivo and in vitro studies with pirfenidone suggest downregulation of profibrotic 
cytokines, chemokines and growth factors (especially TGF-β) and inhibition of myofibroblast 
differentiation together with reduced synthesis of ECM components (Ahluwalia et al., 2014). 
Common treatment strategies for IPF patients so far include antioxidant therapy 
(N-acetylcystein), immunomodulators (corticosteroids, cyclosporine A, azathioprine, 
cyclophosphamide, interferon-γ 1b), agents that antagonize myodifferentiation (pirfenidone, 
nintedanib) and anticoagulants (warfarin, heparin). However, none of these therapies provides 
strong evidence for a better outcome in IPF as clinical trials often show controversial results, but 
they seem to be beneficial in individual cases (Ahluwalia et al., 2014; Raghu et al., 2011). To 
date, several promising drug candidates that act on various different profibrotic processes in IPF 
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are in phase II and III clinical trials. Table 1.1 and Figure 1.7 summarize these candidates. 
Table 1.1. Ongoing and recently completed phase II/III trials in IPF (Ahluwalia et al., 2014)~modified 
Agent Mechanism of action Study phase 
Tralokinumab IL-13 monoclonal antibody Phase II 
Lebrikizumab IL-13 monoclonal antibody Phase II 
Pirfenidone Antifibrotic, antiinflammatory, antioxidant Phase III (completed) 
Nintedanib Tyrosine kinase inhibitor targeting VEGFR, FGFR, PDGFR Phase III (completed) 
STX-100 Integrin ανβ6 monoclonal antibody Phase II 
FG-3019 CTGF inhibitor Phase II 
BMS-986020 Lysophosphatidic acid receptor antagonist Phase II 
Simtuzumab LOXL2 monoclonal antibody Phase II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.4.2 Non-pharmacological interventions 
Non-pharmacological treatment options have been shown to provide beneficial effects in IPF 
patients. The official guidelines of the ATS, ERS, JRS and ALAT recommend long-term oxygen 
therapy for IPF patients with resting hypoxemia and suggest pulmonary rehabilitation, involving 
aerobic training, strength and flexibility training, educational lectures, nutritional interventions 
and psychological support. Despite all efforts to establish curative treatment strategies, the most 
Figure 1.7. Promising investigational therapies for IPF and their pharmacologic interaction 
Several promising drug candidates with different mechanisms of action are in ongoing and recently completed 
clinical studies for therapeutic intervention of IPF. (Taken from Ahluwalia et al., 2014) 
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effective therapy to prolong survival of IPF patients to date still remains lung transplantation 
(Rafii et al., 2013; Raghu et al., 2011). 
1.1.5 The bleomycin mouse model for pulmonary fibrosis 
Several animal models have been established to study the pathomechanism or therapeutic 
interventions of pulmonary fibrosis. Pulmonary fibrosis in mice can be induced by various stimuli 
including exposure to silica, asbestos, fluorescein isothiocyanate (FITC), overexpression of 
TGF-β or radiation (Moore et al., 2013). The most commonly used and best studied animal 
model for pulmonary fibrosis is the bleomycin mouse model. Bleomycin, a cytotoxic 
glycopeptide antibiotic, is a well-known drug in cancer therapy. In tumor cells, it causes DNA 
double strand breaks thereby inducing apoptosis. One severe side effect of bleomycin in cancer 
patients is the development of pulmonary fibrosis. This observation led to the establishment of 
the bleomycin animal model for the investigation of pulmonary fibrosis (Mouratis & Aidinis, 
2011). 
The most common application route in the murine model is a single intratracheal instillation of 
bleomycin into the lungs. Bleomycin initially causes acute lung injury by epithelial cell damage 
and inflammation, followed by fibrotic tissue remodeling in a very short time of about 7 to 9 days 
after instillation. During the initial inflammatory phase (until day 7 post-bleomycin) 
proinflammatory cytokines such as IL-1β, TNFα, IL-6 or interferon-γ (INFγ) are elevated (Moeller 
et al., 2008). The profibrotic response peaks around day 14 with increased expression of 
TGF-β, collagens and fibronectin, accumulation of ECM, and fibrotic remodeling, and persists 
up to 28 days after bleomycin challenge (Moore et al., 2013; Mouratis & Aidinis, 2011). 
However, fibrotic remodeling in the bleomycin mouse model is reversible and fibrosis resolves, 
depending on the mouse strain, within 56 days after bleomycin instillation. Due to the slow, 
irreversible, and progressive course of the disease in IPF patients, the bleomycin mouse model 
therefore cannot completely reflect the pathogenesis of this disease. Also, some characteristic 
hallmarks of IPF such as fibroblast foci are missing in bleomycin-induced pulmonary fibrosis 
(Moeller et al., 2008; Moore et al., 2013; Mouratis & Aidinis, 2011). Despite these limitations, the 
bleomycin mouse model remains the best characterized and probably most convenient model 
for studying the pathogenesis of IPF and testing of novel antifibrotic therapies, so far (Mouratis 
& Aidinis, 2011). 
INTRODUCTION 
 
 
 
13 
1.2 The Ubiquitin-Proteasome System 
The ubiquitin-proteasome system (UPS) is the major degradation pathway for intracellular 
proteins. Substrate recognition and degradation within the ubiquitin-proteasome system is highly 
controlled and therefore guarantees a specific regulation of protein levels in numerous cellular 
processes. The key protease within the ubiquitin-proteasome system is the proteasome, a 
multicatalytic enzyme complex of over 2.5 megadaltons (Ciechanover, 2013; Finley, 2009). 
1.2.1 The proteasome 
The proteasome consists of a barrel-like structured catalytic core particle (CP), also named 20S 
proteasome, and one or two 19S regulatory particles (RP). To avoid uncontrolled proteolysis of 
cellular proteins, the proteasome provides a unique secure arrangement to only allow highly 
specific degradation. Protein cleavage occurs inside the catalytic core of the 20S particle, which 
is closed in its inactive state by the obstacle of a narrow entry pore. Opening and therefore 
activation of the CP occurs when the 19S RP associates with the 20S CP in an ATP-dependent 
manner (Finley, 2009; Groll et al., 2000). Activation of the proteasome is not exclusively 
implemented by the 19S RP, which can bind to one or both ends of the 20S CP to form 26S or 
30S proteasomes, respectively. There are two more types of proteasome activators (PA), the 
11S complexes PA28α/β and PA28γ, and PA200, which are able to open the channel to the 
catalytic core independent of ATP. However, the 19S RP is the only activator, which is able to 
recognize and process K48-polyubiquitinated proteins, thereby assuring highly specific protein 
degradation (Kish-Trier & Hill, 2013; Meiners et al., 2014; Stadtmueller & Hill, 2011).  
1.2.1.1 The 20S catalytic particle 
The 20S CP is symmetrically composed of two outer rings, which are formed by seven 
α-subunits (α1-7) in each case, that enclose two inner rings of seven β-subunits (β1-7), 
respectively (Groll et al., 1997).  
Assembly of the CP starts with the formation of the heptameric α-ring, which then serves as a 
template for the β-ring, resulting in half 20S proteasomes still missing β7. Two so-called 
half-mers (-β7) then dimerize to active 20S proteasomes by incorporation of β7 (Murata et al., 
2009). 20S assembly is tightly regulated and assisted by a variety of chaperones: Proteasome 
assembling chaperone 1 (PAC1)-PAC2 and PAC3-PAC4 heterodimers assist to form the α-ring 
and to avoid uncontrolled aggregation of α-subunits. Ubiquitin-mediated proteolysis 1 (UMP1) is 
required for initial β2 association on the α-ring. Further intramolecular chaperones, which are 
propeptides of β1, β2, β5, β6, and β7 mediate orderly incorporation of the β-subunits into the 
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ring complex and finally promote dimerization of the half-mers (Gu & Enenkel, 2014; Murata et 
al., 2009). 
Three of the seven β-subunits, β1, β2, and β5, contain proteolytic activity and cleave proteins 
after different amino acids into oligomeric peptides of 3-28 amino acids length. The β1 subunit 
prefers cleavage on the C-terminal side of acidic residues, β2 cleaves after basic residues and 
β5 after hydrophobic residues. According to their cleavage site-specificity, they are classified as 
chymotrypsin-like (CT-L), trypsin-like (T-L), and caspase-like (C-L) active sites (Figure 1.8) 
(Borissenko & Groll, 2007; Groll et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
Each active site contains an N-terminal threonine which provides the catalytic nucleophile and 
the primary proton acceptor, responsible for hydrolysis of peptide bonds. In a first step the 
substrate peptide forms an ester bond with the N-terminal threonine which is then hydrolysed by 
incorporation of a nucleophilic water molecule into the product. Cleavage site specificity is 
provided by specificity pockets which stabilize the substrate and orientate it from its N- to its 
C-terminus (Borissenko & Groll, 2007). 
The active sites are safely situated inside the catalytic core particle, which is closed in its 
inactive state to avoid uncontrolled protein degradation, as described above. Hereby, the outer 
α-rings block the entrance to the proteolytic chamber in its closed conformation. The 19S RP 
promotes gate opening and therefore activation of the CP by binding to specific sites of the 
α-subunits, which leads to a rearrangement of the α-rings resulting in channel-opening and 
Figure 1.8. Architecture of the 20S proteasome complex 
Schematic of the 20S CP (left) provides insight into the channel and the arrangement of the catalytic sites. 
Each site, namely caspase-like (C), trypsin-like (T) and chymotrypsin-like (CT) active site, is present twice per 
complex. They reside within the β-rings. The three-dimensional structure of the 20S CP (right) shows the 
arrangement of the α- (orange) and β-rings (grey). (Taken from Makino et al., 2013) 
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activation of the CP (Bhattacharyya et al., 2014; Finley, 2009; Groll et al., 2000). Next to the 
19S RP, the other PAs PA28α/β, PA28γ, and PA200 are able to open the CP in an ATP-
independent manner. Their role in proteasomal degradation is not completely understood yet, 
but might involve specific degradation of certain proteins or the formation of hybrid 
proteasomes, when assembled with 26S proteasomes, to modulate protein degradation 
(Meiners et al., 2014). 
1.2.1.2 The 19S regulatory particle 
The 19S regulatory particle, also known as PA700, consists of at least 18 subunits which form a 
lid complex, containing not less than eight regulatory particle non-ATPase (Rpn) proteins (Rpn3, 
Rpn5-9, Rpn11, Rpn12) with Rpn11 as deubiquitinating enzyme (DUB) and a base, consisting 
of six regulatory particle triple A ATPases (Rpt) (Rpt1-6) and four non-ATPase proteins (Rpn1, 
Rpn2, Rpn10 and Rpn13), whereas Rpn10 and Rpn13 serve as ubiquitin receptors (Gu & 
Enenkel, 2014; Lander et al., 2012). The RP enables binding of polyubiquitinated proteins, 
recycling of ubiquitin via deubiquitination, and ATP-dependent unfolding of protein chains to 
funnel them into the 20S catalytic core (Figure 1.9) (Lander et al., 2013; C.-W. Liu & Jacobson, 
2013; Tomko & Hochstrasser, 2013). 
Assembly of the 19S RP is a very complex process and not completely understood yet. Lid and 
base of the 19S RP might assemble independently from each other, but also assembly of the 
base on top of the 20S CP, thereby using it as a template, has been proposed (Gu & Enenkel, 
2014). The six homologous ATPase subunits of the base (Rpt1-6) assemble together with Rpn1 
and Rpn2 into a hexameric ring. This process is guided by RP base-dedicated chaperones S5b, 
p27, p28, and Rpn14, which interact with one or two base-subunits. Further, Rpn14 and p28 
seem to be involved in the docking process of the base to the 20S CP. Once the base is 
assembled, association of lid and base occur by an unknown mechanism, which might involve 
S5a/Rpn10 (Besche et al., 2009).  
Only little is known about the assembly of the lid. Data from yeast indicate the formation of two 
subunit-agglomerates consisting of Rpn5, Rpn6, Rpn8, Rpn9 and Rpn11 or Rpn3, Rpn7, Rpn12 
and Rpn15. In this model Rpn3 and Rpn5 form a connection (Murata et al., 2009; Sharon et al., 
2006). Furthermore, the molecular chaperone Hsp90 is proposed to assist in assembly and 
maintenance of the lid (Murata et al., 2009).  
In order to form an effectively operating 26S proteasome, the 19S RP somehow has to be 
attached to the 20S CP. This mechanism is barely understood, but there are some factors 
known to stabilize this interaction: Association of the 19S RP with the 20S CP results in 
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plugging in the C-terminal residues of the two base-ATPase subunits of Rpt2 and Rpt5 into 
defined pockets of the α-ring of the 20S CP. This interaction requires ATP binding, therefore the 
intracellular ATP-levels might be a possible key player in 26S formation (Smith et al., 2007). 
Furthermore, ATP is necessary for appropriate 26S functions such as deubiquitination and 
unfolding of polyubiquitinated proteins and hydrolysis (Braun et al., 1999; C.-W. Liu et al., 2006). 
It has also been shown that intracellular ATP levels influence proteasome activity in both 
directions by a yet unknown mechanism (Huang et al., 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Upregulation of proteasome activity by increased assembly of 26S and 30S proteasomes has 
recently been described for embryonic stem (ES) cells by Vilchez et al. In this study, ES cells 
provided high proteasome activities, which decreased upon differentiation into neural progenitor 
cells (NPCs) or further differentiation into neurons. Increased proteasome activities were 
mediated by formation of 26S and 30S proteasomes leading to a higher substrate turnover in 
these cells. In parallel, the 19S lid subunit Rpn6 was highly expressed in ES cells in comparison 
to NPCs and identified as a rate limiting factor that promotes formation of highly active 26S and 
30S proteasomes (Vilchez, Boyer, et al., 2012). In addition, Pathare et al. showed by crystal- 
and cryostructure analysis that Rpn6 closely interacts with 19S ATPase Rpt6 and the α2 subunit 
of the 20S CP within the 26S complex. Here, Rpn6 acts like a clamp holding together the 
Figure 1.9. Three-dimensional reconstruction of the 26S proteasome 
The subnanometre cryoelectron microscopy reconstruction of the 26S proteasome is shown in two views. 
Subunits of the 19S RP are depicted in different colours building a 26S complex with the 20S CP (grey). 
(Taken from Lander et al., 2012)~modified 
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otherwise weakly stabilized 26S proteasome (Figure 1.9) (Pathare et al., 2012). These structural 
findings are supported by data from yeast that show impaired formation of 26S proteasomes 
upon Rpn6 depletion (Isono et al., 2005; Santamaria et al., 2003). 
Taking into account the complexity of 19S assembly and association with 20S CP to form 26S 
proteasomes, this proposes a strong overall regulation on different levels such as presence of 
chaperones or possible rate limiting subunits as shown for Rpn6. However, up to now there is 
only limited knowledge about the factors which might influence 19S assembly and its 
association with the 20S CP to balance protein degradation to an appropriate level adjusted to 
the need of the cell. 
1.2.2 Protein degradation by the ubiquitin-proteasome system 
The ubiquitin-proteasome system is responsible for the controlled degradation of about 90% of 
all intracellular proteins, thereby representing the main protein destruction machinery of the cell 
(Meiners et al., 2014). To avoid uncontrolled protein degradation, their disposal via the ubiquitin-
proteasome system is a highly regulated process. 
For degradation, proteins are specifically recognized by E3 ubiquitin ligases and covalently 
tagged with polyubiquitin chains that are linked via the lysine 48 (K48) residue of the ubiquitin 
moiety as a degradation signal for the ubiquitin-proteasome system. Next to K48, ubiquitin 
chains can also be linked via other lysines such as K11 or K63 to regulate cell signaling or in 
case of K63 to promote degradation via autophagy. Also attachement of monoubiqutins is 
possible. However, there are a variety of different ubiquitin chain modifications but only little is 
known about their function within the cell (Komander & Rape, 2012). 
Ubiquitination is initiated by linkage of one ubiquitin molecule to an ubiquitin-activating enzyme 
(E1) and further transfer to an ubiquitin-conjugating enzyme (E2). The E3 ligase finally links the 
ubiquitin to the protein. E2 enzymes promote further linkage of ubiquitin molecules, thereby 
forming a polyubiquitin chain on the protein (Ciechanover, 2015). 
Disposable proteins are recognized via their polyubiquitin tags by the non-ATPase subunits 
Rpn10 and Rpn13 of the 19S lid complex. The deubiquitinase Rpn11 then cleaves off the 
ubiquitin chain in an ATP dependent manner and the protein substrate is unfolded and carried 
into the catalytic core to undergo degradation into oligomeric peptides (Figure 1.10) (Lander et 
al., 2013). 
Proteasomes are present in the cytoplasm and nucleus, regulating levels of proteins involved in 
numerous cellular processes such as cell cycle control (Benanti, 2012; Teixeira & Reed, 2013), 
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MHC class I antigen processing (Sijts & Kloetzel, 2011), protein quality control (Meiners & 
Eickelberg, 2012), gene transcription (Geng et al., 2012), or differentiation (Cenci, 2012). Also 
the TGF-β pathway is highly regulated by the ubiquitin-proteasome system. During TGF-β 
signaling, proteasomes adjust protein levels of several factors by controlling their degradation. 
Smurf E3 ligases for example ubiquitinate R-SMADs and mediate their degradation, leading to 
repression of TGF-β signaling whereas Arkadia, another E3 ligase, promotes ubiquitination and 
degradation of inhibitory proteins such as SMAD7 or SnoN leading to enhanced signaling 
(David et al., 2013; Imamura et al., 2013; Soond & Chantry, 2011). 
 
 
 
 
 
 
 
 
 
 
 
1.2.3 Inhibition of the proteasome 
Approval of the first proteasome inhibitor, bortezomib (BZ) (Velcade®), for the treatment of 
multiple myeloma by the FDA in 2003 can be regarded as a major milestone in the therapy of 
this disease, greatly improving response rates and survival of patients (Kane et al., 2003). Since 
then, a variety of compounds has been designed to covalently bind or reversibly interact with 
the active sites of the 20S CP, thereby inhibiting the proteasome (Beck et al., 2012; Finley, 
2009). Next to these conventional inhibitors, new concepts are arising to interfere with protein 
degradation by the ubiquitin-proteasome system such as inhibition of ubiquitin E3 ligases, 
proteasome recognition inhibitors or inhibition of 19S deubiquitinases by small molecules (Dou 
& Zonder, 2014). 
Figure 1.10. Degradation of polyubiquitinated proteins by the proteasome 
Proteins, which are tagged with K48-linked ubiquitin chains are recognized by the lid of the 19S RP (Rpn10 
and Rpn13), deubiquitinated (Rpn11), unfolded and carried into the catalytic core of the 20S CP. The active 
sites within the catalytic core promote substrate cleavage into oligomeric peptides. (Taken from Bhattacharyya 
et al., 2014) 
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1.2.3.1 Inhibitors of the 20S core particle 
Inhibitors of the 20S CP are designed to bind to the N-terminal threonine residues inside the 
catalytic core that form the active sites of the β1, β2 and β5 subunits. Most of them are 
peptide-like compounds that have a similar binding mode to the N-terminal threonine as natural 
substrates. Active site-specificity can be achieved by modification of their side chains. 
Covalently binding inhibitors show a common principle, combining a peptide scaffold with an 
electrophilic anchor such as aldehydes, vinyl sulfones, boronates, α,β-epoxyketones, α-
ketoaldehydes and β-lactones (Beck et al., 2012; Huber & Groll, 2012).  
In the past years, a variety of second generation proteasome inhibitors have been developed to 
provide higher selectivity for specific active sites (Dick & Fleming, 2010). Just recently, the 
chymotrypsin-like site-specific α,β-epoxyketone inhibitor carfilzomib (Krypolis®) has been 
FDA-approved for the treatment of multiple myeloma (Herndon et al., 2013). In contrast to 
boronate inhibitors, like bortezomib, which form a reversible tetrahedral transition state with the 
nucleophilic Thr1Oγ of the N-terminal threonine with high binding specificity to the chymotrypsin-
like and caspase-like active sites (Beck et al., 2012; Huber & Groll, 2012), α,β-epoxyketone 
inhibitors irreversibly and selectively bind to the chymotrypsin-like active site by formation of a 
morpholino structure with the N-terminal threonine within the catalytic core particle (Herndon et 
al., 2013) (Table 1.2). 
Next to the FDA-approved inhibitors bortezomib and carfilzomib, a variety of promising drug 
candidates are currently under clinical investigation for treatment of multiple myeloma, solid 
tumors, lymphoma or leukemia (Dou & Zonder, 2014) and are summarized in Table 1.2. 
Oprozomib (OZ) (former ONX0912) is a novel modified derivate of carfilzomib, bearing the 
same epoxyketone pharmacophore. Oprozomib is the first orally available proteasome inhibitor 
(Chauhan et al., 2010; Roccaro et al., 2010) and currently in clinical phase II for the treatment of 
multiple myeloma (Teicher & Tomaszewski, 2015). 
Other promising candidates are ixazomib, an orally available boronic ester prodrug, the boronic 
ester delanzomib and the β-lactone marizomib (Beck et al., 2012; Dou & Zonder, 2014; 
Kubiczkova et al., 2014). Like bortezomib, delanzomib and the prodrug ixazomib citrate, which 
is hydrolyzed in aqueous solution to its active form, exhibit high affinity to the chymotrypsin-like 
active site but also bind to the caspase-like site at higher concentrations. Marizomib, also known 
as salinosporine A, a secondary metabolite of the obligate marine actinomycetes bacterium 
Salinispora tropica, is the only non-peptidic 20S inhibitor in clinical trial so far (Beck et al., 2012). 
It binds irreversibly to all three active sites of the catalytic core. Hereby, the Thr1Oγ of the 
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N-terminal threonine attacks the carbonyl carbon atom of marizomib and opens its β-lactone 
ring resulting in a hydroxyl group and an acyl-enzyme ester (Huber & Groll, 2012).  
Table 1.2. Bortezomib and second generation inhibitors (Dou & Zonder, 2014; Huber & Groll, 
2012)~modified 
Proteasome 
Inhibitor 
Chemical Structure 
Inhibition 
Profile 
Structural Class and Reaction Mechanism 
Bortezomib 
 
Reversible 
β5>β1 
Boronate 
 
Delanzomib 
 
Reversible 
β5>β1 
Ixazomib 
citrate 
 
Reversible 
β5>β1 
Carfilzomib 
 
Irreversible 
β5 
Epoxyketone 
 
Oprozomib 
 
Irreversible 
β5 
 
Marizomib 
 
Irreversible 
β5>β2>β1 
β-lactone 
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1.2.3.2 Novel inhibitors of the ubiquitin-proteasome system 
Next to the 20S CP, the ubiquitin-proteasome system provides a variety of other potential 
druggable targets to interfere with protein degradation. Several compounds, targeting the 
ubiquitin-proteasome system via E1, E2 and E3 ligases or interfering with the 19S RP are 
currently under investigation: 
E3 ligases play a crucial role in controlled protein degradation, as they specifically ubiquitinate 
proteins to promote their degradation by the proteasome. Inhibition of specific E3 ligases 
therefore leads to accumulation of their substrates (Micel et al., 2013). Several E3 ligase 
inhibitors are currently in clinical trial including inhibitors for HDM2, causing accumulation of its 
target, the tumor suppressor protein p53 (Micel et al., 2013; Weathington & Mallampalli, 2014) 
or inhibitors for the inhibitors of apoptosis protein (IAP), resulting in enhancement of 
proapoptotic proteins (Beug et al., 2012). Just recently, a novel mechanistic activity as inhibitor 
of the E3 ligase Cereblon has been investigated for the immunomodulatory agent thalidomide 
and its derivatives lenalidomide and pomalidomide (Chamberlain et al., 2014).  
Other possibilities to target proteasomal protein degradation include inhibition of the ubiquitin-
ubiquitin interface of K48-linked chains by ubistatins, which has been shown to disrupt substrate 
recognition by the 19S RP resulting in cell cycle arrest (Verma et al., 2004). Furthermore, 
inhibition of deubiquitinases of the 19S RP led to accumulation of polyubiquitinated proteins and 
induction of G2/M cell cycle arrest (D’Arcy et al., 2011).  
A novel concept of proteasome inhibition arises in the possibility to target protein-protein 
interactions within the complex, thereby destabilizing subunit interactions or impairing assembly 
as for example shown for rapamycin, which prevents attachment of the 19S to the 20S 
proteasome (Gaczynska & Osmulski, 2015). 
1.2.3.3 Cellular effects of proteasome inhibition 
Due to their cytotoxic effects, proteasome inhibitors of the 20S catalytic core have mainly been 
developed as powerful agents for the treatment of cancer and revolutionized the therapy of 
multiple myeloma, a hematological malignancy (Teicher & Tomaszewski, 2015). As the 
proteasome plays a fundamental role in cellular homeostasis, biological effects of proteasome 
inhibition are multifactorial. However, for bortezomib, some key signaling pathways have been 
identified to mainly contribute to its mechanism of action, which may also be transferable to 
other catalytic core inhibitors of the proteasome. 
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The transcription factor nuclear factor κB (NF-κB) is involved in numerous tumor-related 
processes such as suppression of apoptosis, angiogenesis, cell proliferation and migration. In 
the cytoplasm, it is bound to its inhibitor I-κB, preventing its translocation to the nucleus. 
Activation of NF-κB occurs, when I-κB is phosphorylated as a trigger for polyubiquitination and 
subsequent degradation by the 26S proteasome. Inhibition of the proteasome in various cancer 
cells therefore prevents activation of NF-κB leading to downregulation of genes related to 
angiogenesis, survival, and growth while apoptosis is upregulated (Hideshima et al., 2001). 
Furthermore, proteasome inhibition has been shown to activate several apoptotic pathways via 
accumulation of proapoptotic factors like p53, Bcl-2-associated X protein (Bax) and NOXA and 
downregulation of antiapoptotic mediators such as B-cell lymphoma 2 (Bcl-2) and IAP. This 
might contribute to cytotoxic effects of proteasome inhibitor in cancer cells (Frankland-Searby & 
Bhaumik, 2012). 
Cell cycle progression is tightly controlled by cyclins and cyclin dependent kinases (CDKs), 
which are also substrates of the proteasome (Benanti, 2012). Proteasome inhibition therefore 
has been shown to induce accumulation of cyclins and CDKs, leading to disruption of cell cyle 
progression (Frankland-Searby & Bhaumik, 2012; Kubiczkova et al., 2014). 
Next to these cytotoxic events of proteasome inhibition on cancer cells, low non-toxic doses of 
proteasome inhibitors also have been shown to provide protective effects in several organs. 
This includes antiinflammatory, antiproliferative and antifibrotic actions, which have been 
explained by interference of proteasome inhibition with the corresponding pathways such as 
NF-κB, as described above, or TGF-β (Meiners et al., 2014; Meiners, Ludwig, et al., 2008). 
Here, it has been shown that non-toxic proteasome inhibition counteracted TGF-β mediated 
SMAD activation by upregulation of the transcriptional repressor SnoN (also SNO) (Sakairi et 
al., 2011) or by upregulation of the nuclear hormone receptor peroxisome proliferator-activated 
receptor γ (PPARγ), a suppressor of SMAD-mediated transcription (Mutlu et al., 2012). 
1.2.3.4 Proteasome inhibitors in pulmonary fibrosis 
Inhibitors of the 20S catalytic core of the proteasome have been shown to provide antifibrotic 
effects in several organs including heart, kidney, skin, and lung (Fineschi et al., 2006; Meiners 
et al., 2004; Mutlu et al., 2012; Sakairi et al., 2011). 
For the lung, there are conflicting data regarding the antifibrotic effects of proteasome inhibitors 
in the bleomycin model of lung fibrosis: While Fineschi et al. reported that the daily application 
of the clinically approved proteasome inhibitor bortezomib, starting one day after bleomycin 
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instillation, did not show any protective effects (Fineschi et al., 2008), Mutlu et al. observed that 
bortezomib promoted normal repair and prevented lung fibrosis until day 21 post-bleomycin 
when given at modest doses only at day 7 and 14 after the initial bleomycin lung damage. They 
also reported that application of both drugs, bortezomib and bleomycin, at the same time, 
resulted in excess mortality in these mice (Mutlu et al., 2012). These data indicate that there is 
only a very small therapeutic window for proteasome inhibitors of the CP which has also been 
reported for other disease applications (Di Napoli & McLaughlin, 2005; Meiners, Ludwig, et al., 
2008). 
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1.3 Objectives 
The ubiquitin-proteasome system plays a central role to control protein levels in the cell by 
degradation of old, misfolded, or unneeded proteins to maintain homeostasis. It is involved in 
virtually all cellular functions and its dysregulation has been associated with various lung 
diseases including pulmonary fibrosis (Meiners et al., 2014; Weiss et al., 2010). Therefore, the 
overall goal of this study was to provide a better understanding of proteasomal regulation in IPF 
and to evaluate a novel therapeutic intervention in pulmonary fibrosis, by local application of the 
highly specific, second generation proteasome inhibitor oprozomib.  
To achieve this goal, aims were defined as follows: 
1. Analysis of proteasome activity during myofibroblasts differentiation and fibrotic 
remodeling in vitro and in vivo. 
2. Identification and characterization of factors, which modulate proteasome activity during 
myofibroblasts differentiation. 
3. Evaluation of specificity, toxicity and antifibrotic effects of oprozomib in vitro. 
4. In vivo evaluation of therapeutic potential of oprozomib after local pulmonary application. 
For these purposes, myofibroblast differentiation was induced by TGF-β, the bleomycin mouse 
model for pulmonary fibrosis was applied and lung tissue samples were analyzed. Protein 
lysates of cells, mouse, and human lung tissues were assayed for their proteasome content on 
mRNA and protein levels and proteasome activity was examined. Intracellular proteasome 
function was further characterized by siRNA-mediated gene knockdown and proteasome 
inhibition using specific inhibitors. Animal experiments were performed to investigate antifibrotic 
effects of a novel proteasome inhibitor after local intratracheal instillation into the lung or oral 
gavage. 
Collectively, this study should provide a better insight into proteasomal regulation during lung 
fibrosis and address the ubiquitin-proteasome system as a novel target for antifibrotic therapies 
in IPF. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Antibodies 
Table 2.1. Primary antibodies 
Antigen Host Application (Dilution) Manufacturer 
Anti-Collagen I 
(600401103) 
Rabbit WB (1:5000), IF (1:200) Rockland, Gilbertsville, USA 
Anti-Cyclin D1 (2978) Rabbit WB (1:1000) Cell Signaling, Danvers, USA 
Anti-Fibronectin (sc-9068) Rabbit WB (1:1000) Santa Cruz, Dallas, USA 
Anti-KRT5 (ab75869) Rabbit IHC (1:200) Abcam, Cambridge, UK 
Anti-PSMD11 (Rpn6) 
(NBP1-46191) 
Rabbit WB, NG (1:2000), IHC (1:75), 
IF (1:200) 
Novus Biologicals, Littleton, 
USA 
Anti-TBP1 (Rpt5) 
(A303-538A) 
Rabbit WB, NG (1:5000) Biomol, Hamburg, Germany 
Anti-TTF1 (ab76013) Rabbit IHC (1:75) Abcam, Cambridge, UK 
Anti-Ubi-K48 (05-1307) Rabbit WB (1:3000), IHC (1:75) Millipore, Billerica, USA 
Anti-αSMA (A5288) Mouse WB, NG (1:1000), IF (1:1000) Sigma-Aldrich, St. Louis, USA 
Anti-αSMA (ab5694) Rabbit IHC (1:200) Abcam, Cambridge, UK 
Anti-β1 (20S) (sc-67345) Rabbit NG (1:250) Santa Cruz, Dallas, USA 
Anti-β-actin-peroxidase 
(A3854) 
Mouse WB (1:50000) Sigma-Aldrich, St. Louis, USA 
Anti-20S α3 (ab119419) Mouse WB (1:1000) Abcam, Cambridge, UK 
Anti-20S α1-7 (ab22674) Mouse WB, NG (1:1000) Abcam, Cambridge, UK 
Western blot (WB); Native gel (NG); Immunohistochemistry (IHC); Immunofluorescence (IF); Primary antibodies for 
WB were diluted in Roti-Block and for IF in Roti-Immunoblock. 
Table 2.2. Secondary antibodies 
Antigen Host Application Manufacturer 
Horse anti-mouse IgG HRP-linked 
(7076S) 
Horse WB, NG 
(1:50000) 
Cell Signaling, Danvers, USA 
Goat anti-rabbit IgG HRP-linked 
(7074S) 
Goat WB, NG 
(1:50000) 
Cell Signaling, Danvers, USA 
Alexa Fluor 488 goat anti-mouse lgG 
(A11001) 
Goat IF (1:250) Life Technologies, Carlsbad, USA 
Alexa Fluor 488 goat anti-rabbit lgG 
(A11008) 
Goat IF (1:250) Abcam, Cambridge, UK 
Western blot (WB); Native gel (NG); Immunofluorescence (IF) 
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2.1.2 Buffers, solutions and chemicals 
Table 2.3. Buffers and solutions for protein extraction from cells and tissue 
Buffer Reagent Concentration Manufacturer 
Hypoosmotic 
lysis solution: 
(WB, NG) 
 
cOmplete® protease inhibitor 
(11697498001) 
1x 
 
Roche Diagnostics, Mannheim, 
Germany 
PhosSTOP® phosphatase 
inhibitor (04906845001) 
1x 
 
Roche Diagnostics, Mannheim, 
Germany 
RIPA extraction 
buffer: 
(WB) 
 
 
 
Tris/HCl pH 7.5 50 mM AppliChem, Darmstadt, Germany 
NaCl 150 mM AppliChem, Darmstadt, Germany 
Nonident P40 1% (v/v) AppliChem, Darmstadt, Germany 
Sodiumdeoxycholate 1% (w/v) Carl Roth, Karlsruhe, Germany 
SDS 0.1% (w/v) AppliChem, Darmstadt, Germany 
cOmplete® protease inhibitor 1x Roche Diagnostics, Mannheim, 
Germany 
TSDG buffer: 
(WB, NG) 
 
 
 
 
Tris/HCl pH 7.0 50 mM AppliChem, Darmstadt, Germany 
NaCl 10 mM AppliChem, Darmstadt, Germany 
MgCl2 1.1 mM AppliChem, Darmstadt, Germany 
EDTA 0.1 mM AppliChem, Darmstadt, Germany 
NaN3 1 mM AppliChem, Darmstadt, Germany 
DTT 1 mM AppliChem, Darmstadt, Germany 
ATP 2 mM Roche Diagnostics, Mannheim, 
Germany 
Glycerol 87% 10% (v/v) AppliChem, Darmstadt, Germany 
cOmplete® protease inhibitor 1x Roche Diagnostics, Mannheim, 
Germany 
Western blot (WB); Native gel (NG); All buffers and solutions were prepared with Milli-Q water. 
Table 2.4. Buffers and solutions for Native-PAGE (Native polyacrylamide gel electrophoresis) 
Buffer Reagent Concentration Manufacturer 
5x Loading 
buffer: 
 
Tris/HCl pH 7.5 250 mM AppliChem, Darmstadt, Germany 
Glycerol 87% 50% (v/v) AppliChem, Darmstadt, Germany 
Bromphenol blue 0.01% (w/v) AppliChem, Darmstadt, Germany 
Native-PAGE 
resolving gel 
(10%): 
 
 
 
Tris/HCl pH 8.3 90 mM AppliChem, Darmstadt, Germany 
Boric acid 1.6 mM AppliChem, Darmstadt, Germany 
EDTA 0.08 mM AppliChem, Darmstadt, Germany 
Acrylamide 30% 10% (v/v) Carl Roth, Karlsruhe, Germany 
APS 0.125% (w/v) AppliChem, Darmstadt, Germany 
TEMED 0.15% (v/v) AppliChem, Darmstadt, Germany 
Native-PAGE 
stacking gel 
(3.5%):  
 
Tris/HCl pH 6.8 125 mM AppliChem, Darmstadt, Germany 
Acrylamide 30% 3.5% (v/v) Carl Roth, Karlsruhe, Germany 
APS 0.125% (w/v) AppliChem, Darmstadt, Germany 
TEMED 0.3 % (v/v) AppliChem, Darmstadt, Germany 
MATERIALS AND METHODS 
 
 
 
27 
Native-PAGE 
running buffer 
(TBE): 
 
 
 
Tris/HCl pH 8.3 89 mM AppliChem, Darmstadt, Germany 
Boric acid 89 mM AppliChem, Darmstadt, Germany 
EDTA 2 mM AppliChem, Darmstadt, Germany 
DTT 0.5 mM AppliChem, Darmstadt, Germany 
ATP 0.5 mM Roche Diagnostics, Mannheim, Germany 
MgCl2 2 mM AppliChem, Darmstadt, Germany 
Proteasome 
activity reaction 
buffer: 
 
 
Tris pH 7.5 50 mM AppliChem, Darmstadt, Germany 
SLLVY-AMC (I-1395) 50 mM Bachem, Bubendorf, Switzerland 
MgCl2 10 mM AppliChem, Darmstadt, Germany 
ATP 1 mM Roche Diagnostics, Mannheim, Germany 
DTT 0.5 mM AppliChem, Darmstadt, Germany 
Luciferase 
reaction buffer: 
Glycylglycine pH 7.8 25 mM Sigma-Aldrich, St. Louis, USA 
Potassium 
phosphate pH 7.8 
15 mM Sigma-Aldrich, St. Louis, USA 
MgSO4 15 mM Sigma-Aldrich, St. Louis, USA 
EGTA 4 mM AppliChem, Darmstadt, Germany 
ATP 2 mM Roche Diagnostics, Mannheim, Germany 
DTT 1 mM AppliChem, Darmstadt, Germany 
Luciferin stock: Beetle luciferin 1 mM Promega, Fitchburg, USA 
Glycylglycine pH 7.8 25 mM Sigma-Aldrich, St. Louis, USA 
DTT 10 mM AppliChem, Darmstadt, Germany 
Solubilization 
buffer: 
SDS 2% (w/v) AppliChem, Darmstadt, Germany 
Na2CO3 66 mM AppliChem, Darmstadt, Germany 
β-Mercaptoethanol 1.5% (v/v) AppliChem, Darmstadt, Germany 
Native-PAGE 
transfer buffer: 
 
Tris 25 mM AppliChem, Darmstadt, Germany 
Glycine 0.192 M AppliChem, Darmstadt, Germany 
Methanol 10% (v/v) AppliChem, Darmstadt, Germany 
ABP labeling 
buffer: 
MV151 0.5 µM (Cravatt et al., 2008) 
HEPES pH 7.4 50 nM AppliChem, Darmstadt, Germany 
KCl 100 mM AppliChem, Darmstadt, Germany 
MgCl2 10 mM AppliChem, Darmstadt, Germany 
All buffers were prepared with Milli-Q water. 
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Table 2.5. Buffers and solutions for SDS-PAGE (Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis) 
Buffer Reagent Concentration Manufacturer 
6x loading buffer 
(Lämmli buffer): 
 
 
 
Tris/HCl pH 6.8 300 mM AppliChem, Darmstadt, Germany 
Glycerol 87% 60% (v/v) AppliChem, Darmstadt, Germany 
SDS 6% (w/v) AppliChem, Darmstadt, Germany 
Bromphenol blue 0.01% (w/v) AppliChem, Darmstadt, Germany 
DTT 600 mM AppliChem, Darmstadt, Germany 
SDS-PAGE resolving 
gel (10%): 
 
 
 
Tris/HCl pH 8.8 375 mM AppliChem, Darmstadt, Germany 
Acrylamide 30% 10% (v/v) Carl Roth, Karlsruhe, Germany 
SDS 0.06% (w/v) AppliChem, Darmstadt, Germany 
APS 0.125% (w/v) AppliChem, Darmstadt, Germany 
TEMED 0.15% (v/v) AppliChem, Darmstadt, Germany 
SDS-PAGE stacking gel 
(3.6%): 
 
 
 
Tris/HCl pH 6.8 125 mM AppliChem, Darmstadt, Germany 
Acrylamide 30% 3.6% (v/v) Carl Roth, Karlsruhe, Germany 
SDS 0.1% (w/v) AppliChem, Darmstadt, Germany 
APS 0.125% (w/v) AppliChem, Darmstadt, Germany 
TEMED 0.3 % (v/v) AppliChem, Darmstadt, Germany 
SDS-PAGE running 
buffer: 
 
Tris 25 mM AppliChem, Darmstadt, Germany 
Glycine 0.192 M AppliChem, Darmstadt, Germany 
SDS 0.1% (w/v) AppliChem, Darmstadt, Germany 
SDS-PAGE transfer 
buffer: 
 
Tris 25 mM AppliChem, Darmstadt, Germany 
Glycine 0.192 M AppliChem, Darmstadt, Germany 
Methanol 10% (v/v) AppliChem, Darmstadt, Germany 
PBST washing buffer: 
 
 
 
 
NaCl 137 mM AppliChem, Darmstadt, Germany 
KCl 2.7 mM AppliChem, Darmstadt, Germany 
Na2HPO4 10 mM AppliChem, Darmstadt, Germany 
KH2PO4 2 mM AppliChem, Darmstadt, Germany 
Tween 20 1% (v/v) AppliChem, Darmstadt, Germany 
All buffers were prepared with Milli-Q water. 
Table 2.6. Buffers and solutions IF and IHC 
Buffer Reagent Concentration Manufacturer 
Citrate buffer 
pH 6.0: 
Citric acid monohydrate 1.8 mM AppliChem, Darmstadt, Germany 
Sodium citrate tribasic 8.2 mM AppliChem, Darmstadt, Germany 
All buffers and solutions were prepared with Milli-Q water. 
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Table 2.7. Chemicals 
Product Manufacturer 
5x First Strand Buffer Life Technologies, Carlsbad, USA 
Atipamezole Orion Pharma, Hamburg, Germany 
Bleomycin Sigma-Aldrich, St. Louis, USA 
Bortezomib (Velcade®) Millennium, Cambridge, USA 
Bovine serum albumin (BSA) AppliChem, Darmstadt, Germany 
Carboxymethylecelllulose (CMC) AppliChem, Darmstadt, Germany 
Citric acid monohydrate AppliChem, Darmstadt, Germany 
DAPI staining Sigma-Aldrich, St. Louis, USA 
DTT 0.1 M Life Technologies, Carlsbad, USA 
ECL Prime Western Blotting Reagent GE Healthcare, Cölbe, Germany 
Entellan Merck Millipore, Darmstadt, Germany 
Eosin G 0.5% in water Carl Roth, Karlsruhe, Germany 
Fentanyl Janssen-Cilag, Neuss, Germany 
Flumazenil Hexal, Holzkirchen, Germany 
Fluorescent Mounting Medium Dako, Hamburg, Germany 
Giemsa Azur-Eosin_Methylenblue Solution Merck Millipore, Darmstadt, Germany 
Glo-Lysis Buffer Promega, Fitchburg, USA 
Hemalaun Carl Roth, Karlsruhe, Germany 
Isopropanol (p.A.) AppliChem, Darmstadt, Germany 
Ketamine Bela Pharm, Vechta, Germany 
Lipofectamine RNAiMAX Life Technologies, Carlsbad, USA 
May-Grünwalds Eosin-Methylenblue solution Merck Millipore, Darmstadt, Germany 
Medetomin Orion Pharma, Hamburg, Germany 
Midazolam Roche Pharma, Mannheim, Germany 
MV151 ABP (Cravatt et al., 2008) 
Naloxone Actavis, Munich, Germany 
Nucleotide mix 10 mM  (dNTP’s) Promega, Fitchburg, USA 
Oprozomib (ONX012) Onyx Pharmaceuticals, South San Francisco, USA 
Opti-MEM Reduced-Serum Medium Life Technologies, Carlsbad, USA 
PageBlue Protein Staining solution Fermentas, Thermo Fisher Scientific, Waltham, USA 
Phalloidin Alexa Fluor 568 Life Technologies, Carlsbad, USA 
Pluronic F-127 Calbiochem, Billerica, USA 
Random Hexamers 250 µM Promega, Fitchburg, USA 
Recombinant human EGF protein R&D Systems, Minneapolis, USA 
Recombinant human TGF-β1 protein R&D Systems, Minneapolis, USA 
RNAsin, RNAse inhibitor 40 U/µl Promega, Fitchburg, USA 
Rompun Bela Pharm, Vechta, Germany 
Roti-Block Carl Roth, Karlsruhe, Germany 
Roti-Immunoblock Carl Roth, Karlsruhe, Germany 
Sodium citrate tribasic dihydrate AppliChem, Darmstadt, Germany 
SuperSignal West FEMTO Max. Sensitivity 
Substrate, 200 mL 
Thermo Fisher Scientific, Waltham, USA 
Thiazolyl blue tetrazolium Bromide (MTT) Sigma-Aldrich, St. Louis, USA 
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Triton X-100 Life Technologies, Carlsbad, USA 
Trypan blue solution (0,4%) Sigma-Aldrich, St. Louis, USA 
Trypsin EDTA 0,25% Life Technologies, Carlsbad, USA 
Xylene AppliChem, Darmstadt, Germany 
2.1.3 Cell lines and primary cells 
Table 2.8. Cell culture media 
Cell type Culture medium Manufacturer 
phLF MCDB 131 medium PAN-Biotech, Aidenbach, Germany 
 FBS 10% PAA Laboratories, Cölbe, Germany 
Penicillin/Streptomycin 100 U/ml Life Technologies, Carlsbad, USA 
L-glutamine 2 mM Life Technologies, Carlsbad, USA 
basic-FGF 2 ng/ml Life Technologies, Carlsbad, USA 
EGF 0.5 ng/ml Sigma-Aldrich, St. Louis, USA 
Insulin 5 µg/ml Life Technologies, Carlsbad, USA 
pmLF DMEM-F12 Life Technologies, Carlsbad, USA 
Penicillin/Streptomycin 100 U/ml Life Technologies, Carlsbad, USA 
FBS 20% PAA Laboratories, Cölbe, Germany 
A459 DMEM Life Technologies, Carlsbad, USA 
FBS 10% PAA Laboratories, Cölbe, Germany 
Penicillin/Streptomycin 100 U/ml Life Technologies, Carlsbad, USA 
CCL-206 DMEM-F12 Life Technologies, Carlsbad, USA 
FBS 10% PAA Laboratories, Cölbe, Germany 
Penicillin/Streptomycin 100 U/ml Life Technologies, Carlsbad, USA 
Table 2.9. Cell lines 
Name Organism/Age/Tissue/Cell type Supplier 
CCL-206 Mouse/New-born/Lung/ Lung fibroblast ATCC, Manassas, USA 
A549 Human/58 years/Lung/Alveolar basal epithelial cell ATCC, Manassas, USA 
Table 2.10. Primary human lung fibroblast lines 
ID Patient data 
Gi-151 Female, 60 years, histologically normal areas of lung specimens obtained after resective 
surgery for benign or malignant tumors 
Gi-152 Female, 72 years, histologically normal areas of lung specimens obtained after resective 
surgery for benign or malignant tumors 
406 Female, 50 years, peripheral normal lung tissue, organ donor 
409sp Male, 51 years, peripheral normal lung tissue, organ donor 
411a Female, 44 years, peripheral normal lung tissue, organ donor 
423G Female, 41 years, peripheral normal lung tissue, organ donor 
Primary human lung fibroblast lines were provided by the group of Prof. Dr. Andreas Günther of the “Universities of 
Giessen and Marburg Lung Center” (UGMLC), Giessen, Germany. 
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2.1.4 Consumables 
Table 2.11. Consumables 
Product Manufacturer 
6/24/96 well plates TPP, Trasadingen, Switzerland 
96 well plates, white, for luminescence detection Berthold Technologies, Bad Wildbad, Germany 
Cell culture dishes Nunc, Wiesbaden, Germany 
Cell culture flasks Nunc, Wiesbaden, Germany 
Cell strainer, nylon 70 µm BD Bioscience, Heidelberg, Germany 
Cryovials 1.5 ml Greiner Bio-One, Frickenhausen, Germany 
Dismembrator Tubes (Nalgene Cryogenic Tubes) Thermo Fisher Scientific, Waltham, USA 
Falcon tubes (15 ml, 50 ml) BD Bioscience, Heidelberg, Germany 
Film X-Omat LS, Kodak Carestream Health, Rochester, USA 
Filter pipet tips Biozym Scientific, Hessisch Oldendorf, Germany 
Glass pasteur pipettes VWR International, Darmstadt, Germany 
NuPAGE Novex 3-8% Tris-Acetate Gel 1.5 mm, 10 
well 
Life Technologies, Carlsbad, USA 
PCR plates, white, 96 well Biozym Scientific, Hessisch Oldendorf, Germany 
Pipet tips Eppendorf, Hamburg, Germany 
PVDF membrane Bio-Rad, Hercules, USA 
Reaction tubes (0.5 ml, 1.5 ml) Eppendorf, Hamburg, Germany 
Sealing foil, qPCR Kisker Biotech, Steinfurt, Germany 
Sterican cannulas BD Bioscience, Heidelberg, Germany 
Syringes (10 ml, 20 ml, 50 ml) Neolab, Heidelberg, Germany 
Whatman blotting paper 3 mm GE Healthcare, Freiburg, Germany 
2.1.5 Enzymes 
Table 2.12. Enzymes 
Product Manufacturer 
Collagenase type I Biochrom, Berlin, Germany 
DNAse 2 U/µl Peqlab, Erlangen, Germany 
Luciferase, recombinant Promega, Fitchburg, USA 
Purified 20S proteasome Enzo Life Sciences, Lörrach, Germany 
M-MLV Reverse Transcriptase Sigma-Aldrich, St. Louis, USA 
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2.1.6 Human lung tissue 
Table 2.13. Human lung tissue 
ID Patient data 
198 Male, 61 years, peripheral normal lung tissue, organ donor 
2B Male, 29 years, peripheral normal lung tissue, organ donor 
22 Unknown, peripheral normal lung tissue, organ donor 
46 Unknown, peripheral normal lung tissue, organ donor 
58 Male, 53 years, peripheral normal lung tissue, organ donor 
Gi-151 Female, 60 years, histologically normal areas of lung specimens obtained after 
resective surgery for benign or malignant tumors 
200 Male, 42 years, peripheral normal lung tissue, organ donor 
406 Female, 50 years, peripheral normal lung tissue, organ donor 
409sp Male, 51 years, peripheral normal lung tissue, organ donor 
411a Female, 44 years, peripheral normal lung tissue, organ donor 
146 Male, 60 years, IPF patient 
190 Female, 44 years, IPF patient 
207 Male, 47 years, IPF patient 
302 Male, 54 years, IPF patient 
324 Male, 34 years, IPF patient 
325 Female, 51 years, IPF patient 
327 Male, 61 years, IPF patient 
330 Female, 46 years, IPF patient 
331 Male, 57 years, IPF patient 
334 Female, 42 years, IPF patient 
335 Female, 57 years, IPF patient 
Human lung tissue samples were provided by the group of Prof. Dr. Andreas Günther of the “Universities of Giessen 
and Marburg Lung Center” (UGMLC), Giessen, Germany. 
2.1.7 Laboratory equipment and software 
Table 2.14. Laboratory equipment 
Product Manufacturer 
-20°C freezer MediLine LGex 410  Liebherr, Biberach, Germany  
-80°C freezer U570 HEF  New Brunswick, Hamburg, Germany 
Analytical scale XS20S Dual Range  Mettler-Toledo, Gießen, Germany  
Autoclave DX-45  Systec, Wettenberg, Germany  
Autoclave VX-120  Systec, Wettenberg, Germany  
Cell culture work bench Herasafe KS180  Thermo Fisher Scientific, Waltham, USA 
Centrifuge MiniSpin plus  Eppendorf, Hamburg, Germany  
Centrifuge Rotina 420R  Hettich, Tuttlingen, Germany  
Centrifuge with cooling, Micro200R  Hettich, Tuttlingen, Germany  
CO2 cell Incubator BBD6620  Thermo Fisher Scientific, Waltham, USA 
Cytospin 2 centrifuge Shandon Life Science, Cheshire, UK 
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Demineralized water  Thermo Fisher Scientific, Waltham, USA 
Dismembrator S Sartorius, Göttingen, Germany 
Dry ice container Forma 8600 Series, 8701  Thermo Fisher Scientific, Waltham, USA 
Electronic pipet filler  Eppendorf, Hamburg, Germany  
Electrophoretic Transfer Cell, Mini Protean Tetra 
Cell  
Bio-Rad, Hercules, USA  
Film developer Curix 60  AGFA, Morsel, Belgium  
Flexivent system Scireq, Montreal, Canada 
Fluorescent scanner Typhoon TRIO+ Amersham Biosciences, Amersham, UK 
Gel imaging system ChemiDoc XRS+  Bio-Rad, Hercules, USA  
Hemocytometer Brand, Wertheim, Germany 
Hyrax M55 microtome Zeiss, Jena, Germany 
Ice machine ZBE 110-35  Ziegra, Hannover, Germany  
Intelli-Mixer RM-2  Schubert & Weiss Omnilab, Munich, Germany  
Light Cycler LC480II  Roche Diagnostics, Mannheim, Germany  
Liquid nitrogen cell tank BioSafe 420SC  Cryotherm, Kirchen/Sieg, Germany  
Liquid nitrogen tank Apollo 200  Cryotherm, Kirchen/Sieg, Germany  
Magnetic stirrer KMO 2 basic  IKA, Staufen, Germany  
Mastercycler gradient  Eppendorf, Hamburg, Germany  
Mastercycler Nexus  Eppendorf, Hamburg, Germany  
Microm HMS 740 Robot-Stainer Thermo Fisher Scientific, Waltham, USA 
Microm STP 420D Tissue Processor Thermo Fisher Scientific, Waltham, USA 
Microscope LSM 710 (confocal)  Zeiss, Jena, Germany  
MicroSprayer Aerosolizer, Model IA-1C Penn-Century, Wyndmoor, USA 
Milli-Q Advantage A10 Ultrapure Water Purification 
System (Milli-Q water) 
Merck Millipore, Darmstadt, Germany  
Mini Centrifuge MCF-2360  Schubert & Weiss Omnilab, Munich, Germany  
MIRAX SCAN Zeiss, Jena, Germany 
Multipette stream  Eppendorf, Hamburg, Germany  
Nalgene Freezing Container (Mister Frosty)  Omnilab, Munich, Germany  
NanoDrop 1000  PeqLab, Erlangen, Germany  
pH meter InoLab pH 720  WTW, Weilheim, Germany  
Pipettes Research Plus  Eppendorf, Hamburg, Germany  
Plate centrifuge 5430  Eppendorf, Hamburg, Germany  
Plate reader TriStar LB941  Berthold Technologies, Bad Wildbach, Germany  
Plate reader Sunrise  Tecan, Crailsheim, Germany  
Roll mixer  VWR International, Darmstadt, Germany  
Power Supply Power Pac HC Power Supply  Bio-Rad, Hercules, USA  
Sartorius Micro-Dismembrator S  Thermo Fisher Scientific, Waltham, USA 
Scale XS400 2S  Mettler-Toledo; Gießen, Germany  
Shaker Duomax 1030  Heidolph, Schwabach, Germany  
Thermomixer compact  Eppendorf, Hamburg, Germany  
Vortex Mixer  IKA, Staufen, Germany  
Vacuum pump NO22AN.18 with switch 2410  KNF, Freiburg, Germany  
Water bath Aqua Line AL 12  Lauda, Lauda-Königshofen, Germany  
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Xcell SureLock Mini Cell Life Technologies, Carlsbad, USA 
Table 2.15. Software 
Product Manufacturer 
GraphPad Prism 5  GraphPad Software, La Jolla, USA  
Image Lab Version  Bio-Rad, Hercules, USA  
LightCycler® 480 SW 1.5  Roche Diagnostics, Mannheim, Germany  
Magelan Software  Tecan, Crailsheim, Germany  
Microsoft Office Professional Plus 2010 Microsoft, Redmond, USA 
Tristar MicroWin 2000  Berthold Technologies, Bad Wildbach, Germany  
2.1.8 Oligonucleotides 
Table 2.16. Primer for qPCR 
Gene Species  Sequence 5’-3’ 
ACTA (αSMA) human fw CGAGATCTCACTGACTACCTCATGA 
  rev AGAGCTACATAACACAGTTTCTCCTTGA 
Col1A1 human fw CAAGAGGAAGGCCAAGTCGAG 
  rev TTGTCGCAGACGCAGATCC 
Fibronectin1 human fw CCGACCAGAAGTTTGGGTTCT 
  rev CAATGCGGTACATGACCCCT 
PSMA3 human fw AGATGGTGTTGTCTTTGGGG 
  rev AACGAGCATCTGCCAACAA 
PSMB5 human fw TCAGTGATGGTCTGAGCCTG 
  rev CCATGGTGCCTAGCAGGTAT 
PSMB6 human fw CAGAACAACCACTGGGTCCT 
  rev CCCGGTATCGGTAACACATC 
PSMB7 human fw TCGCTGGGGTGGTCTATAAG 
  rev TCCCAGCACCACAACAATAA 
PSMC3 human fw GTGAAGGCCATGGAGGTAGA 
  rev GTTGGATCCCCAAGTTCTCA 
PSMD11 human fw GCTCAACACCCCAGAAGATGT 
  rev AGCCTGAGCCACGCATTTTA 
Vimentin human fw CTTTTCCTCCCTGAACCTGAG 
  rev AGAAGTTTCGTTGATAACCTGTCC 
RPL19 human fw TGTACCTGAAGGTGAAGGGG 
  rev GCGTGCTTCCTTGGTCTTAG 
mCollagen mouse fw CCAAGAAGACATCCCTGAAGTCA 
  rev TGCACGTCATCGCACACA 
mFibronectin mouse fw GTGTAGCACAACTTCCAATTACGAA 
  rev GGAATTTCCGCCTCGAGTCT 
mPSMA3 mouse fw TGAAGAAGGCTCCAATAAACGTCT 
  rev AACGAGCATCTGCCAGCAA 
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mPSMB5 mouse fw TGCTCGCTAACATGGTGTATCAGTA 
  rev GGCCTCTCTTATCCCAGCCA 
mPSMB6 mouse fw AGACGCTGTCACTTACCAACTTGG 
  rev AAGAGACTGGCGGCTGTGTG 
mPSMB7 mouse fw TGCCTTATGTCACCATGGGTTC 
  rev TTCCTCCTCCATATCTGGCCTAA 
mPSMC3 mouse fw AAGCTGAGCAAGATGGCATT 
  rev TTCATGGGTGACTCGCAATA 
mPSMD11 mouse fw GAATGGGCCAAATCAGAGAA 
  rev TGTACTTCCACCAAAAGGGC 
mRPL19 mouse fw CGGGAATCCAAGAAGATTGA 
  rev TTCAGCTTGTGGATGTGCTC 
Table 2.17. siRNA for gene knockdown 
siRNA Species Supplier 
Silencer Select PSMD11 s11413 human Life Technologies, Carlsbad, USA 
Silencer Select PSMD11 s11414 human Life Technologies, Carlsbad, USA 
Silencer Select PSMD11 s11415 human Life Technologies, Carlsbad, USA 
Silencer Select PSMD11 s87417 mouse Life Technologies, Carlsbad, USA 
Silencer Select Negative Control #1 human, mouse Life Technologies, Carlsbad, USA 
Silencer Select Negative Control #2 human, mouse Life Technologies, Carlsbad, USA 
All siRNAs were diluted with purified water to a stock solution of 10 µM. 
2.1.9 Standards and kits 
Table 2.18. Kits 
Product Manufacturer 
Bright-Glo Luciferase Assay System Promega, Fitchburg, USA 
Cell Proliferation ELISA, BrdU (colorimetric) Roche Diagnostics, Mannheim, Germany 
Proteasome-Glo 3-Substrate System Promega, Fitchburg, USA 
LightCycler 480 SYBR Green I Master Roche Diagnostics, Mannheim, Germany 
PeqGOLD Total RNA-Kit Peqlab, Erlangen, Germany 
Pierce BCA Protein Assay Kit Thermo Fisher Scientific, Waltham, USA 
Roti-Quick-Kit  Carl Roth, Karlsruhe, Germany 
Table 2.19. Standards 
Product Manufacturer 
Protein marker V (10-175 kDa) AppliChem, Darmstadt, Germany 
Protein marker VI (10-245 kDa) AppliChem, Darmstadt, Germany 
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Cell culture of mammalian cell lines 
The A549 human alveolar epithelial cell line and the CCL-206 mouse lung fibroblast cell line 
were obtained from ATCC (American Type Culture Collection, Manassas, USA). 
A549 cells were cultured in DMEM medium supplemented with 10% FBS and 100 U/ml 
penicillin/streptomycin. Treatment with proteasome inhibitors (bortezomib and oprozomib) was 
performed in whole culture medium. 
CCL-206 fibroblasts were cultured in DMEM-F12 medium supplemented with 10% FBS and 
100 U/ml penicillin/streptomycin. Before TGF-β treatment, fibroblasts were starved in reduced 
culture medium containing 1% FBS for 24 hours. TGF-β then was added to the starvation 
medium to a final concentration of 5 ng/ml. 
All cells were kept at 37°C under humidified atmosphere containing 5% CO2. 
2.2.1.2 Isolation and cell culture of primary human lung fibroblasts 
Primary human lung fibroblasts (phLF) were provided by the “Universities of Giessen and 
Marburg Lung Center” (UGMLC) and isolated in the laboratory of Prof. Dr. Andreas Günther. 
All experiments were carried out with normal phLF in passages 2 and 3. Prior TGF-β treatment, 
phLF were starved for 24 hours in reduced culture medium containing 1% FBS. 
2.2.1.3 Isolation and cell culture of primary murine lung fibroblasts 
Primary murine lung fibroblasts (pmLF) were isolated from whole lungs of female FVB.129S6-
Gt(ROSA)26Sortm2(HIF1A/luc)Kael/J mice (ODD-luc mice), which contain the ODD-luc transgene. 
Animals were sacrificed by cervical dislocation and lungs were dissected. Isolated lungs were 
collected in pre-warmed pmLF culture medium containing DMEM-12 medium supplemented 
with 20% FBS and 100 U/ml penicillin/streptomycin and chopped into small pieces. Lung pieces 
were placed into falcon tubes and digested at 37°C for 2 hours, using collagenase type I. 
Digested tissue then was pressed through a 70 µm nylon filter for further mincing. After washing 
and pelleting minced tissue was resuspended in culture medium and incubated at 37°C in 
humidified atmosphere and 5% CO2 to allow fibroblast outgrowth off the tissue. Media was 
exchanged every three days. Primary murine lung fibroblasts were split for the first time after 
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reaching confluency of 80-90% and used up to passage 3. Cells were treated with oprozomib in 
whole culture medium. 
2.2.1.4 Isolation and cell culture of primary murine alveolar epithelial type II cells 
Primary murine alveolar epithelial type II cells (pmATII) were isolated by Dr. Kathrin Mutze in 
collaboration with the lab of Melanie Königshoff at the Comprehensive Pneumology Center. 
Isolation was performed as described before (Königshoff et al., 2009). 
2.2.1.5 Subculturing and cryopreservation of mammalian cells 
In general, all cell lines and primary cells were subcultured after reaching confluency of about 
80-90%. In the meantime, culture medium was exchanged every 3-4 days. For subculturing, 
adherent cells were washed with pre-warmed PBS and incubated with Trypsin-EDTA (0.25%) at 
37°C under humidified atmosphere containing 5% CO2 for 2-4 minutes. After incubation, 
detachment of cells by trypsin digestion was monitored under the light microscope. Digestion 
was stopped by adding culture medium and the cell suspension then was split in a ratio of five 
to ten, depending on the cell type and individual growth. 
For cryopreservation, cells were harvested by trypsin digestion as described above and 
collected in cell specific culture medium. Cell pellets were obtained by centrifugation and 
resuspended in culture medium containing 20% FBS and 10% DMSO at a concentration of 
1-2x106 cells/ml. Cryovials were filled, each with 1 ml of cell suspension and slowly frozen in a 
Nalgene freezing container at -80°C for 24 hours. For long-term storage, cells were kept in liquid 
nitrogen. 
2.2.1.6 Gene silencing of lung fibroblasts 
Partial gene knockdown experiments of murine Rpn6 in CCL-206 mouse lung fibroblasts and of 
human Rpn6 in phLF were performed by reverse liposomal transfection of small interfering RNA 
(siRNA) using the Lipofectamine RNAiMAX system. For that, CCL-206 and phLF cells were 
seeded in transfection medium at a density of 4-5x105 cells per 10 cm dish and cultured 
overnight. Transfection of CCl-206 fibroblasts was performed by using the Silencer Select 
s87417 siRNA for knockdown of murine Rpn6 in a final concentration of 0.1 nM. Silencer Select 
s11413 siRNA alone or a pool of Silencer Select siRNAs s11413, s11414, and s11415 was 
used for knocking down human Rpn6 in phLF at a final concentration of 0.5 nM siRNA. The 
control siRNA Silencer Select Control#2 was used as a control for mouse and human single 
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siRNA knockdown and a pool of Silencer Select Control#1 and #2 was used as a control for 
pooled Rpn6 siRNA experiments.  
Rpn6 siRNA and Control siRNA were diluted with Opti-MEM, taking into account the final siRNA 
concentration of 0.1 nM for mouse and 0.5 nM for human Rpn6 siRNA, gently mixed with 
Lipofectamine RNAiMAX (10 µl/ml), and incubated for 15 minutes at room temperature to allow 
formation or siRNA-liposome complexes. Cells were trypsinized and resuspended in culture 
medium without penicillin/streptomycin and cell suspension was transferred to 10 cm culture 
dishes at a concentration of 4-5x105 cells per dish. The siRNA-Lipofectamine RNAiMAX-mix 
was added to every dish and gently mixed with the cell suspension. Cells were incubated for 
24 hours.  
For investigation of Rpn6 knockdown effects in phLF, transfection medium was exchanged with 
culture medium after 24 hours and phLF were incubated for additional 48 hours. Then they were 
harvested by trypsinization and cell pellets were snap frozen in liquid nitrogen until further 
investigation. 
To examine TGF-β effects upon Rpn6 knockdown, transfection medium of CCl-206 and phLF 
was removed after 24 hours and replaced with reduced culture medium, containing 1% FBS and 
5 ng/ml TGF-β. Cells were harvested 48 hours after TGF-β treatment. 
2.2.1.7 MTT assay 
Cell viability in response to proteasome inhibitors was analyzed applying the 3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. In this colorimetric assay, the water 
soluble yellow tetrazolium salt is taken up by viable cells and reduced to its purple insoluble 
formazan by mitochondrial dehydrogenases. Formazan crystals are soluble in acidified 
isopropanol and light absorbance of the solution can be measured colorimetrically. The 
extension of tetrazolium-formazan reduction can be used as indirect indicator for the amount of 
viable cells. 
Here, 5×104 cells (pmLF, A549) per well were seeded in 24-well plates or 25x104 cells (pmATII) 
were seeded in 48-well plates. The next day, cells were incubated with different concentrations 
of oprozomib or bortezomib for up to 72 hours (pmLF, A549) or up to 52 hours (pmATII). Then, 
100 μl 5 mg/ml MTT dissolved in PBS was added to each well and cells were incubated at 37°C 
for 1 hour to allow reduction of the tetrazolium dye to its formazan within the cell. After 
aspiration of the supernatant, the purple formazan crystals were dissolved in isopropanol 
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containing 0.1% Triton X-100 and solution was transferred to transparent 96 well plates. 
Absorbance was measured at 570 nm in a Tristar LB 941 plate reader. 
2.2.1.8 Immunofluorescence staining 
Primary murine lung fibroblasts were cultured at a density of 5000 cells per 0.32 cm2 (96 well 
plate) in culture medium. The next day, cells were incubated for 72 hours with 50 nM or 100 nM 
of oprozomib or DMSO as control. For growth factor treatment cells were incubated with 5 ng/ml 
of TGF-β for 24 hours in starvation medium containing 1% FBS. 50 nM of oprozomib was added 
and immunofluorescence staining was performed 24 hours later. Cells were then washed with 
PBS and fixed with 4% paraformaldehyde (PFA), washed again and permeabilized with 0.25% 
Triton X-100. After further washing, primary antibody for collagen I was added for 1 hour. 
Secondary antibody Alexa Fluor 488 was added after washing and incubated for additional 
45 minutes in darkness. Phalloidin Alexa Fluor 568 and DAPI staining was performed and finally 
cells were fixed with 4% PFA and stored at 4°C in the dark. Imaging was performed by 
fluorescent microscopy (LSM710 System). 
2.2.1.9 BrdU cell proliferation assay 
A colorimetric BrdU cell proliferation assay (Roche) was performed according to the 
manufacturer’s protocol. For that, pmLF or CCL206 fibroblasts were plated at a density of 
5000 cells or 2000 cells per 0.32 cm2 (96 well plate) in their culture medium, respectively. 
Treatment with oprozomib, siRNA or TGF-β was performed as described in chapters 2.2.1.6 
and 2.2.1.7. To assay changes in proliferation, cells were then labeled by adding BrdU at a final 
concentration of 10 µM to the medium and incubated for 2-4 hours to allow BrdU incorporation 
into the DNA. Then the medium was removed, cells were dried at room temperature, and stored 
at 4°C overnight. The next day, cells were fixed and DNA was denatured by adding the 
FixDenat solution of the kit and incubated with anti-BrdU-POD antibody for 90 minutes at room 
temperature. Cells were washed and the substrate solution was added and converted by the 
anti-BrdU antibody conjugated peroxidase. The reaction was stopped after 30 minutes by 
adding H2SO4 at a final concentration of 0.2 M. Absorbance measurement was performed within 
5 minutes at 450 nm using the Tristar LB 941 plate reader. 
2.2.2 Animal experiments 
All animal experiments were conducted according to international guidelines and were approved 
by the local government for the administrative region of Upper Bavaria.  
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Pathogen-free female C57BL/6 mice (10-12 weeks old) were obtained from Charles River and 
pathogen-free female FVB wild type and FVB.129S6-Gt(ROSA)26Sortm2(HIF1A/luc)Kael/J reporter 
mice were obtained from Jackson Laboratory. All animals were housed in rooms maintained at 
constant temperature and humidity with a 12 hours light cycle. Animals were allowed food and 
water ad libitum.  
Prior sacrifice, mice were narcotised by i.p. administration of 100 mg/ml ketamine and 0.7 mg/ml 
rompun per kg body weight and lung function measurement was performed in some animals 
using the Flexivent system. Subsequently, animals were sacrificed by exsanguination and lungs 
and trachea were exposed. Bronchoalveolar lavage (BAL) was performed by inserting a cannula 
into the trachea and lungs were lavaged four times with 0.5 ml of sterile PBS supplemented with 
cOmplete® protease inhibitor cocktail. The combined BAL fluid then was centrifuged at 400 x g 
and the obtained cell pellet was resuspended in RPMI 1640 medium supplemented with 10% 
FBS. Total cell counts were determined in a hemocytometer via Trypan Blue exclusion. Cell 
suspension then was subjected to a Cytospin 2 centrifuge to transfer BAL cells on glass slides. 
May-Grünwald-Giemsa-staining was performed and 200 cells per sample were counted and 
distinguished using morphological criteria. 
Then lungs were perfused with PBS and right lungs were snap frozen in liquid nitrogen for 
further analysis of mRNA and protein. Left lungs were infused with 4% PFA via the left main 
bronchus and submerged in 4% PFA for at least 24 hours. Paraffin embedding was performed 
using the tissue processor Microm STP 420 D. Sections of 3 µm were cut using a Hyrax M55 
microtome, mounted on glass slides, and stored at 4°C until further preparation. 
Animal experiments were performed in collaboration with the research groups of Prof. Dr. Oliver 
Eickelberg (OE) and Dr. Tobias Stöger (TS).  
Experimental design and organisation: Dr. Silke Meiners, Nora Semren 
Bleomycin instillation: David Kutschke (Technician, TS), Isis Fernandez (Postdoc, OE), Nora 
Semren, Nunja Habel-Ungewitter (PhD student, TS), Constanze Heise (Technician, OE) 
Proteasome inhibitor treatment: Nora Semren, David Kutschke, Nunja Habel-Ungewitter, Isis 
Fernandez 
Sacrifice, organ extraction: Nora Semren, Isis Fernandez, Nunja Habel-Ungewitter, David 
Kutschke, Constanze Heise, Daniela Dietel (Technician, OE) 
Sample preparation and analysis: Nora Semren 
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2.2.2.1 Bleomycin mouse model for pulmonary fibrosis 
For bleomycin application, mice were narcotized by i.p. administration of 0.2 mg/ml 
medetomidin, 2.0 mg/ml midazolam and 0.02 mg/ml fentanyl per kg body weight (MMF 
narcosis). Then, 50 µl of bleomycin (3 U/kg), dissolved in sterile PBS, were intratracheally 
instilled into the lungs using the Micro Sprayer Aerosolizer, Model IA-1C as published before 
(Aumiller et al., 2013). Control mice were instilled with 50 µl of PBS.  
MMF narcosis was antagonized by s.c. administration of 0.29 mg/ml atipamezole, 0.059 mg/ml 
flumazenil and 0.14 mg/ml naloxone per kg body weight. 
2.2.2.2 Proteasome inhibitor treatment 
For initial dose finding female FVB wild type mice were used. Oprozomib was suspended in a 
solution of 0.1 % Pluronic F-127 in Milli-Q water and applied once via intratracheal instillation 
under MMF narcosis and subsequent s.c. administration of antagonist as described for 
bleomycin application in chapter 2.2.2.1. Mice were sacrificed 24 hours or 96 hours after 
proteasome inhibitor application. 
Validation of antifibrotic effects was performed in FVB.129S6-Gt(ROSA)26Sortm2(HIF1A/luc)Kael/J 
reporter mice or in C57BL/6 mice. Pulmonary fibrosis was induced as described under 2.2.2.1 
and oprozomib was either instilled intratracheally into the lungs as described for FVB wild type 
mice or applied orally using a gavage needle. For oral application oprozomib was suspended in 
1% carboxymethyl cellulose (CMC). Oral application was performed without narcosis. Detailed 
treatment schemes of different animal experiments are given in the results part. 
2.2.2.3 Hematoxylin & Eosin staining 
Paraffin embedded lung sections were incubated at 60°C for at least 30 minutes, deparaffinized 
in xylene twice for 5 minutes, rehydrated in a graded alcohol series (ethanol 99.8% twice 1 
minute; 90% 1 minute; 80% 1 minute; 70% 1 minute) and transferred in distilled water by using 
the robot stainer Microm HMS 740. Subsequently, hematoxylin and eosin (H&E) staining was 
performed. For that, slices were incubated in Hemalaun for 6 minutes, washed in distilled water 
and transferred into a solution of 0.5% Eosin G in water containing one drop of acidic acid per 
100 ml and incubated for 10 minutes. Sections were washed in distilled water, stepwise 
dehydrated in ascending ethanol series (ethanol 70% 1 minute; 80% 1 minute; 90% 1 minute; 
99.8% twice 1 minute) and transferred in xylene by two incubation steps of 5 minutes each. 
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Sections were mounted using Entellan. For imaging, sections were scanned in by a MiraxScan 
and analyzed using the Panoramic Viewer software. 
2.2.2.4 Immunofluorescence staining 
For immunofluorescence staining, paraffin-embedded lung tissue sections were heated and 
rehydrated as described in chapter 2.2.2.3. Antigen retrieval was performed in citrate buffer (pH 
6.0) for 30 seconds at 125°C and 10 seconds at 90°C. Slides were blocked with 5% BSA to 
avoid unspecific antibody binding and primary antibodies against Collagen I and αSMA were 
applied on tissue slides. Slides were washed with Tris buffer and incubated with secondary 
antibodies Alexa Fluor 568 anti-rabbit (Coll-I) and Alexa Fluor 488 anti-mouse (αSMA) for 1 hour 
in darkness. Counterstaining with DAPI was performed and slides were covered with 
Fluorescent Mounting Medium. Imaging was performed by fluorescent microscopy using the 
LSM710 System. 
2.2.2.5 Immunohistochemistry 
Immunohistochemistry of bleomycin challenged mouse lungs was performed by Dr. Martina 
Korfei in collaboration with the group of Prof. Dr. Andreas Günther of the “Universities of 
Giessen and Marburg Lung Center” (UGMLC). 
2.2.3 Human lung tissue 
Tissue samples of explanted human lungs were provided by the “Universities of Giessen and 
Marburg Lung Center” (UGMLC) and processed in the laboratory of Prof. Dr. Andreas Günther. 
For that, explanted lungs or lobes were obtained from the Department of Thoracic Surgery, 
Vienna. Tissue samples from the subpleural region of the lungs were used and diagnosis of IPF 
was retrospectively validated by A. Günther and an expert pathologist using current American 
Thoracic Society/European Respiratory Society guidelines (Travis et al., 2002). The study 
protocol was approved by the Ethics Committee of the Justus-Liebig-University School of 
Medicine (No. 31/93, 84/93, 29/01) and the University of Vienna Hospital ethics committee (EK-
Nr 076/2009). 
2.2.3.1 Immunohistochemistry 
Immunohistochemistry of human and mouse lungs was performed and analyzed by Dr. Martina 
Korfei in collaboration with the group of Prof. Dr. Andreas Günther of the “Universities of 
Giessen and Marburg Lung Center” (UGMLC). 
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IHC was performed for 10 IPF and 6 control lung tissue samples. Furthermore, lungs of 3 PBS 
treated control animals and 14 bleomycin challenged animals (4 animals after 7 days, 6 animals 
after 14 days and 4 animals after 56 days of bleomycin instillation) were analyzed. 
2.2.4 Proteinbiochemistry 
2.2.4.1 Protein extraction from cells and tissue 
Prior protein extraction, cells were harvested by trypsin digestion, collected in culture medium, 
centrifuged, and washed with PBS. Cell pellets were snap-frozen in liquid nitrogen.  
For disintegration, frozen mouse or human tissue samples were transferred into dismembrator 
vials containing a grinding ball and applied to the shaking flask of a Mikro-Dismembrator S. A 
shaking frequency of 3000 RPM was applied two times for 30 seconds to provide disruption and 
mixing of the tissue to obtain a homogenous tissue powder. To avoid thawing, samples were 
frequently submerged in liquid nitrogen.  
Hypoosmotic protein extraction or extraction with TSDG buffer (composition of lysis solutions 
are described in Table 2.3) was performed to maintain native proteasome complexes and 
preserve their activity as detergents like SDS are known to activate the proteasome by opening 
of the entry pore (Shibatani & Ward, 1995). Cell pellets or frozen tissue powder were suspended 
in hypoosmotic lysis solution or TSDG buffer. Lysis was performed by 5-7 freeze and thaw 
cycles by repeatedly subjecting sample tubes to liquid nitrogen and warm water of 37°C. Cell 
debris and non-soluble fractions were removed by centrifugation (15000 g, 4°C, 30 minutes) 
and supernatants were collected for further analysis. 
For RIPA lysis, cell pellets or frozen tissue powder were suspended in RIPA buffer (Table 2.3) 
and incubated on ice for 30 minutes to allow cell lysis. Regular shaking of the tubes during 
incubation promoted maximal protein extraction. Cell debris and non-soluble fractions were 
removed by centrifugation (15000 g, 4°C, 30 minutes) and supernatants were collected for 
further analysis. 
2.2.4.2 Protein quantification by bicinchoninic acid assay (BCA)  
To quantify protein concentrations in cell and tissue lysates the Pierce BCA kit was used 
according to the manufacturer’s protocol. Lysates were diluted 1:5 in PBS and 25 µl of this 
dilution was mixed in a 96 well plate with 200 µl working reagent provided by the kit. Bovine 
serum albumin standards of known concentrations were assayed on the same plate to obtain a 
standard curve for final protein quantification. Sample plates were incubated for 30 minutes at 
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37°C for optimal color development and absorbance was measured at a wavelength of 562 nm 
using the Sunrise Plate Reader. 
2.2.4.3 Proteasome activity assay 
Chymotrypsin-like, trypsin-like and caspase-like proteasome activities were determined in cell 
and tissue lysates applying the Proteasome-Glo Assay kit according to the manufacturer’s 
protocol. For that, hypoosmotic lysates were diluted to 0.12-0.2 µg/µl and 25 µl of this dilution 
was mixed with the same volume of reaction buffer, provided by the kit, in a white 96 well 
microplate. Three different reaction buffers were provided by the assay to measure 
chymotrypsin-like, trypsin-like and caspase-like proteasome activities. These buffers contain 
specific luminogenic substrates (Suc-LLVY-aminoluciferin for CT-L, Z-LLR-aminoluciferin for T-L 
and Z-nLPnLD-aminoluciferin for C-L activity, respectively) for each active site that are cleaved 
to release aminoluciferin, which is transformed by luciferase to produce a luminescent signal 
(Figure 2.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Proteasome activity assay 
Suc-LLVY-, Z-LRR- or Z-nLPnLD-aminoluciferase are specific substrates of the CT-L, T-L or C-L active sites, 
respectively. Substrate cleavage by the proteasome releases aminoluciferin which is then transformed by 
luciferase. This reaction leads to light emission which is directly proportional to the rate of substrate cleavage 
by the proteaseome. (Taken from Moravec et al. 2009)~modified 
 
 Light 
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The microplate was subjected to a Tristar LB941 plate reader immediately after addition of the 
reaction buffer and luminescent signal was measured every 2 minutes for 30 minutes. For final 
analysis, values were obtained after 10-20 minutes of reaction, when light emission reached a 
plateau. Data are shown as relative values to the activity of untreated controls of the same 
experiment. In cell culture experiments, the control of each experiment and in animal 
experiments the average value of control groups is set as one. 
2.2.4.4 Native gel analysis 
Native gel electrophoresis was performed using the XCell SureLock Mini-Cell system. 18-40 µg 
protein per sample from hypoosmotic or TSDG lysates, respectively, were loaded on gradient 
(3-8% acrylamide) tris-acetate NuPAGE Novex gels and proteasome complexes were 
separated in running buffer (composition of all buffers are described in Table 2.4) for 4 hours at 
150 V and 4°C. Subsequently, native gels were incubated for 30 minutes at 37°C in proteasome 
activity reaction buffer containing 50 µM Suc-LLVY-AMC, a fluorogenic, synthetic peptide 
substrate of the chymotrypsin-like activity of the proteasome and gently washed in 50 mM Tris 
buffer. Gels were imaged at an excitation wavelength of 380 nm and emission wavelength of 
460 nm using the ChemiDoc XRS+ system. Subsequently, gels were soaked in solubilisation 
buffer for 10-15 minutes and blotted onto methanol activated polyvinylidene difluoride (PVDF) 
membranes for 1.5 hours at 250 mA and 4°C using the Mini Protean Tetra electrophoretic 
transfer cell. Subsequently, membranes were blocked with Roti®-Block for at least 1 hour and 
incubated with primary antibody, diluted in Roti®-Block, overnight at 4°C under constant 
shaking. The next day, membranes were washed three times for 10 minutes with PBST and 
incubated with HRP-linked secondary antibody for 1 hour at room temperature under constant 
shaking. Membranes were washed once more and chemiluminescence was generated by 
applying ECL Plus Detection Reagent for normal or SuperSignal West Femto Maximum 
Sensitivity Substrate for weak signals followed by exposure of Kodak X-Omat LS films and 
development of films in a Curix 60 developer or with the ChemiDoc XRS+. Quantification of in-
gel proteasome activity and immunoblotted bands were analyzed with the volume tool of Image 
Lab software and normalized to non-treated controls. 
To assay luciferase activity, native gels were soaked in luciferase reaction buffer and 
luminescence was imaged for 30 minutes using the ChemiDoc XRS+. Afterwards gels were 
washed with 50 nM Tris and in-gel proteasome activity was assayed as described above. To 
determine total protein concentrations within the gel, gels were soaked in PageBlue Protein 
Staining Solution, microwaved for 1 minute and washed several times with deionized water. 
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ABP labeling experiments were performed by Vanessa Welk (PhD Student, 2015). For labeling 
of active proteasomes, the pan-reactive proteasome ABP MV151 was used (Verdoes et al., 
2006). TSDG buffer lysates of whole human lung tissue were diluted with ABP labeling buffer to 
a total protein concentration of 0.5 µg/µl. 30 µl of sample were incubated with 0.5 µM MV151 for 
1 hour at 37°C and subsequently quenched by the addition of 1x sample buffer. Native gel 
separation was performed as described above and proteasome activity was visualized using a 
fluorescent scanner Typhoon TRIO+. Images were taken at 450 PTM and 50 µm pixel 
resolution with fluorescence Cy3/TAMRA. 
2.2.4.5 SDS-PAGE and Western blotting 
Protein samples (hypoosmotic, RIPA or TSDG lysates) were mixed with Lämmli loading buffer 
(compositions of all buffers are described in Table 2.5) and cooked at 95°C for 5 minutes. 
Samples were cooled down and 15-20 µg of protein per sample were loaded onto 10% 
SDS-PAGE gels. Electrophoresis was performed at 100-110 V in running buffer and gels were 
subsequently blotted onto methanol activated PVDF membranes for 90 minutes at 250 mA and 
4°C in transfer buffer using the Mini Protean Tetra electrophoretic transfer cell. Proteins of 
interest were detected by standard immunodetection techniques applying primary and 
HRP-linked secondary antibodies as described in chapter 2.2.4.4. β-actin was used as loading 
control. For densitometric analysis protein bands were quantified using the volume tool of Image 
Lab software and normalized to their β-actin protein bands. 
2.2.4.6 Luciferase assay 
pmLF, isolated from FVB.129S6-Gt(ROSA)26Sortm2(HIF1A/luc)Kael/J mice as described in 2.2.1.3, 
were seeded at a density of 5000 cells per 0.32 cm2 (96 well plate) in culture medium and 
treated with different concentrations of oprozomib the next day. 24 hours later, luciferase activity 
was assayed using the Bright-Glo system according to the manufacturer’s protocol. For that, 
cells were lysed in 50 µl of Glo-Lysis buffer per well. 20 µl of cell lysate was then transferred into 
a white walled 96 well plate and 20 µl of Bright-Glo-Luciferase was added to each well. 
Luminescence was measured immediately using a Tristar LB 941 plate reader. 
2.2.5 RNA analysis 
2.2.5.1 mRNA extraction 
Total RNA from cells was prepared using the Roti-Quick Kit according to manufacturer’s 
protocol, which is based on the acid guanidinium thiocyanate-phenol-chloroform method for total 
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RNA extraction (Chomczynski & Sacchi, 1987). Frozen cell pellets were lysed in 500 µl 
Roti-Quick 1 and 650 µl cold Roti-Quick 2 was added and mixed by vortexing of the sample tube 
to allow RNA extraction by phase separation. Samples were incubated on ice for 10 minutes 
and subsequently centrifuged for 15 minutes at 10000 rpm and 4°C to separate RNA. Two 
phases were clearly separated and the upper water phase, containing RNA, was collected, 500 
µl Roti-Quick 3 was added, and gently mixed. Samples were incubated for 40 minutes at -20°C 
to precipitate RNA, which was finally sedimented via centrifugation for 20 minutes at 13.000 and 
4°C. RNA pellets were washed with ethanol 70% three times and ethanol was removed via 
evaporation. Finally RNA was dissolved in Milli-Q water.  
Frozen human or mouse tissue was grinded to powder as described in 2.2.4.1. Tissue powder 
was suspended in Roti-Quick 1 and incubated on ice as described above to allow cell lysis, 
Roti-Quick 2 was added, and RNA extraction via phase separation was performed. In a next 
step, RNA was purified using the Peqlab-Gold Total RNA-Kit according to the manufacturer’s 
protocol starting with loading of the prepared RNA extract onto RNA-binding columns.  
RNA concentrations were assessed via absorbance measurement at 260 nm using a 
NanoDrop 1000.  
2.2.5.2 Reverse transcription of mRNA into cDNA 
For reverse transcription of RNA into cDNA, 1 µg of sample RNA was mixed with 2 µl of 
Random Hexamers (250 µM) and Milli-Q water was added to a final volume of 11.5 µl. Samples 
were incubated at 70°C for 10 minutes and immediately placed on ice. 8.5 µl master mix was 
added to every preparation to obtain a final concentration of 1x First Strand Buffer, 10 mM DTT, 
0.5 mM dNTP’s, 1 U/µl RNAsin RNAse Inhibitor, 10 U/µl M-MLV Transcriptase. Reverse 
transcription was performed using a Mastercycler Nexus applying the following settings: 
Annealing 5 minutes at 25°C, elongation 60 minutes at 37°C. 
Finally, DNAse was added to the cDNA at a final concentration of 0.05 U/µl and genomic DNA 
was digested by incubation of the samples for 15 minutes at 37°C. Subsequently, DNAse was 
heat-inactivated for 10 minutes at 75°C and cDNA was diluted 1:5 with Milli-Q water.  
2.2.5.3 Quantitative polymerase chain reaction (qPCR) 
For quantitative PCR reactions, the SYBR Green LC480 System was used. Per sample, 
2.5 µl cDNA solution was mixed with 5 µl of LC480 SYBR Green I Master mix and 2.5 µl primer 
mix was added, containing forward and reverse primer at a final concentration of 0.5-0.75 µM 
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(primer sequences are listed in Table 2.16). qPCR was performed in duplicates per sample in a 
LightCycler 480II applying standard conditions: 95°C for 5 minutes for initial denaturation were 
followed by 45 cycles of 95°C for 5 seconds (denaturation), 59°C for 5 seconds (annealing), 
72°C for 20 seconds (elongation), 60-95°C for 1 minute with continuous acquisition (melting 
curve). Expression of target genes was normalized to the hypoxanthine phosphoribosyl 
transferase gene (HPRT) or the 60S ribosomal protein L19 as a housekeeping gene. 
2.2.6 Statistics  
Data are presented as means ± SEMs as indicated in the figure legends and were considered 
statistically significant when p ≤ 0.05 (*p ≤ 0.05, **p < 0.01, ***p < 0.001). Data were analyzed 
using Prism 5 software. Statistical analysis was performed using one-way ANOVA, followed by 
Post-hoc testing for multiple comparisons (Bonferroni-Holmes or Dunnett’s test), Mann-Whitney 
t-test, two-tailed paired t-test or Spearman correlation as indicated in the figure legends. Dixon 
outlier test was performed. 
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3 RESULTS 
In this study, proteasome activity and composition was analyzed during myofibroblast 
differentiation and fibrotic lung remodeling to evaluate a possible role of the proteasome as a 
trigger of IPF. To further validate the proteasome as a target in lung fibrosis, a novel second-
generation inhibitor, oprozomib, was tested for therapeutic effects in the bleomycin mouse 
model of pulmonary fibrosis. 
3.1 The Proteasome as a Trigger of IPF 
This chapter is based on the following manuscript: 
Nora Semren, Vanessa Welk, Martina Korfei, Ilona E. Keller, Isis E. Fernandez, Heiko Adler, 
Andreas Günther, Oliver Eickelberg, and Silke Meiners. Regulation of 26S proteasome activity 
in pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine, 2015 
Nov;192(9):1089-1101. 
 
The ubiquitin-proteasome system is critical for maintenance of intracellular homeostasis by 
degrading proteins in a spatially and timely controlled manner. During fibrotic tissue remodeling, 
cell and protein homeostasis are altered. A contribution of the proteasome to the development 
of pulmonary fibrosis, however, is unknown. Therefore it was hypothesized that proteasome 
function is altered in fibrotic lung remodeling and adds to the pathogenesis of IPF. 
To investigate a possible role of the proteasome in profibrotic TGF-β signaling, the murine lung 
fibroblast line CCL-206 was stimulated with TGF-β to induce myofibroblast differentiation. After 
serum starvation, fibroblasts were incubated with 5 ng/ml of TGF-β for 6, 24 and 48 hours to 
analyze short and long-term effects on the proteasome. Proteasome activity was measured in 
hypoosmotic cell lysates to preserve cellular proteasome function, as detergents such as SDS, 
which are present in many lysis buffers, are known to activate the proteasome (Coux et al., 
1996). The chymotrypsin-like active site was analyzed as it is regarded as the most important 
proteolytic site of the proteasome (Marques et al., 2009). For that, cell lysates were incubated 
with the chymotrypsin-like site specific luminogenic substrate Suc-LLVY-aminoluciferin, which 
generates a luminescent signal via the luciferase reaction after cleavage by the proteasome 
(Moravec et al., 2009) (Figure 2.1). 
A significant elevation of the chymotrypsin-like activity was observed after 24 hours of 
The Proteasome as a Trigger of IPF 
 
 
 
50 
TGF-β treatment, which further increased within 48 hours compared to untreated fibroblasts 
(Figure 3.1A). This activation of the proteasome by TGF-β could be counteracted by subsequent 
treatment with the proteasome inhibitor bortezomib for 1.5 hours before cell lysis, confirming the 
specificity of the activity assay for the proteasome (Figure 3.1B). 
 
 
 
 
 
 
 
 
 
 
 
Levels of proteins, which are tagged with K48-linked polyubiquitin chains, were measured by 
Western blot analysis as their accumulation here can be regarded as an indicator for induced 
protein degradation in response to elevated protein turnover. Therefore, a significant increase in 
K48-polyubiquitinated proteins in response to 48 hours of TGF-β treatment here confirmed 
TGF-β-induced activation of proteasomal substrate turnover (Figure 3.2). 
 
 
 
 
 
 
 
 
Figure 3.1: TGF-β increases proteasome activity in lung fibroblasts 
CT-L activity in cell lysates of CCL-206 fibroblasts treated with TGF-β for (A) 6h, 24h and 48h (Mean ± SEM. 
n=4 for 6h and 24h, n=7 for 48h. One-way ANOVA, Dunnett‘s Multiple Comparison Test) or for (B) 48h and 
additional incubation with bortezomib (BZ) 10 nM for 1.5h (Mean ± SEM. n=4. One-way ANOVA, Bonferroni‘s 
Multiple Comparison Test). 
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Figure 3.2. TGF-β increases protein turnover in CCL-206 fibroblasts 
Western blot and densitometric analysis of hypoosmotic lysates of CCL-206 fibroblasts treated with TGF-β for 
48h (Mean ± SEM. n=3. Paired t-test). 
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3.1.1 TGF-β increases formation of highly active 26S/30S proteasomes 
To dissect different proteasome complexes, native gel analysis was performed. Hypoosmotic 
lysates were loaded on native gels and electrophoresis was performed at 4°C. In this setup, 
proteasomes are separated as native, functional, whole complexes and their enzymatic activity 
can be assayed (Elsasser et al., 2005). In-gel proteasome activity can be assessed by overlay 
of gels with fluorogenic substrates. Proteasome activity was visualized by enzymatic cleavage 
of the chymotrypsin-like site-specific substrate Suc-LLVY-AMC, which, upon cleavage, releases 
the fluorophore 7-amino-4-methylcoumarin in a similar manner as described for the luminogenic 
substrates before (Figure 2.1). Using this method, different proteasome complexes (30S, 26S 
and 20S complexes) could be separated. In a next step, gels were immunoblotted for the α1-7 
subunits of the 20S CP and 19S ATPase Rpt5. In TGF-β stimulated cells, a significant increase 
in formation of highly active 26S and 30S complexes was observed, which might contribute to 
the previously observed elevation of protein degradation rates by the proteasome (Figure 3.3). 
 
 
 
 
 
 
 
 
 
Figure 3.3. TGF-β increases formation of highly active 26S and 30S proteasomes 
Native gel analysis and immunoblotting of hypoosmotic cell lysates of CCL-206 fibroblasts after treatment with 
TGF-β for 48h and densitometric analysis of 26S/30S complexes obtained from α1-7 immunoblots (Mean ± 
SEM. n=3. Paired t-test). 
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3.1.2 Formation of 26S/30S proteasomes is regulated by the 19S subunit Rpn6 
In a next step, it was analyzed whether Rpn6, a 19S subunit which is rate-limiting for 26S 
formation (Vilchez, Boyer, et al., 2012; Vilchez, Morantte, et al., 2012), might also mediate 
TGF-β-induced assembly of 26S and 30S proteasome complexes.  
Expression of Rpn6, Rpt5 and α1-7 subunits was analyzed by Western blot. Rpn6 protein levels 
were clearly increased after 48 hours of TGF-β treatment. This induction was not observed for 
the 19S ATPase subunit Rpt5 or the 20S subunits α1-7 (Figure 3.4A). Furthermore, 
immunofluorescence staining showed an increased cytoplasmic distribution of Rpn6 in TGF-β 
treated lung fibroblasts (Figure 3.4B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To validate whether Rpn6 is involved in TGF-β mediated formation of 26S and 30S 
proteasomes, a partial knockdown of Rpn6 was performed in CCL-206 murine lung fibroblasts 
and proteasome complexes were analyzed in response to 48 hours of TGF-β treatment. Partial 
knockdown of approximately 40% of Rpn6 was well tolerated (Figure 3.5A and B) whereas 
higher knockdown efficiencies resulted in cell death (data not shown), which is probably 
Figure 3.4. TGF-β increases expression of Rpn6 
(A) Western blot and densitometric analysis of hypoosmotic cell lysates of CCL-206 fibroblasts treated with 
TGF-β for 48h (Mean ± SEM. n=3. One-way ANOVA, Dunnett‘s Multiple Comparison Test). 
(B) Immunostaining of CCL-206 fibroblasts after treatment with TGF-β for 48h. Green: Rpn6; red: Phalloidin 
(F-actin); blue: Dapi (Nucleus) (scale bars for 20x=50 µm and 63x=20 µm). 
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triggered by the incapacity of the cell to provide enough 26S/30S proteasomes for protein 
degradation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Rpn6 mediates formation of 26S and 30S proteasomes 
(A) Western blot of hypoosmotic cell lysates of CCL-206 fibroblasts after knockdown of Rpn6 followed by 
treatment with TGF-β for 48h and densitometric analysis of Rpn6 protein expression (Mean ± SEM. n=4. 
One-way ANOVA Bonferroni‘s Multiple Comparison Test). (B) Morphological changes of CCL-206 fibroblasts 
after Rpn6 silencing and TGF-β treatment. (C) Native gel analysis and immunoblotting of hypoosmotic cell 
lysates of CCL-206 fibroblasts after Rpn6 knockdown and treatment with TGF-β for 48h. 
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Partial knockdown of Rpn6 effectively counteracted TGF-β induced upregulation of Rpn6 
compared to control cells which had been transfected with scrambled siRNAs (Figure 3.5A). 
Moreover, Rpn6 silencing neutralized TGF-β-mediated assembly of 26S and 30S proteasome 
complexes, as determined by native gel activity assay and subsequent immunoblot analysis 
(Figure 3.5C). These data strongly propose that TGF-β induced upregulation of Rpn6 mediates 
increased assembly of 26S and 30S proteasome complexes. Higher amounts of 26S/30S 
proteasomes might be necessary during TGF-β mediated myofibroblast differentiation to adjust 
rates of ubiquitin-dependent protein degradation for a rapid disposal of unneeded proteins. 
3.1.3 26S proteasome activity is reversibly increased during fibrotic remodeling 
After verification of Rpn6 as a regulator of TGF-β-stimulated proteasome activation, proteasome 
activities were assayed in the bleomycin mouse model of lung fibrosis.  
In this study, whole lung tissue was assayed at day 7 (inflammatory phase), day 14 (fibrotic 
phase), and day 56 (physiologic state after resolution of fibrosis) after bleomycin instillation. 
Lung function was performed to monitor fibrotic remodeling and resolution of fibrosis and 
showed a significant decline during inflammation and ongoing fibrotic remodeling at day 7 and in 
fibrotic lungs at day 14 post-bleomycin. Lung function was restored after resolution of fibrosis at 
day 56 (Figure 3.6A).  
To further validate fibrosis development at day 14 after bleomycin challenge, qRT-PCR was 
performed and significant elevation of mRNA levels of the fibrotic marker collagen I and 
fibronectin confirmed induction of fibrosis (Figure 3.6B). 
Proteasome activities were measured in whole lung lysates and revealed a pronounced 
increase in substrate cleavage by all three active sites during the early inflammatory phase at 
day 7 and in fibrotic lungs at day 14. This increase in proteasome activities, however, 
normalized to levels of control animals at day 56 when fibrosis was resolved (Figure 3.7A, B, 
and C). 
Alterations in proteasome activities thus closely followed the course of adaptive lung damage 
and lung function decline in bleomycin-induced lung fibrosis. Native gel analysis of fibrotic lungs 
at day 14 showed that the observed increase in proteasomal activities was due to enhanced 
formation of 26S/30S proteasome complexes as corroborated by immunoblotting for the 
catalytic 20S subunit β1 and the 19S subunits Rpt5 and Rpn6 (Figure 3.7D). 
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Figure 3.6. Lung function and gene expression of profibrotic markers in the bleomycin mouse model 
(A) Compliance measurement at day 7, 14 and 56 after bleomycin treatment of C57BL/6N (Mean ± SEM. 
n=5-9 per group. Two-tailed Mann Whitney Test). (B) qRT-PCR analysis of whole lung tissue at day 14 after 
bleomycin challenge (Mean ± SEM. n=6 per group. Two-tailed Mann Whitney Test). Compliance 
measurement was performed by Isis Fernandez (Scientist CPC, 2014). 
Figure 3.7. Proteasome activities are increased in bleomycin-induced pulmonary fibrosis 
Proteasome activities of the (A) CT-L, (B) T-L and (C) C-L active sites in hypoosmotic lysates of whole lung 
tissues of C57BL/6N mice 7, 14 and 56 days after treatment with bleomycin (Mean ± SEM. n=5-15 per group. 
Two-tailed Mann Whitney Test, Dixons outlier test was performed and outlier is shown in brackets). (D) Native 
gel analysis and immunoblotting of hypoosmotic lysates of whole lung tissue at day 14 post-bleomycin 
instillation. 
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Moreover, Western blot analysis of these tissue lysates revealed significant upregulation of only 
Rpn6 in fibrotic mouse lungs while expression of 20S and other singular 19S subunits was not 
altered (Figure 3.8). 
 
 
 
 
 
 
 
 
 
To investigate a possible transcriptional regulation of the proteasome, qRT-PCR of several 
proteasome genes, including Rpn6, was performed in whole lung tissue of fibrotic animals 14 
days after bleomycin challenge. None of the investigated mRNAs coding for several 19S or 20S 
subunits revealed significant elevation in fibrotic mouse lungs suggesting that the increase in 
Rpn6 protein levels might be induced via protein stabilization rather than transcriptional 
regulation. 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. mRNA expression of several proteasomal subunits is not altered in bleomycin-induced 
pulmonary fibrosis 
qRT-PCR of whole lung tissue of animals 14 days after bleomycin instillation compared to PBS-treated 
controls (Mean ± SEM. n=6 per group. Two-tailed Mann Whitney Test). 
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Figure 3.8. Rpn6 expression is increased in fibrotic lungs 
Western blot and densitometric analysis of hypoosmotic lysates of whole lung tissue of C57BL/6N mice 14 
days after bleomycin instillation (Mean ± SEM. n=6 per group. Two-tailed Mann Whitney Test). Western blot 
was performed by Vanessa Welk (PhD student CPC, 2014). 
PhD student CPC, 2014). 
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To assess the dynamics and cellular source of Rpn6 expression in the course of reversible 
fibrotic remodeling, cellular composition of the lungs and expression of Rpn6 at days 7, 14 and 
56 after bleomycin instillation were analyzed in detail (Figure 3.10). 
For that, detailed histological analysis on the cellular composition of the lungs was performed. 
Serial sections of PBS control lungs and of lungs 7, 14 and 56 days after bleomycin challenge 
were Masson-Goldner stained for overall collagen deposition and extent of fibrosis, and 
immunostaining was performed for Rpn6, αSMA (myofibroblast and smooth muscle cell 
marker), and NK2 homeobox 1 (NKX2-1), also known as thyroid transcription factor 1 TTF1 
(marker for AECII and bronchiolar Clara cells). This analysis revealed a strikingly altered cellular 
composition of mouse lungs at days 7 and 14 after bleomycin challenge, which normalized 
almost completely to a physiological lung structure at day 56: While the histology of healthy 
lungs of PBS-treated control animals showed little collagen deposition and very low levels of 
Rpn6 expression, beginning of fibrotic remodeling, indicated by increased collagen deposition, 
was observed 7 days after bleomycin challenge. In addition, a pronounced increase in 
proliferation of AECII cells and bronchial Clara cells, a typical feature of fibrotic remodeling 
(Korfei et al., 2011), was observed. Interestingly, these highly active proliferating cells also 
showed pronounced expression of Rpn6 in the nucleus and cytoplasm. Inflammatory cells were 
also detectable at this time point, but they expressed only moderate levels of Rpn6. These data 
indicate that increased proteasome activity at day 7 might be mediated by highly proliferating 
AECII, which are widely regarded as key drivers of fibrotic remodeling in response to lung injury 
(King et al., 2011; Wynn, 2011). During the fibrotic phase at day 14 after bleomycin challenge, 
dense fibrosis was observed with strong deposition of collagen in the interstitial area. 
Hyperplastic AECII were found to be surrounded by dense fibrosis and strongly overexpressed 
Rpn6. Myofibroblasts were present as well and partially stained positive for Rpn6. Inflammatory 
lymphocytes showed also some expression of Rpn6. 
These data thus demonstrate that Rpn6 expression is upregulated in epithelial and fibroblast 
effector cells of reversible wound healing in the bleomycin model of lung fibrosis. Expression 
closely follows the course of proteasome activity suggesting that increased 26S/30S 
proteasome activity is responsible for the observed activation of the proteasome as shown for 
fibrotic lungs at day 14. 
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Figure 3.10. Rpn6 expression is upregulated in hyperplastic AECII, Clara cells and myofibroblasts 
during reversible fibrotic remodeling in bleomycin-induced pulmonary fibrosis 
Paraffin embedded lung sections of PBS-treated control animals or animals, which were sacrificed 7, 14 or 56 
days post-bleomycin, were analyzed by Masson-Goldner staining for fibrotic remodeling (red: keratin and 
muscle fibres; blue/green: collagen; pink: cytoplasm; brown/black: nucleus). Expression of αSMA 
(myofibroblasts and smooth muscle cells) and Rpn6 is indicated in red and expression of TTF1 (AECII and 
Clara cells) in brown color (arrows indicate Rpn6 positive hyperplastic AECII cells). Pictures show 
representative stainings from 3-6 animals per group. Staining was performed by Martina Korfei (Scientist 
UGMLC, 2014). 
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3.1.4 Rpn6 levels are upregulated in IPF lungs 
To investigate whether Rpn6 upregulation might also be relevant in IPF, fibrotic lung tissue 
samples of IPF patients were analyzed for expression of proteasome subunits. To confirm 
fibrosis in these samples, qRT-PCR analysis of fibrotic marker Acta (coding for αSMA) and 
collagen I was performed and showed a significant increase in lung tissue of IPF patients 
(Figure 3.11). 
 
 
 
 
 
 
 
 
 
The fibrotic marker αSMA was also used to reconfirm fibrosis in IPF lung tissue on protein level 
(Figure 3.12A). Indeed, Western blot analysis revealed a significant upregulation of Rpn6 and 
also Rpt5 in lung tissue of IPF patients compared to donor lungs. Expression of the 20S subunit 
α3, however, was not altered. Furthermore, levels of K48-ubiquitinated proteins were highly 
increased in IPF lungs (Figure 3.12A) and positively correlated with Rpn6 expression (Figure 
3.12B), indicating an elevated protein turnover in fibrotic lungs, which might be connected to 
higher expression levels of Rpn6 levels. 
To further investigate a possible regulation of proteasome function in fibrotic lungs, proteasome 
activity was assayed in donor and IPF lung tissues. For that, the proteasome activity-based 
probe (ABP) MV151 (Cravatt et al., 2008) was used and combined with native gel analysis to 
resolve the different complexes. ABPs covalently bind to the active sites of the proteasome and 
can be detected by their attached fluorescent tag, thus allowing quantification of active 
proteasome complexes. Proteasome activity was neither consistently inhibited nor activated in 
IPF lungs compared to donor tissue (Figure 3.13A), but in IPF samples, Rpn6 levels positively 
correlated with formation of 26S/30S proteasomes (Figure 3.13B). This was not evident in donor 
Figure 3.11. Gene expression of profibrotic marker in IPF lungs 
qRT-PCR analysis of whole lung tissue samples of 8 donors and 13 IPF patients (Mean ± SEM. n=8 donors 
and n=13 IPF patients. Two-tailed Mann Whitney Test). 
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samples and suggests some distinct activation of 26S proteasome activity in diseased IPF 
lungs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. Expression of Rpn6 and K48-polyubiquitinated proteins is increased in human IPF lungs 
(A) Western blot analysis of RIPA lysates of whole lung tissue of donor and IPF lungs. Expression of Rpn6, 
Rpt5, K48-polyubiquitinated proteins, αSMA, and the α3 subunit of the 20S proteasome was quantified by 
densitometry after normalization to β-actin (Mean ± SEM. n=11-13 per group. Two-tailed Mann Whitney Test). 
(B) Correlation analysis of normalized expression of K48-polyubiquitinated proteins and Rpn6 obtained from 
the Western blot data. Donor and IPF values were pooled (Two-tailed Spearman correlation, r=0.5079, 
p=0.0134). Western blot was performed by Vanessa Welk (PhD student CPC, 2014). 
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Increased Rpn6 expression in IPF lung tissue was further confirmed by histological analysis of 
donor and IPF lungs. Here, Rpn6 levels were highly elevated in pathologic myofibroblasts, 
abnormal hyperplastic basal cells, and smooth muscle cells, as revealed by co-staining with 
αSMA and the basal cell marker keratin 5 (KRT5), respectively (Figure 3.14). 
Figure 3.13. Rpn6 expression correlates with formation of active 26S/30S proteasomes in IPF lungs 
(A) ABP-labeling of proteasomes in whole lung extracts and subsequent native gel analysis (Donor 35 was 
excluded from analysis as a case of chronic thromboembolic pulmonary hypertonia). Samples were labeled 
and run in parallel on two gels and imaged at the same time to allow for comparable exposure and 
densitometric analysis of signals (Mean ± SEM. n=10 donors and n=13 IPF patients. Two-tailed Mann 
Whitney Test). (B) Separate correlation analysis of donor and IPF lungs for the amount of active 26S/30S 
proteasomes as obtained from densitometric analysis of ABP native gel analysis and β-actin normalized Rpn6 
expression levels obtained from the Western blot (Figure 3.12) (Two-tailed Spearman correlation, IPF 
r=0.6484, p=0.0165; Donor r=-0.1273, p=0.7092). Native gel blot was performed by Vanessa Welk (PhD 
student CPC, 2014). 
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Figure 3.14. Rpn6 is elevated in myofibroblasts and hyperplastic basal cells in human IPF lungs 
Immunohistochemistry of paraffin-embedded donor and IPF lung tissues stained for Rpn6, KRT5 (basal cells), 
or αSMA (smooth muscle cells and myofibroblasts). Pictures show representative stainings of 10 IPF and 6 
donor lungs. (red: Rpn6, αSMA, and KRT5; blue: Nuclei). Staining was performed by Martina Korfei (Scientist 
UGMLC, 2014). 
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Myofibroblasts and abnormal basal cells are hallmarks of pulmonary remodeling in IPF and not 
present in healthy donor lungs (Korfei et al., 2011). Therefore, non-fibrotic lungs of organ donors 
showed an overall weak expression of Rnp6 with higher level mainly in smooth muscle cells 
(Figure 3.14). 
Co-staining for K48-linked polyubiquitin revealed accumulation of polyubiquitinated proteins 
mainly in myofibroblasts and hyperplastic basal cells of IPF lungs. These cells also showed 
increased Rpn6 expression suggesting an enhanced turnover of polyubiquitinated proteins in 
areas of active fibrotic remodeling (Figure 3.15). In contrast to that, K48-linked polyubiquitinated 
proteins were hardly present in donor lungs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15. Levels of K48-polyubiquitinated proteins are increased and correlate with Rpn6 
upregulation in myofibroblasts and hyperplastic basal cells in human IPF lungs 
Immunohistochemistry of donor and IPF lungs stained for Rpn6 and K48-polyubiquitinated proteins (Ubi-K48) 
(red: Rpn6 and Ubi-K48, blue: Nuclei). Staining was performed by Martina Korfei (Scientist UGMLC, 2014). 
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To validate a possible transcriptional regulation of proteasomal genes in IPF, qRT-PCR analysis 
was performed for several subunits of the 19S and 20S proteasome (Figure 3.16). Confirming 
RNA data obtained from the bleomycin mouse model, no significant changes on mRNA level 
were observed in whole lung tissue samples of donors and IPF patients. This finding again 
points towards a posttranscriptional regulation of Rpn6. 
 
 
 
 
 
 
 
 
 
 
Enhanced levels of Rpn6 together with increased accumulation of polyubiquitinated proteins in 
tissue samples of IPF patients indicate increased protein turnover along with an overall 
upregulation of the ubiquitin-proteasome system in fibrotic IPF lungs. Further, elevated levels of 
Rpn6 and polyubiquitinated proteins in myofibroblasts and hyperplastic basal cells of IPF lungs 
propose an important role of increased protein turnover in these highly active cells, which might 
contribute to the pathogenesis of this disease. 
Figure 3.16. mRNA expression of proteasome subunits is not significantly altered in IPF lungs 
qRT-PCR analysis of whole lung tissue of donor and IPF lungs (Mean ± SEM. n=8 donors and n=13 IPF 
patients per group. Two-tailed Mann Whitney Test). 
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3.1.5 Silencing of Rpn6 counteracts profibrotic remodeling of human lung fibroblasts 
Next, it was investigated whether Rpn6-mediated induction of 26S/30S proteasome formation 
and increase in overall proteasome activity is involved in the implementation of TGF-β-mediated 
profibrotic effects like myofibroblast differentiation and proliferation. Treatment with TGF-β 
significantly induced proliferation of CCL-206 fibroblasts within 24 hours as shown by increased 
incorporation of BrdU into the DNA. Knockdown of Rpn6 alone had no effects on cellular growth 
but efficiently counteracted TGF-β-mediated induction of proliferation (Figure 3.17). 
 
 
 
 
 
 
 
 
 
 
 
Further experiments were performed in primary human lung fibroblast lines prepared from six 
healthy organ donors to perform specific Rpn6 knockdown in the absence and presence of 
TGF-β. Prior to these experiments Rpn6 siRNA was titrated to find an optimal well tolerated and 
non-toxic dose as a high knockdown efficiency and therefore extensive destruction of 26S/30S 
complexes resulted in increased cell death and morphological changes like elongation or 
formation of stress fibres (Figure 3.18). 
Partial Rpn6 knockdown of approximately 40% of physiological protein levels was achieved by 
transfection with a final concentration 0.5 nM siRNA and well tolerated by the cells as indicated 
by minor morphological changes (Figure 3.18).  
Knockdown experiments in phLF were conducted using a single siRNA and single control 
siRNA or a pool of three siRNAs and a pool of two control siRNAs at a final concentration of 
0.5 nM to counteract Rpn6 expression. Information about the particular siRNA treatment is 
Figure 3.17. Rpn6 knockdown counteracts TGF-β mediated induction in proliferation 
BrdU assay of CCL-206 fibroblasts treated for 48h with TGF-β starting 24h after Rpn6 knockdown (Mean ± 
SEM. n=3. One-way ANOVA, Bonferroni‘s Multiple Comparison Test). 
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given in each figure legend. 
 
 
 
 
 
 
 
 
 
40% reduction of Rpn6 already showed impairment of basal expression of the profibrotic marker 
collagen I and induced G1 cell cycle arrest as indicated by a clear increase in cyclin D1 (Figure 
3.19). This is well in accordance with the growth inhibitory effects observed upon silencing of 
Rpn6 in CCL-206 murine lung fibroblast as detected by BrdU incorporation before (Figure 3.17). 
Furthermore, accumulation of K48-polyubiquitinated proteins in response to Rpn6 knockdown 
confirmed reduced 26S/30S proteasome activity as a direct effect of impaired 26S/30S 
formation (Figure 3.19).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18. Morphological changes of primary human lung fibroblasts in response to Rpn6 knockdown 
phLF were transfected with different final concentrations of Rpn6 siRNA (single siRNA) and analyzed 72h after 
transfection. 
Figure 3.19. Rpn6 silencing reduces basal expression of myogenic marker in phLF 
Western blot and densitometric analysis of unstimulated primary human lung fibroblasts after partial 
knockdown of Rpn6 (single siRNA) (Mean ± SEM. n=6. Paired t-test, two-tailed). 
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To investigate whether Rpn6 silencing also counteracts TGF-β induced profibrotic effects, phLF 
were stimulated with TGF-β for 48 hours after Rpn6 knockdown. Knockdown efficiency was 
controlled on mRNA level. Rpn6 (here named PSMD11 to refer to the gene name) was 
significantly increased on mRNA level in response to TGF-β and could efficiently be knocked 
down by siRNAs to about 60% of baseline levels (Figure 3.20). 
 
 
 
 
 
 
 
 
 
 
Native gel analysis was performed and confirmed TGF-β-mediated induction of 26S/30S 
formation in phLF (Figure 3.21). Furthermore, 26S/30S formation could efficiently be 
counteracted by knockdown of Rpn6. 
 
 
 
 
 
 
 
 
 
 
Figure 3.20. TGF-β mediated increase in mRNA levels of Rpn6 can efficiently be counteracted by 
siRNA knockdown 
mRNA expression of Rpn6 (gene name PSMD11) of donor phLF stimulated with TGF-β for 48h starting 24h 
after Rpn6 knockdown (Mean ± SEM. n=7. One-way ANOVA, Bonferroni‘s Multiple Comparison Test). 
Figure 3.21. Rpn6 knockdown counteracts TGF-β induced formation of 26S/30S proteasomes 
Native gel analysis of CT-L proteasome activity and immunoblotting for Rpt5 and α1-7 (pool of three siRNAs) 
(n=3, representative gel is shown). Native gel was performed by Vanessa Welk (PhD student CPC, 2014). 
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qRT-PCR analysis for mRNA expression of profibrotic genes was performed to investigate 
whether Rpn6 knockdown might counteract profibrotic effects of TGF-β in phLF (Figure 3.22A 
and B). mRNA levels of collagen I and fibronectin were significantly induced by TGF-β. 
Knockdown of Rpn6 could efficiently antagonize overexpression of these myogenic marker 
genes. Indeed, collagen I mRNA levels of TGF-β-treated phLF were almost reduced to baseline 
expression when Rpn6 was silenced. This effect was not as strong for fibronectin but still 
significant compared to scrambled siRNA treated phLF. Counteraction of TGF-β-mediated 
expression of collagen I and fibronectin after Rpn6 knockdown could also be confirmed on 
protein level by Western blot analysis (Figure 3.22 C). Even though reduction here was not 
significant, a decrease in protein expression was reproducible in four different phLF lines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22. Silencing of Rpn6 counteracts TGF-β-induced myofibroblast differentiation in phLF 
mRNA expression of fibrotic marker (A) collagen I and (B) fibronectin in phLF, treated for 48h with TGF-β, 
starting 24h after Rpn6 knockdown (results are pooled from single siRNA and pool of three siRNA 
experiments) (Mean ± SEM. n=7. One-way ANOVA, Bonferroni‘s Multiple Comparison Test). (C) Western blot 
analysis of RIPA lysates for fibronectin, collagen I and Rpn6 in phLF after Rpn6 knockdown and TGF-β 
treatment and densitometric analysis (single siRNA) (Mean ± SEM. n=4. Two-tailed Mann Whitney Test). 
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Using a pool of three Rpn6 siRNAs and two control siRNAs, Rpn6 was significantly reduced on 
protein level up to 25% of basal expression (Figure 3.23). However, in this experiment TGF-β 
treatment did not significantly induce Rpn6 protein expression, even though increased 
proteasome activity was observed for the same experiment as shown before in Figure 3.21. 
This indicates that there might be other factors, besides Rpn6, involved in TGF-β-mediated 
upregulation of 26S/30S formation. However, Rpn6 silencing induced pronounced accumulation 
of polyubiquitinated proteins, thereby showing efficient reduction of 26S/30S formation. 
Furthermore, expression of cyclin D1 was also increased in phLF, which were treated with 
TGF-β and Rpn6 siRNA and confirmed cell cycle arrest as a consequence of reduced levels of 
26S/30S complexes (Figure 3.23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23. Silencing of Rpn6 counteracts TGF-β-induced proliferative effects in phLF 
Protein expression of Rpn6, Cyclin D1, K48-polyubiquitinated proteins and β-actin was assessed by Western 
blot analysis. phLF were treated as described in Figure 3.22 applying a pool of three siRNAs. Densitometric 
data were first normalized to the respective β-actin loading control and then to the scrambled 
siRNA/non-TGF-β control (Mean ± SEM. n=3. One-way ANOVA, Bonferroni’sMultiple Comparison Test). 
- + - +
0
5
10
15
Ubi-K48
TGF-
Scrambled
siRNA
Rpn6
siRNA
***
***
P
ro
te
in
 e
x
p
re
s
s
io
n
(f
o
ld
 o
v
e
r 
s
c
ra
m
b
le
d
 s
iR
N
A
 c
o
n
tr
o
l,
n
o
rm
a
liz
e
d
 t
o

-A
c
tin
)
- + - +
0.0
0.5
1.0
1.5
2.0
Cyclin D1
TGF-
Scrambled
siRNA
Rpn6
siRNA
*
P
ro
te
in
 e
x
p
re
s
s
io
n
(f
o
ld
 o
v
e
r 
s
c
ra
m
b
le
d
 s
iR
N
A
 c
o
n
tr
o
l,
n
o
rm
a
liz
e
d
 t
o

-A
c
tin
)
- + - +
0.0
0.5
1.0
1.5
Rpn6
TGF-
Scrambled
siRNA
Rpn6
siRNA
**
P
ro
te
in
 e
x
p
re
s
s
io
n
(f
o
ld
 o
v
e
r 
s
c
ra
m
b
le
d
 s
iR
N
A
 c
o
n
tr
o
l,
n
o
rm
a
liz
e
d
 t
o

-A
c
tin
)
Cyclin D1 
Ubi-K48 
β-Actin 
Rpn6 
Scrambled 
siRNA 
Rpn6 
siRNA 
- + - + TGF-β 
The Proteasome as a Trigger of IPF 
 
 
 
70 
These results thus identify Rpn6-induced formation of 26S/30S proteasome complexes as an 
essential mediator of myofibroblast differentiation in primary human lung fibroblasts, which can 
be counteracted by depletion of Rpn6.  
Taken together, increased expression of Rpn6 in activated myofibroblasts and pulmonary 
fibrosis along with elevated 26S/30S formation and accumulation of K48-polyubiquitinated 
proteins suggests an increased protein turnover in fibrotic remodeling of the lung. Successful 
counteraction of 26S/30S formation and myofibroblast differentiation by knockdown of Rpn6 
further proposes a novel pathomechanism of lung fibrosis, involving Rpn6-mediated proteasome 
activation upon myofibroblast differentiation. 
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3.2 The Proteasome as a Target in IPF 
This chapter is based on the following manuscript: 
Nora Semren, Nunja C. Habel-Ungewitter, Isis E. Fernandez, Melanie Königshoff, Oliver 
Eickelberg, Tobias Stöger, and Silke Meiners. Validation of the 2nd Generation Proteasome 
Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis. PloS One, 10(9), e0136188. 
 
Application of proteasome inhibitors for the treatment of pulmonary fibrosis has been shown to 
prevent fibrotic lung remodeling in the bleomycin mouse model (Mutlu et al., 2012) but also 
provided high toxicity leading to excessive mortality in fibrotic animals (Fineschi et al., 2008). 
These results are controversial and indicate a narrow therapeutic window for the use of 
proteasome inhibitors in lung fibrosis. Therefore, it was hypothesized that local pulmonary 
application of a novel site-specific proteasome inhibitor, oprozomib, efficiently reduces lung 
fibrosis at low doses and provides less systemic side effects. 
3.2.1 Oprozomib is less toxic compared to bortezomib in alveolar epithelial cells 
Local pulmonary drug application exposes lung epithelial cells to high drug concentrations as 
they constitute the first cellular barrier for the lung towards the environment (Haghi et al., 2014). 
Any local treatment strategy for lung fibrosis should thus provide antifibrotic effects in lung 
fibroblasts while maintaining pulmonary epithelial integrity. Therefore, cytotoxicity and 
proteasome inhibition profile of the novel second generation inhibitor oprozomib was analyzed 
and compared with the FDA-approved proteasome inhibitor bortezomib in the human alveolar 
adenocarcinoma cell line A549, which is also widely used as alveolar epithelial-like cell line, and 
in primary murine alveolar epithelial type II cells. 
Treatment of A549 cells with doses of 10 to 100 nM oprozomib for 72 hours was well 
tolerated, while 250 nM caused pronounced loss of cell viability as assessed by MTT assay 
(Figure 3.24A). In contrast, bortezomib doses of more than 10 nM induced severe cytotoxicity 
as demonstrated by cell death of about 60% (for 50 nM) and 75% (for 100 nM), respectively 
(Figure 3.24B). Reduced toxicity of oprozomib compared to bortezomib correlated well with its 
high selectivity towards the chymotrypsin-like active site of the proteasome: After 24 hours of 
inhibitor treatment, 10 and 50 nM of oprozomib specifically inhibited only the chymotrypsin-like 
active site, while the trypsin-like and caspase-like activities were only marginally affected 
(Figure 3.24D). A non-toxic dose of 10 nM bortezomib also specifically inhibited the 
chymotrypsin-like active site only, while higher doses, in addition, significantly blocked trypsin-
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like and caspase-like activities (Figure 3.24C). Higher specificity for the chymotrypsin-like active 
site of oprozomib compared to bortezomib thus provided reduced toxicity in alveolar epithelial-
like cells. To confirm lower toxicity of oprozomib compared to bortezomib in a more 
physiological setting, pmATII were isolated and treated for 52 hours with different doses of 
these proteasome inhibitors. While 50 nM of oprozomib was well tolerated, 50 nM of bortezomib 
reduced cell survival by up to 35% (Figure 3.24E and F). These findings were well in 
accordance with results obtained from A549 cells. 
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Figure 3.24. Toxicity and inhibitory profile of bortezomib and oprozomib in alveolar epithelial cells 
MTT assay after 72h of treatment with (A) bortezomib (BZ) or (B) oprozomib (OZ) (Mean ± SEM. n=3. One-
way ANOVA, Dunnett‘s Multiple Comparison Test). (C) Proteasome activity 24h after treatment with BZ or (D) 
OZ (Mean ± SEM. n=3. One-way ANOVA, Dunnett‘s Multiple Comparison Test). (E) and (F) MTT assay of 
pmATII cells after 52h of treatment with OZ or BZ (Mean ± SEM. n=4. One-way ANOVA, Dunnett‘s Multiple 
Comparison Test). pmATII cells were isolated by Dr. Kathrin Mutze (Postdoc CPC, 2015). 
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3.2.2 Non-toxic doses of oprozomib specifically inhibit the CT-L active site in pmLF 
To evaluate the inhibitory profile and toxicity of oprozomib in lung fibroblasts, the main effector 
cells of pulmonary fibrosis, primary mouse lung fibroblasts were treated with different 
concentrations of oprozomib for up to 72 hours. These fibroblasts were isolated from mice 
containing the ODD-luc reporter for proteasome inhibition. In the ODD-luc mouse model, an 
oxygen-dependent degradation domain (ODD) is fused to luciferase (luc), which serves as a 
proteasomal degradation signal for the luciferase fusion protein (Goldman et al., 2011; Safran et 
al., 2006). The ODD domain is derived from the hypoxia inducible factor (HIF)-1α and allows for 
proteasomal degradation of the HIF-1α transcription factor under physiological oxygen 
conditions. Under hypoxic conditions, however, ODD is hydroxylated and stabilizes HIF-1α 
thereby activating a protective gene program to counteract hypoxia (Lee et al., 2004). The ODD-
luc reporter thus accumulates at hypoxic conditions but also after inhibition of the proteasome 
and has been established to quantitatively monitor inhibition of the proteasome in cells and mice 
(Figure 3.25) (Kimbrel et al., 2009). 
 
 
 
 
 
 
 
 
 
 
In primary lung fibroblasts of ODD-luc reporter mice, significant and specific reduction of the 
chymotrypsin-like activity of the proteasome was observed already at a concentration of 10 nM 
after 24 hours of treatment with oprozomib whereas trypsin-like and caspase-like activities were 
not affected. Higher doses of 100 nM oprozomib inhibited the chymotrypsin-like activity by 85% 
but only marginally affected the other two active sites (Figure 3.26A). Accumulation of the 
luciferase reporter was observed only at a dose of 100 nM oprozomib as measured by an 
increase in luminescence intensity, due to the luciferase reaction, in the same cell extracts 
Physiological conditions 
PI 
Proteasome inhibition 
Figure 3.25. The ODD-luc reporter for proteasome inhibition 
Under normal conditions, ODD-luc is degraded by the proteasome. After inhibition of the proteasome ODD-luc 
accumulates and the luciferase reaction can be applied to monitor proteasome activity. (Taken from Meiners, 
Ludwig, et al., 2008)~modified 
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(Figure 3.26B). Native gel analysis was applied to directly visualize the dose-dependent 
inhibition of the proteasome and accumulation of luciferase in a single experiment (Figure 
3.26C). Subsequent overlay of the native gel with the chymotrypsin-like specific fluorogenic 
substrate Suc-LLVY-AMC and luciferin showed a dose dependent reduction in proteasome 
activity from 10 to 500 nM oprozomib and a corresponding dose-dependent increase in 
luciferase levels starting at 50 nM oprozomib and clearly visible from 100 nM onwards (Figure 
3.26C). These experiments show that oprozomib-mediated specific inhibition of the proteasomal 
chymotrypsin-like activity by 70-90% results in the accumulation of a proteasomal reporter 
protein. Importantly, a dose of 50 nM oprozomib still was in the non-toxic range. However, 
viability of primary mouse lung fibroblasts was reduced after 72 h treatment with 100 nM 
oprozomib (Figure 3.26D). 
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Figure 3.26. Inhibition profile of oprozomib in primary mouse lung fibroblasts 
(A) Proteasome activity and (B) luciferase activity of ODD-luc pmLF 24h after treatment with OZ (Mean ± 
SEM. n=3. One-way ANOVA, Dunnett‘s Multiple Comparison Test). (C) Native gel of ODD-luc pmLF 24h after 
OZ treatment. (D) MTT assay of ODD-luc pmLF 72h after treatment with OZ (Mean ± SEM. n=3. One-way 
ANOVA, Dunnett‘s Multiple Comparison Test). 
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3.2.3 Oprozomib provides antifibrotic effects in primary lung fibroblasts 
To evaluate whether the observed site-specific and non-toxic inhibition of the proteasome by 
oprozomib also provided antifibrotic effects in lung fibroblasts, pmLF were treated with 50 nM or 
100 nM of oprozomib for 72 hours and expression of the profibrotic marker collagen I was 
determined by immunocytochemistry. Collagen I expression was strongly reduced as shown by 
immunofluorescence staining of the cells (Figure 3.27A). Furthermore, BrdU incorporation and 
therefore proliferation was significantly decreased in oprozomib-treated fibroblasts in 
comparison to DMSO-treated control cells (Figure 3.27B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Several studies identified impaired TGF-β signaling in response to proteasome inhibition as a 
possible mechanism for the antifibrotic effects of proteasome inhibitors (Mutlu et al., 2012; 
Sakairi et al., 2011). Therefore, it was tested whether oprozomib also counteracts profibrotic 
TGF-β signaling. For that, pmLF were pre-treated with TGF-β for 24 hours to induce 
myofibroblast differentiation, then 50 nM of oprozomib was added and cells were incubated for 
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Figure 3.27. Antifibrotic effects of oprozomib in primary mouse lung fibroblasts 
(A) Immunofluorescence staining for Coll-I (green), F-Actin (red) and nuclei (blue) after 72h of treatment with 
OZ. (B) BrdU proliferation assay of primary lung fibroblasts treated with OZ for 72h (Mean ± SEM. n=4. One-
way ANOVA, Dunnett‘s Multiple Comparison Test). 
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another 24 hours for immunofluorescence staining and 72 hours for mRNA expression analysis. 
Oprozomib treatment of mouse lung fibroblasts efficiently inhibited TGF-β-induced collagen I 
expression, both on protein and mRNA level (Figure 3.28A and B). In addition, mRNA 
expression of the myofibroblasts marker αSMA was also significantly reduced in cells incubated 
with oprozomib. Of note, basal αSMA mRNA levels were already reduced by oprozomib in the 
absence of TGF-β stimulation (Figure 3.28C). These data indicate that oprozomib efficiently 
counteracts TGF-β mediated profibrotic responses by transcriptional downregulation of 
myogenic marker genes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.28. Oprozomib impairs TGF-β mediated induction of profibrotic marker 
(A) Immunofluorescence staining for Coll-I (green), F-Actin (red) and nuclei (blue) after treatment with TGF-β 
and OZ. (B) and (C) mRNA expression of Coll-I and αSMA after treatment with TGF-β and OZ (Mean ± SEM. 
n=3. Paired t-Test). 
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Results obtained from these in vitro studies provide strong evidence that oprozomib represents 
a novel, chymotrypsin-like-specific, second generation proteasome inhibitor conferring 
anti-proliferative and antifibrotic effects on lung fibroblasts at low concentrations without major 
cytotoxic effects on fibroblast and alveolar epithelial cells.  
3.2.4 Intratracheal application of oprozomib efficiently inhibits proteasome activity in 
the lung  
To confirm antifibrotic effects of oprozomib in pulmonary fibrosis, an optimal well tolerated but 
still effective dose had to be determined for local pulmonary application. Therefore, increasing 
doses of 0.5 mg, 1 mg or 5 mg oprozomib per kg body weight were instilled intratracheally into 
the lungs of healthy mice. Oprozomib was suspended in 0.1% Pluronic F-127, a well-tolerated, 
FDA-approved, biodegradable copolymer surfactant, which has been shown to be non-toxic in 
epithelial cells (Horie et al., 2013; Kabanov & Alakhov, 2000; Malmsten, 2000). Animals were 
sacrificed 24 or 96 hours after application of oprozomib to analyze the chymotrypsin-like 
proteasome activity of whole lung tissue as a measure of efficient proteasome inhibition and to 
determine cell counts in the BAL as a read-out for acute lung injury (Figure 3.29A). 
24 hours after instillation, no significant reduction in proteasome activity was observed for any of 
the applied oprozomib doses (Figure 3.29B) but the amount of polymorphonuclear leukocytes 
(PMNs) in the BAL increased up to 30% at the highest dose of 5 mg, indicating an acute 
inflammatory response in the airspace of the lungs (Figure 3.29C). Proteasome activity was, 
however, significantly decreased in lungs 96 hours after application of 0.5 mg or 1 mg/kg 
oprozomib (Figure 3.29D). The acute response declined and there was no indication of 
inflammatory PMN accumulation with these doses after 96 hours of instillation as determined by 
BAL cell count (Figure 3.29E). For further experiments, a concentration of 1 mg OZ per kg body 
weight was chosen as an optimal non-harmful dose, thereby providing effective proteasome 
inhibition in the lungs after local application by intratracheal instillation. 
 
The Proteasome as a Target in IPF 
 
 
 
78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.5 Local pulmonary application of oprozomib fails to prevent lung fibrosis 
To investigate the therapeutic potential of locally applied oprozomib on lung fibrosis, oprozomib 
was intratracheally instilled into bleomycin challenged mice. The ODD-luc proteasome reporter 
mouse model was used to monitor the degree of proteasome inhibition by accumulation of the 
ODD-luc reporter in mouse lungs. FVB-ODD-luc mice were first challenged with bleomycin 
(3 U/kg) by intratracheal instillation. Oprozomib was applied 11 and 16 days 
after bleomycin challenge at a dose of 1 mg/kg of body weight and mice were sacrificed at day 
21 (Figure 3.30A). Of note, treatment of bleomycin challenged mice with oprozomib did not 
Figure 3.29. Dose response to local pulmonary application of 0.5, 1 and 5 mg/kg oprozomib 
(A) Treatment scheme: local pulmonary application of OZ, (B) CT-L proteasome activity after 24h, (C) percent 
of PMNs to total BAL count after 24h (D) CT-L proteasome activity after 96h and (E) percent of PMNs to total 
BAL count after 96h (Mean ± SEM. n=5 per group. One-way ANOVA, Dunnett‘s Multiple Comparison Test). 
Animal experiment was performed together with Nunja Habel-Ungewitter (PhD student CPC, 2012). 
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counteract bleomycin induced expression of the fibrotic marker genes collagen I and fibronectin 
(Figure 3.30B and C). In accordance, H&E staining also did not show any therapeutic effects on 
lung fibrosis in response to oprozomib (Figure 3.30D). 
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Figure 3.30. Local pulmonary application of oprozomib does not provide antifibrotic effects in the 
bleomycin mouse model 
(A) Treatment scheme: local pulmonary application of OZ. (B) and (C) mRNA levels of Coll-I and Fn (Mean ± 
SEM. n=6 per group. One-way ANOVA, Bonferroni‘s Multiple Comparison Test). (D) H&E staining of lung slices. 
Animal experiment was performed together with Nunja Habel-Ungewitter (PhD student CPC, 2012). 
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Chymotrypsin-like proteasome activity in whole lung tissue of control mice that had been treated 
with oprozomib was only slightly, but not significantly, decreased. However, inhibition of the 
proteasome was not detected in bleomycin-treated animals, but proteasome activity was rather 
slightly increased in fibrotic lungs (Figure 3.31A). This is well in accordance with previous 
findings showing activation of the proteasome during fibrotic lung remodeling (Chapter 3.1.3). 
The luciferase reporter, supposed to accumulate upon reduction of proteasome activity, did not 
give any indication of reduced proteasomal cleavage rates. Rather, a significant increase in 
luciferase activity was observed in lungs of bleomycin-challenged mice compared to controls 
indicating an unexpected accumulation of the luciferase reporter in fibrotic lungs (Figure 3.31B). 
 
 
 
 
 
 
 
 
 
 
Collectively, these results indicate that the ODD-luc reporter mouse model is not suitable for 
assessment of proteasome inhibition in bleomycin-induced pulmonary fibrosis as the reporter 
accumulated independently of any proteasome inhibition upon fibrotic lung remodeling. In 
addition, the applied oprozomib treatment scheme did not effectively inhibit proteasomal activity 
in the lungs and no protective effects with regard to lung fibrosis were observed. For these 
reasons and in view of the described resistance of FVB mice to develop liver fibrosis 
(Hillebrandt et al., 2002), the mouse strain was changed to C57BL/6 mice in subsequent animal 
experiments and a 14 days bleomycin mouse model was applied which is well established at 
the institute (Aumiller et al., 2013). In addition, the number of local oprozomib instillations was 
increased to obtain more sustained local proteasome inhibition in the lung. In the next set of 
experiments, animals were treated at day 6, 8 and 12 after bleomycin challenge and sacrificed 
at day 14 (Figure 3.32A). While bleomycin or oprozomib treatment alone was well tolerated, the 
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Figure 3.31. Oprozomib fails to inhibit proteasome activity after local pulmonary application in the 
bleomycin mouse model 
(A) CT-L proteasome activity and (B) luciferase activity of whole lung tissue (Mean ± SEM. n=6 per group. 
One-way ANOVA, Bonferroni‘s Multiple Comparison Test). 
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double challenge resulted in severe weight loss of all animals of this group, therefore the 
experiment had to be aborted for ethical reasons at this point (Figure 3.32B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
These data suggest that local application of oprozomib to diseased and fibrotic lungs may even 
be fatal as proper proteasome function might be essential during tissue remodeling. This 
proposes a very narrow therapeutic window for antifibrotic therapy with proteasome inhibitors. 
Figure 3.32. Local application of oprozomib provides high toxicity in fibrotic mouse lungs 
(A) Treatment scheme: repeated local pulmonary application of OZ. (B) Weight loss of animals at different time 
points (Mean ± SEM. n=6 per group. One-way ANOVA Bonferroni‘s Multiple Comparison Test). Animal 
experiment was performed together with Isis Fernandez (Scientist CPC, 2012). 
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3.2.6 Systemic application of oprozomib fails to prevent lung fibrosis 
In a final approach, it was tested whether oprozomib might be better tolerated in the diseased 
lung after systemic application rather than after local delivery. An initial dose-finding experiment 
identified a concentration of 10 mg/kg body weight as an optimal dose of oprozomib that was 
well tolerated after repeated oral application in bleomycin challenged animals (data not shown). 
For oral application, oprozomib was suspended in 1% carboxymethylcellulose (CMC) and 
applied via a gavage needle 7 and 12 days after bleomycin treatment in female C57BL/6 mice. 
Animals were then sacrificed at day 14 (Figure 3.33A). Oprozomib significantly reduced the 
chymotrypsin-like proteasome activity in healthy mouse lungs. This reduction was, however, not 
observed in fibrotic lungs (Figure 3.33B). Oral oprozomib treatment alone did not show any 
toxic effects but co-treatment with bleomycin resulted in significant reduction of body weight 
(Figure 3.33C) similar to previous results after local application. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mRNA expression of collagen I and fibronectin was not altered by therapeutic oprozomib 
treatment compared to the bleomycin control group. Indeed, fibronectin mRNA was even 
increased in oprozomib-treated fibrotic lungs (Figure 3.34A and B). H&E staining was performed 
to compare structural changes of the lung and sections were immunofluorescence stained to 
Figure 3.33. Oral application of oprozomib does not reduce proteasome activity in fibrotic lungs and is 
not well tolerated in bleomycin challenged animals 
(A) Treatment scheme: repeated oral application of OZ. (B) CT-L proteasome activity (Mean ± SEM. n=5-6 
per group. Mann Whitney t-test) and (C) weight loss of animals at different time points (Mean ± SEM. n=5-6 
per group. One-way ANOVA, Bonferroni‘s Multiple Comparison Test). Animal experiment was performed 
together with Nunja Habel-Ungewitter and Isis Fernandez (PhD student and scientist CPC, 2013). 
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assess expression of fibrotic markers collagen I and αSMA (Figure 3.34C). However, no 
antifibrotic effects of oprozomib were observed in bleomycin challenged animals confirming 
mRNA data of this experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Taken together, reduced toxicity of oprozomib in alveolar epithelial cells and promising 
antifibrotic effects in lung fibroblasts could not be confirmed in the bleomycin mouse model for 
pulmonary fibrosis. Indeed, local or oral application of oprozomib rather seemed to accelerate 
damage in fibrotic lungs. This study therefore provides evidence for a crucial role of the 
proteasome during fibrotic lung remodeling and a very narrow therapeutic window for 
proteasome inhibitors in this disease. 
Figure 3.34. Oral application of oprozomib provides no antifibrotic therapeutic effects 
(A) and (B) mRNA levels of Coll-I and Fn (Mean ± SEM. n=5-6 per group. One-way ANOVA, Bonferroni‘s 
Multiple Comparison Test). (C) H&E staining of mouse lung slices and immunofluorescence staining for Coll-I 
(red), αSMA (green), and nuclei (blue). 
- + - +
0
5
10
15
20
OZ:
PBS Bleo
ns
***
Fn
m
R
N
A
 e
x
p
re
s
s
io
n
[2
-

C
t ]
- + - +
0
5
10
15 ns
OZ:
PBS Bleo
***
Coll-I
m
R
N
A
 e
x
p
re
s
s
io
n
[2
-

C
t ]
B) A) 
C) 
H
&
E
 
Im
m
u
n
o
fl
u
o
re
s
c
e
n
c
e
 
PBS/+OZ PBS/-OZ Bleo/-OZ Bleo/+OZ 
PBS/+OZ PBS/-OZ Bleo/-OZ Bleo/+OZ 
200 µm 200 µm 200 µm 200 µm 
Dapi Coll-I αSMA 
 
 
 
 
84 
 
 
 
 
 
 
DISCUSSION 
 
 
 
85 
4 DISCUSSION 
4.1 The Proteasome as a Trigger of IPF 
IPF is a fast progressive and lethal lung disease with very limited treatment options. It is 
characterized by excessive deposition of ECM and destruction of the delicate alveolar 
architecture, leading to severe impairment of respiration and gas exchange, which finally results 
in organ failure and death.  
IPF can also be regarded as a disease of impaired proteostasis as shown for UPR and 
ER-stress in familial and sporadic cases and reduced autophagy (Balch et al., 2014; Meiners et 
al., 2015). Therefore a possible contribution of the ubiquitin-proteasome system, as a key 
regulator of proteostasis (Balch et al., 2014), seems to be obvious. However, no study so far 
comprehensively analyzed a possible role of dysregulated proteasome function during fibrotic 
tissue remodeling and myofibroblast differentiation. 
The present study shows for the first time that proteasome function is indeed regulated during 
fibrotic remodeling and proposes a TGF-β-dependent mechanism. Here, TGF-β upregulated 
proteasome activity and ubiquitin-mediated protein turnover in the process of myofibroblast 
differentiation. Proteasome activation involved increased formation of highly active 26S/30S 
proteasomes via the 19S regulatory subunit Rpn6, which was required for myodifferentiation of 
lung fibroblasts. Moreover, enhanced 26S/30S proteasome activity and upregulation of Rpn6 in 
activated parenchymal lung cells closely followed the course of reversible fibrotic tissue 
remodeling in bleomycin challenged mice. In IPF lungs, Rpn6 levels were increased particularly 
in myofibroblasts and hyperplastic basal cells of fibroblast foci. Accumulation of 
K48-polyubiquitin protein conjugates in these cells and the positive correlation of whole lung 
Rpn6 protein levels with K48-polyubiquitinated proteins suggest activation of 
ubiquitin-dependent protein degradation by the 26S proteasome as a pathologic feature of 
profibrotic remodeling in IPF. This study thus identified a novel pathomechanism involving 
proteasome activation upon TGF-β mediated myofibroblast differentiation and pulmonary 
fibrosis which might represent a common feature for fibrotic tissue remodeling in general. 
4.1.1 TGF-β mediates activation of the 26S proteasome via Rpn6 
In this study, TGF-β-dependent increase in protein degradation was mediated by induced 
formation of 26S/30S proteasome complexes in mouse and human pulmonary fibroblasts. 
26S/30S proteasomes can be regarded as the active form of the proteasome as 20S 
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proteasomes are quite ineffective in protein degradation due to the narrow entry pore formed by 
by the α-ring (Dahlmann, 2005; Y. Saeki & Tanaka, 2012). In vitro measurement of proteasome 
activity for example showed a 3-20 fold higher peptide cleavage of fluorogenic substrates in the 
presence of 26S proteasomes in comparison to 20S proteasomes (Hoffman et al., 1992; 
Rechsteiner, 2008). Furthermore, only proteasome complexes containing 19S particles are able 
to degrade polyubiquitinated proteins and thus to conduct controlled proteolysis. It is not clear if 
the 20S CP itself is actually able to degrade proteins in vivo therefore free 20S pools might be 
necessary to provide fast assembly of active proteasomes to deal with an increased 
requirement of protein degradation in the cell (Savulescu & Glickman, 2011).  
Here, TGF-β induced elevation of the 19S subunit Rpn6 was identified to promote assembly of 
26S/30S proteasomes as Rpn6 knockdown counteracted TGF-β-mediated formation of 26S/30S 
complexes in lung fibroblasts. Of note, no changes in expression levels were observed for Rpt5, 
another 19S subunit, or the 20S subunits α1-7, indicating an exclusive role of Rpn6 as rate 
limiting subunit for 26S/30S formation. De facto, first cryo-EM structures of the 26S proteasome 
revealed that Rpn6 indeed serves as a clamp, which stabilizes the interaction between 19S RPs 
and the 20S CP. Here, Rpn6 interacts with α2 of the 20S α-ring and Rpt6 of the 19S ATPase 
ring (Pathare et al., 2012). In accordance with this structural finding, Rpn6 has also been 
proposed to serve as a rate limiting subunit to promote assembly of 19S regulators with the 20S 
catalytic core in yeast cells: Depletion of Rpn6 impaired assembly of 26S proteasomes and 
suggests an essential role for their integrity and formation (Isono et al., 2005; Santamaria et al., 
2003). These results are also supported by recent studies in ES cells and Caenorhabditis 
elegans (C. elegans). ES cells have been shown to maintain high levels of 26S/30S 
proteasomes together with high degradation rates, which is lost upon differentiation into NPCs 
and neurons (Vilchez, Boyer, et al., 2012). Similarly, long-lived mutants of C. elegans displayed 
elevated levels of active 26S/30S proteasome complexes compared to wild type animals 
leading to increased proteasome activity (Vilchez, Morantte, et al., 2012). In both studies, 
increased formation of 26S/30S complexes was critically and specifically dependent on the 19S 
subunit Rpn6 as shown by overexpression, knockdown and genetic deletion analysis, 
respectively (Vilchez, Boyer, et al., 2012; Vilchez, Morantte, et al., 2012).  
Assuming that a pool of free 20S and 19S particles exists in the cell, upregulation of a single 
subunit such as Rpn6, which then mediates formation of 26S/30S proteasomes, provides a fast, 
flexible and economic mechanism to adapt cellular degradation capacities to intrinsic and 
extrinsic changes, rather than time and energy consuming synthesis of new, whole 
proteasomes. 
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Enhanced formation of 26S/30S complexes along with increased proteasome activity has also 
been observed by Rodriguez et al. in the exceptionally long-lived naked mole rat when 
compared to C57BL/6 mice. This study revealed higher expression levels of the 19S subunits 
Rpn10 and Rpt5 and some subunits of the immunoproteasome (Rodriguez et al., 2012). 
However, these findings were not confirmed by mechanistic data to actually increase 
proteasome activity and may be controversial as animals of two different species were 
compared.  
Furthermore, increased 26S-dependent proteasome activity has been observed in endothelial 
cells which were challenged with high glucose and confirmed in hyperglycaemic mice. This 
increase in 26S activity was found to be mediated by augmented tyrosine nitration of the 19S 
RP (H. Liu et al., 2012). Another study identified ATP levels as regulatory factor for proteasome 
activity within the cell. Here, high proteasomal degradation rates were only observed in a certain 
concentration range of intracellular ATP, whereas higher or lower ATP levels decreased 26S 
activity (Huang et al., 2010). ATP-dependent regulation of proteasome activity is also supported 
by a study from Liu et al, who showed that ATP is required during various steps of 26S 
formation and activation (C.-W. Liu et al., 2006). Furthermore, a recent study unravelled a 
previously unknown link between the induction of mechanistic target of rapamycin complex 1 
(mTORC1) and 26S proteasome activation. Here, induced protein synthesis by mTORC1 
activation in response to growth signals coincided with increased expression of proteasomes, 
transcriptionally regulated by nuclear factor (erythroid-derived 2)-like 1 (Nrf1) (Zhang et al., 
2014). 
Activation of proteasomal protein degradation indeed seems to be a general mechanism to 
maintain protein homeostasis in the cell. Similar to the present findings on TGF-β mediated 
upregulation of proteasome activity, Liu et al. observed induction of genes, which are part of the 
ubiquitin-proteasome system, in response to EGF signaling in C. elegans, leading to increased 
proteasome activity and polyubiquitination in these animals. In this study, fertile adult C. 
elegans, which upregulate EGF, were assayed for proteasome activity and showed 
EGF-dependent augmentation of proteasomal degradation rates as observed by a reduced 
signal of their GFP reporter. This reporter is polyubiquitinated and subsequently degraded by 
the proteasome, resulting in a decreased fluorescence signal at higher degradation rates and 
therefore specifically identifies 26S/30S-mediated protein degradation. However, the underlying 
mechanism for EGF-dependent increase in proteasomal degradation rates was not studied in 
detail by Liu et al., but they proposed enhanced activity of ubiquitin ligases, which might drive 
this process (G. Liu et al., 2011).  
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Various studies, as described here, show adjustment of proteasome activity in response to 
certain stimuli. Regulation of the 19S regulatory subunit Rpn6, however, has either not been 
investigated or not been found to be affected in these studies, suggesting that multiple 
mechanisms can promote upregulation of 26S proteasome activity including post-translational 
modifications, assembly or half-life of proteasomes, or association of 26S proteasomes with 
additional activators such as PA200 or PA28γ (Meiners et al., 2014) 
In lung fibroblasts, the extent of TGF-β-mediated Rpn6 induction was stronger on protein than 
on mRNA level and was only observed on the protein level in mouse and human fibrotic lung 
tissue. Here, upregulation of Rpn6 appears to involve both, transcriptional activation and 
posttranscriptional stabilization of Rpn6. Rpn6 induction was also a quite slow process, as 
pronounced increase was observed in CCL206 lung fibroblasts after 24 to 48 hours. Therefore, 
it might even be possible that accumulation of polyubiquitinated proteins itself could mediate a 
feedback loop leading to higher degradation rates. 
In phLF, Rpn6 was slightly induced on mRNA but not on protein level, however, 26S/30S 
formation was clearly increased by TGF-β and could be counteracted by Rpn6 knockdown, as 
shown by native gel analysis. These findings are indeed controversial, as 26S/30S formation 
here cannot solely be explained by overexpression of Rpn6. Therefore, it can be assumed that 
other mechanisms than Rpn6 induction are involved in TGF-β-mediated activation of the 
proteasome, which might also depend on the particular cell type. 
These findings are in contrast to Rpn6 regulation in ES cells or C. elegans. In both studies, 
Vilchez et al. report transcriptional regulation via the forkhead box O (FOXO) transcription factor 
4 (FOXO4) in ES cells or DAF-16 in C. elegans. However, they also did not find FOXO4 
regulation of Rpn6 in other cells like BJ human foreskin fibroblasts or the human embryonic 
kidney cell line HEK293T (Vilchez, Boyer, et al., 2012; Vilchez, Morantte, et al., 2012). Even 
though transcriptional changes of proteasomal genes are moderate, some transcription factors 
have been identified to regulate expression of proteasome genes. Nrf1 and Nrf2, for example, 
upregulate expression of proteasome subunits in response to oxidative stress (Koch et al., 
2011; Meiners et al., 2014). The molecular pathways regulating TGF-β-induced upregulation of 
Rpn6, however, remain to be elucidated. 
4.1.2 TGF-β-mediated induction of 26S-dependent protein turnover is necessary for 
myofibroblast differentiation 
A tight interaction between the ubiquitin-proteasome system and TGF-β signaling has been 
implicated in several studies. Ubiquitin-dependent degradation of TGF-β receptors, SMADs and 
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their interacting proteins up- or downregulate TGF-β signaling. Hereby, E3 ligases like Smurfs 
or Arkadia promote ubiquitination and proteasomal degradation of mediators, thereby 
influencing signaling within the TGF-β pathway (David et al., 2013; Imamura et al., 2013; Soond 
& Chantry, 2011). However, a possible regulation of the ubiquitin-proteasome system by TGF-β 
signaling has not been studied so far. This study therefore shows for the first time that TGF-β 
activates the ubiquitin-proteasome system during myofibroblast differentiation of lung 
fibroblasts. 
In addition to increased proteasome activity by 26S formation, CCL206 lung fibroblasts also 
showed accumulation of polyubiquitinated proteins in response to TGF-β as an indicator of 
enhanced protein turnover. Levels of polyubiquitinated proteins were also elevated in response 
to Rpn6 knockdown in phLF and confirmed impairment of ubiquitin-mediated protein 
degradation by the 26S proteasome. As shown here, accumulation of K48-polyubiquitinated 
proteins is widely used as an indicator not only for proteasome inhibition but also for increased 
protein turnover and is supported by several publications (D’Arcy et al., 2011; G. Liu et al., 
2011; van Rijt et al., 2012). Therefore additional monitoring of proteasome activity is essential to 
draw conclusions about the initial reason for elevated levels of K48-polyubiquitinated proteins. 
However, accumulation of polyubiquitinated proteins was less pronounced in TGF-β-stimulated 
phLF than in CCL206 fibroblasts, it therefore seems that the extent of such activation of protein 
turnover depends very much on the cell type and in vitro cell culture conditions. 
Indeed, a special need for elevated proteolysis seems to be quite reasonable during 
TGF-β-mediated myofibroblast differentiation, which is induced by binding of TGF-β to its 
receptors, thereby starting a signal transduction within the cell through the SMAD family of 
transcription activators. SMADs then translocate into the nucleus and induce massive 
biogenesis of profibrotic proteins in fibroblasts, finally resulting in their transformation into 
myofibroblasts (Leask & Abraham, 2004). This also leads to a strong cellular need for 
deposition of such pre-existing proteins, which are no longer required. In addition, protein quality 
control also plays an important role during biosynthesis of proteins to ensure their correct 
biological actions (Amm et al., 2014). Misfolded proteins, which fail this control, can be toxic and 
might impair proper cellular functions (Sontag et al., 2014). Therefore, they have to be degraded 
to avoid damage as shown for a variety of neurodegenerative maladies such as Alzheimer’s, 
Huntington’s or Parkinson’s disease (Ciechanover & Kwon, 2015; Dennissen et al., 2012). 
Protein quality control in the cell is mainly conducted by chaperones, which maintain solubility of 
misfolded proteins and facilitate their refolding or degradation (Sontag et al., 2014). Indeed, 
dysregulated management of misfolded proteins has been implicated to contribute to a variety 
The Proteasome as a Trigger of IPF 
 
 
 
90 
of lung related diseases such as cystic fibrosis, chronic obstructive pulmonary disease, and also 
IPF (Balch et al., 2014). Therefore, upregulation of protein degradation during differentiation 
seems to be a reasonable mechanism to rapidly dispose needless or damaged proteins. 
In contrast to that, Vilchez et al. observed decreased proteasome activity upon differentiation of 
ES cells into neuronal cells as shown by cleavage of chymotrypsin-like-specific substrates and 
accumulation of polyubiquitinated proteins as a read-out for reduced proteasome activity 
(Vilchez, Boyer, et al., 2012). Here, increased protein turnover together with high proteasomal 
cleavage rates might be important to assure survival and function of ES cells (Vilchez et al., 
2014). The importance of the ubiquitin-proteasome system for maintenance of proliferation, 
three germ layer differentiation, and cellular reprogramming of self-renewing human ES cells 
has been supported by the identification of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) as a 
novel pluripotency gene, which regulates proteasome maturation via the assembly factor POMP 
(Jang et al., 2014). Similar to this, normal function of hematopoietic stem cells, which generate 
mature blood cells, has been shown to critically depend on protein regulation via the ubiquitin-
proteasome system (Moran-Crusio et al., 2012). The importance of the ubiquitin-proteasome 
system during differentiation has also been described for a variety of cell types besides stem 
cells, including plasma cells (Cenci, 2012) or during spermatogenesis (Bose et al., 2014). Still, 
there is only little known about the regulation of the proteasome to adapt its activity and 
controlled degradation to the need of the cell within different processes.  
In this study, partial knockdown of Rpn6 not only prevented TGF-β-mediated formation of 
26S/30S proteasomes but also counteracted expression of profibrotic marker and impaired 
myofibroblast differentiation of phLF. This indicates that Rpn6-induced formation of 26S/30S 
proteasomes is important for ubiquitin-mediated protein degradation in the process of 
myofibroblast differentiation.  
Very similar to these findings, hypertrophic growth of cardiomyocytes involved activation of 
ubiquitin-mediated protein turnover via the 26S proteasome (Mearini et al., 2008). Collectively, 
these data fit well into the previously proposed concept that signal-induced formation of 26S 
proteasomes represents a novel regulatory mechanism that allows the cell to rapidly adjust 
ubiquitin-mediated protein degradation in order to maintain protein homeostasis during 
differentiation and remodeling (Bhattacharyya et al., 2014; Meiners et al., 2014; Schmidt & 
Finley, 2014).  
While activation of proteasome function in myofibroblast differentiation is a novel observation of 
this study, the overall importance of proteasome activity for this process has been noted before 
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by the use of proteasome inhibitors and has also been confirmed by treatment of pmLF with 
oprozomib in this study. Interestingly, knockdown of Rpn6 provided similar antifibrotic effects as 
treatment of fibroblasts, obtained from different organs, with specific inhibitors of the 20S 
catalytic activities. Here, myofibroblast differentiation was uniformly impaired as indicated by 
reduced expression of matrix metalloproteases, collagens or other profibrotic factors (Koca et 
al., 2012; Meiners et al., 2002; Mutlu et al., 2012). While the use of proteasome inhibitors 
indiscriminately inhibits all 20S containing proteasomal complexes, knockdown of Rpn6 (as 
applied here) impairs the formation of 26S/30S complexes and thus specifically affects ubiquitin-
dependent degradation of proteins. These results therefore indicate that myofibroblast 
differentiation requires enhanced ubiquitin-mediated turnover of proteins by 26S proteasomes 
and that ubiquitin-independent protein degradation by 20S proteasomes, here, is unable to 
complement for this activity. 
4.1.3 The ubiquitin-proteasome system is regulated in pulmonary fibrosis 
Confirming in vitro data, proteasome activity, formation of 26S/30S proteasomes and Rpn6 
expression were also upregulated in fibrotic lung tissue of bleomycin challenged mice. Only few 
studies, so far, show increased proteasome activities in vivo in response to certain stimuli. 
Furthermore, Rpn6 levels and polyubiquitinated proteins were significantly increased in human 
lungs of IPF patients. 
EGF-upregulating C. elegans or hyperglycaemic mice are two examples, which have been 
discussed in chapter 4.1.1 (G. Liu et al., 2011; H. Liu et al., 2012). But no study so far also 
showed normalization of proteasome activity after switchback to physiologic conditions as 
observed at day 56 post-bleomycin challenge, when proteasome activity returned to control 
levels. This finding again highlights the ability of the ubiquitin-proteasome system to rapidly 
adapt its degradation capacity to changing cellular conditions. 
In fibrotic mouse lungs, only Rpn6 was increased, whereas Rpt5 and α1-7 did not change. 
Together with increased 26S/30S formation, this leads to the assumption that Rpn6 indeed 
might also regulate 26S/30S formation in lung fibrosis. However, to finally prove this hypothesis, 
transgenic animals with reduced Rpn6 expression might be necessary. 
Interestingly, in fibrotic mouse lungs Rpn6 levels were highly elevated in proliferating AECII and 
bronchial Clara cells, which are hallmarks of fibrotic remodeling (Korfei et al., 2011). Indeed, 
AECs are discussed to be the primary source of profibrotic mediators to attract resident 
mesenchymal cells to induce their proliferation and differentiation (King et al., 2011). This raises 
the hypothesis that Rpn6-mediated induction of proteasomal degradation might be a common 
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mechanism in activated cells. In contrast to in vitro experiments, myofibroblasts here only 
partially stained positive for Rpn6. However, in human IPF lungs, myofibroblasts are one of the 
predominant cell types and arranged in foci. Myofibroblast foci are not present in bleomycin 
induced lung fibrosis and therefore represent one critical limitation of this model (Moore & 
Hogaboam, 2008). This also explains why Rpn6 in this model is not found to be highly 
expressed in myofibroblasts. Furthermore, expression of several proteasomal subunits of the 
20S CP and 19S RP, including Rpn6, was not changed on mRNA level as obtained by qRT-
PCR, again indicating a non-transcriptional regulation of Rpn6.  
Similarly, Rpn6 was also specifically increased in IPF lungs compared to donor tissue. Here, a 
second 19S subunit, Rpt5, was also significantly elevated while the α3 subunit of the 20S 
proteasome was unaffected. mRNA expression of several 19S and 20S proteasomal subunits, 
including Rpn6, was not significantly altered in IPF tissue, which is well in agreement with 
publicly available array data. Here, no genes coding for proteasomal subunits were regulated 
but changes in mRNA expression of E3 ubiquitin protein ligases were observed, indicating that 
protein turnover indeed is changed in IPF (Bauer et al., 2014). mRNA data of the present study 
propose a posttranscriptional regulation of Rpn6 as also suggested by in vitro and mouse data. 
It can be assumed that Rpn6-mediated increase of 26S/30S proteasome formation adapts 
proteasomal degradation rates to cope with activated protein turnover in fibrotic lung tissue. In 
line with this study, it has recently been shown that 26S proteasome content and activity is 
increased in human IPF lungs compared to donor lungs (Baker et al., 2014). The authors also 
observed an increased 20S content in IPF tissue compared to donor lungs, which was 
determined by a proteasome ELISA that was developed by the same group. In contrast to that, 
here no changes in 20S subunits were observed by direct Western blot analysis. However, in 
this publication, the authors calculate 20S and 26S ratios assuming a specific molecular weight 
for all proteasomes without taking into account the existence of other 20S containing complexes 
such as PA200- and PA28-associated or doubly capped 30S complexes, which are also present 
in human lungs (Korfei et al., 2013). This might influence the results on actual 20S to 26S ratios. 
Levels of polyubiquitinated proteins were significantly increased in IPF patients and positively 
correlated with protein expression of Rpn6. This finding is interesting, as it clearly shows that 
Rpn6 levels increase together with ubiquitinated proteins to cope with a higher demand for 
protein degradation. Increased expression of Rpn6 was also observed in myofibroblasts of 
fibrotic foci in human IPF lungs and, as well, associated with augmented staining for 
polyubiquitinated proteins. These data indicate that increased protein turnover and activation of 
ubiquitin-dependent degradation by the proteasome via Rpn6 induced 26S formation is also a 
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feature of aberrant myofibroblast differentiation in IPF pathogenesis. Of interest, prominent 
staining of Rpn6 and polyubiquitin in hyperplastic bronchiolar basal cells of IPF patients was 
observed. Bronchiolar basal cells have been discussed to serve as progenitor cells for the 
bronchial epithelium with stem cell-like characteristics (Rock et al., 2009), which is in line with 
the findings of Vilchez et al. (Vilchez, Boyer, et al., 2012). It is tempting to speculate that 
overexpression of Rpn6 and activation of proteasomal degradation might be related to aberrant 
stem cell properties or hypertrophic growth of these cells. 
High levels of Rpn6 in myofibroblasts of IPF lungs are in contrast to stainings of fibrotic mouse 
lung sections, which mainly showed overexpression of Rpn6 in hyperplastic alveolar epithelial 
cells and Clara cells. However, the bleomycin model for fibrosis reflects the reversible wound 
healing response to acute lung injury and not the slow and irreversible progression of tissue 
remodeling as seen in IPF. This is also indicated by the absence of some characteristic 
hallmarks of IPF like fibroblast foci in bleomycin induced pulmonary fibrosis (Moeller et al., 
2008; Moore et al., 2013; Mouratis & Aidinis, 2011). But still, a common feature of these mouse 
and human data is that activated parenchymal cells had highly increased levels of Rpn6, 
indicative of elevated 26S/30S proteasome activity, which supports the idea that increased 
protein turnover in highly active cells indeed depends on increased proteasomal degradation 
rates. 
To investigate whether the observed increase in K48-polyubiquitinated proteins in IPF lung 
tissue related to proteasome activation, comprehensive analysis of proteasome activity in lung 
homogenates was performed using activity-based probes (ABPs) and native gel analysis. Of 
note, activity profiles for the different donor and IPF tissues were quite heterogeneous. This 
finding most probably reflects the well-known problem of cellular heterogeneity between healthy 
donor and diseased IPF tissue. In addition, as activity of intact enzymatic complexes that are 
highly sensitive to prolonged transport and storage conditions was analyzed, it cannot fully be 
ruled out that some activity was lost in these tissue samples. In contrast, expression analysis by 
Western blotting was very robust as also seen by the stable expression of the housekeeping 
protein β-actin. Comparing Rpn6 protein levels with amounts of active 26S/30S proteasomes, 
which were obtained from APB labeled proteasomes, a significant positive correlation was only 
observed in IPF samples but not in donor tissue. This indicates that 26S/30S formation indeed 
might be highly regulated during fibrotic remodeling in IPF lungs in contrast to healthy lungs.  
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4.2 The Proteasome as a Target in IPF 
Various reports propose the proteasome as a possible target for antifibrotic therapies based on 
the observation that treatment with proteasome inhibitors provides antifibrotic effects in several 
organs such as lung, skin, liver or heart (Fineschi et al., 2008; Meiners, Dreger, et al., 2008; 
Mutlu et al., 2012; I. Saeki et al., 2013). However, therapeutic application of first generation 
proteasome inhibitors in lung fibrosis showed controversial results in the bleomycin mouse 
model, providing both, high toxicity and beneficial antifibrotic effects (Fineschi et al., 2008; Mutlu 
et al., 2012). Therefore, inhibition profiles and antifibrotic effects of the novel, more specific and 
possibly less toxic second generation proteasome inhibitor oprozomib was comprehensively 
analyzed. Indeed, oprozomib showed higher specificity towards the chymotrypsin-like active site 
of the proteasome and provided less toxicity in alveolar epithelial cells. Furthermore, in vitro 
studies showed antifibrotic effects of low dose oprozomib treatment in pmLF. Oprozomib was 
applied locally into the lungs of bleomycin challenged animals to reduce inhibitor doses and 
systemic side effects. Indeed, as shown before, proteasome inhibitor treatment of fibrotic lungs 
was not tolerated and did not provide antifibrotic effects. Similar results were obtained after oral 
application of oprozomib. This study therefore provides strong evidence that proteasome 
inhibitors of the 20S core particle may be too toxic for application in pulmonary fibrosis. 
4.2.1 Toxicity and inhibition profile of oprozomib 
To compare cytotoxicity and inhibition profile of bortezomib, a well-studied FDA-approved 
proteasome inhibitor, and the second generation proteasome inhibitor oprozomib concerning 
toxicity and inhibition profile, inhibitors were applied to A549 and pmATII cells. In both cell types, 
oprozomib showed less toxicity than bortezomib. The “No Observed Adverse Effect Level” 
(NOAEL) of oprozomib exceeded that of bortezomib by a factor of 10 and oprozomib provided 
high selectivity for the chymotrypsin-like active site, whereas bortezomib inhibited also the 
caspase-like active site. It has been shown before that toxicities of proteasome inhibitors 
strongly depend on their inhibition profile (Meiners, Ludwig, et al., 2008). Inhibition studies with 
selective inhibitors of the chymotrypsin-like active site revealed that maximal toxicity in myeloma 
cells was only achieved by co-inhibition of the chymotrypsin-like activity with one of the other 
two catalytic sites of the proteasome (Britton et al., 2009; Mirabella et al., 2011). These data 
indicate that efficient inhibition of more than one active site is required for inducing cell death 
(Meiners, Ludwig, et al., 2008). Although oprozomib has been shown to cause apoptosis in 
different multiple myeloma and cancer cell lines at doses similar to the ones applied here, 
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unselective co-inhibition of the trypsin-like and caspase-like active sites at toxic doses cannot be 
ruled out in these studies (Chauhan et al., 2010; Roccaro et al., 2010; Zang et al., 2012).  
Inhibition profile and cytotoxicity of oprozomib were very similar in pmLF compared to A549 
cells. These fibroblasts were isolated from FVB-ODD-luc reporter mice, in which the ODD-luc 
reporter is supposed to accumulate upon proteasome inhibition. Therefore, inhibition of the 
proteasome can also be monitored by the increase of luciferase activity. In this study, only 
efficient inhibition of about 90% of the chymotrypsin-like proteasome activity showed an effect 
on the reporter, which was rather weak with an increase of about twofold only. In contrast, 
previous studies reported a pronounced increase of luciferase activity of more than 14 fold after 
proteasome inhibition with bortezomib or MG132, another proteasome inhibitor of the 20S CP, 
in ODD-luc-transfected HCT116 or Hela cells (Chou & Deshaies, 2011; Kimbrel et al., 2009). As 
both MG132 and bortezomib inhibit two active sites of the proteasome, it might be possible that 
proteasomal degradation of ODD-luc is not solely dependent on an active chymotrypsin-like 
activity but also might depend on the trypsin-like and/or caspase-like activities of the 
proteasome. Such active site specific effects on substrate degradation have been shown before 
in vitro (Kisselev et al., 2006). Furthermore, direct transfection of cells with the reporter 
construct might lead to higher expression levels of the reporter than in cells of transgenic 
animals as used here. 
4.2.2 Oprozomib provides antifibrotic effects in lung fibroblasts 
Oprozomib treatment of primary lung fibroblasts showed antifibrotic effects as indicated by dose 
dependent reduction in proliferation and collagen I expression. In addition, oprozomib 
counteracted TGF-β-induced expression of collagen I and αSMA. Similar effects on lung 
fibroblasts have been shown by Mutlu et al. after treatment with a comparable dose of 200 nM 
bortezomib (Mutlu et al., 2012). Further, these results are in line with several studies that used 
fibroblasts of different tissue origins such as skin (Fineschi et al., 2006), heart (Meiners et al., 
2004), or kidney (Sakairi et al., 2011), and observed antifibrotic effects after treatment with 
inhibitors of the 20S CP. Therefore, it can be assume that partial and non-toxic inhibition of the 
20S CP in fibroblasts generally results in reduced proliferation and expression of profibrotic 
markers.  
The underlying mechanisms of these antifibrotic actions are not well understood, but several 
studies highlight the interaction with the TGF-β pathway (Soond & Chantry, 2011; Weiss et al., 
2010). Fineschi et al. report a dose- and time-dependent reduction of collagen I and tissue 
inhibitor of metalloproteinase-1 (TIMP-1) and increase of MMP-1 on mRNA and protein level, 
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which mediates increased collagenolytic activity on collagen I after application of different 
proteasome inhibitors on dermal fibroblasts. These antifibrotic effects of proteasome inhibitors 
were still dominant after profibrotic TGF-β stimulation of fibroblasts. They further observed 
induction of c-Jun phosphorylation and accumulation upon inhibition of the proteasome, which 
acts as part of the transcription factor AP-1, upregulating MMP-1 and therefore decreasing 
collagen I levels, which may here in part explain antifibrotic effects of proteasome inhibitors 
(Fineschi et al., 2006). 
Increased MMP-1 expression by alteration of the binding of c-Jun and SP1 transcription factors 
upon proteasome inhibition has further been observed by Goffin et al. to result in decreased 
synthesis of collagen I in dermal fibroblasts, confirming findings by Fineschi et al. (Goffin et al., 
2010).  
Contradictory to these studies, proteasome inhibition with MG132 in rat cardiac fibroblasts 
effectively counteracted IL-1β-mediated induction of MMP-2 and -9 expressions. This was 
associated with downregulation of collagen Iα1, Iα2 and IIIα1 (Meiners et al., 2004). 
Another mechanism contributing to proteasome inhibitor-mediated antifibrotic effects has been 
investigated by Mutlu at al. in human lung and dermal fibroblasts. Treatment with bortezomib 
after TGF-β stimulation showed significant reduction of αSMA and connective tissue growth 
factor (CTGF) on mRNA and protein level. Here, bortezomib counteracted TGF-β mediated 
target gene expression by inhibition of SMAD activation. The nuclear hormone receptor PPARγ, 
which acts as repressor of SMAD-mediated transcription, was upregulated upon inhibition of the 
proteasome (Mutlu et al., 2012). 
Treatment of renal fibroblasts using the proteasome inhibitors MG132 or lactacystin provided 
inhibition of TGF-β-induced αSMA expression on protein and mRNA level. MG132 did not 
counteract TGF-β-induced upregulation of phosphorylated SMAD2 or nuclear translocation of 
SMAD2/3 but attenuated the activity of the R-SMAD/SMAD4 complex as a transcriptional 
regulator as indicated by a luciferase assay for SMAD response elements. The transcriptional 
repressor SnoN was upregulated by proteasome inhibition, which may be responsible for 
decreased transcriptional activity of the R-SMAD/SMAD4 complex (Sakairi et al., 2011) 
Furthermore, Pujols et al. applied non-toxic doses of the proteasome inhibitor MG262 to nasal 
fibroblasts and observed growth arrest, inhibited DNA replication and retinoblastoma 
phosphorylation, and increased expression of the cell cycle inhibitors p21 and p27. They 
confirmed decrease in basal and TGF-β-induced collagen mRNA expression and IL-1β-induced 
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production of IL-6, IL-8, monocyte chemoattractant protein-1, and granulocyte/macrophage 
colony-stimulating factor in MG262 treated fibroblasts (Pujols et al., 2012). 
Antifibrotic effects of proteasome inhibitors as observed in the present study is not a novel 
finding, but it should be highlighted that all previous studies used multicatalytic-site inhibitors of 
the proteasome, (Fineschi et al., 2006; Koca et al., 2012; Meiners et al., 2004; Mutlu et al., 
2012) whereas oprozomib only inhibits the chymotrypsin-like active site. Therefore, this study 
shows for the first time that inhibition of one active site only is sufficient to provide antifibrotic 
effects in fibroblasts and to counteract TGF-β signaling. 
However, given the pleiotropic effects of proteasome inhibition on cellular signaling molecules 
and transcriptional activators, narrowing the antifibrotic effects of proteasome inhibitors down to 
a single signaling pathway might be oversimplified. Non-toxic inhibition of the proteasome 
further has been shown to induce a protective stress response in cells irrespective of the tissue 
origin, which confers cell cycle arrest, overall attenuation of transcriptional regulation, and 
protection from stress (Bieler et al., 2009; Meiners et al., 2006). To provide a more 
comprehensive view on the cellular changes that mediate the observed antifibrotic effects 
application of high-throughput techniques might be necessary. 
4.2.3 Oprozomib fails to provide antifibrotic effects in vivo 
In this study, oprozomib was initially applied locally into the lungs of mice to reduce systemic 
side effects and to increase local drug absorption. Indeed, oprozomib reduced proteasome 
activity in the lungs of healthy mice after local application in a well-tolerated dose range. 
Pulmonary application of oprozomib in bleomycin-challenged mice, however, was not well 
tolerated, especially when animals were treated three times within 7 days. Moreover, decreased 
pulmonary proteasome activities in response to oprozomib treatment was not observed, 
suggesting that proteasome inhibitors are either not effectively inhibiting the proteasome in 
fibrotic lungs or that a compensatory increase in proteasome activity counteracts this inhibition 
as shown by Rpn6-mediated induction of 26S/30S proteasomes. Any attempt to obtain a more 
efficient inhibition of the proteasome in the lung by repeated oprozomib treatment even 
worsened lung damage. This observation is in line with studies by Fineschi et al., where 
treatment with proteasome inhibitors did not attenuate bleomycin induced lung fibrosis. Instead, 
bleomycin-challenged animals, which were systemically treated every 3-4 days with 0.8 mg 
bortezomib per kg body weight displayed reduced survival (Fineschi et al., 2008). Very similar, 
no therapeutic effects were observed when oprozomib was applied systemically by oral 
application to reduce potential local toxicity of oprozomib after direct instillation into the lungs. 
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Proteasome activity was significantly reduced by oprozomib treatment in lungs of healthy 
animals but not in damaged and fibrotic lungs. Treatment of bleomycin-challenged animals with 
oprozomib rather led to increased weight loss and reduced survival. However, Mutlu et al. could 
prevent lung fibrosis in the bleomycin mouse model by intraperitoneal application of 0.12 mg/kg 
body weight bortezomib twice at day 7 and 14 with sacrificing of the mice at day 21 after 
bleomycin challenge (Mutlu et al., 2012). This is in contrast to the present study and the report 
of Fineschi et al. but highlights the difficulty of a very narrow therapeutic window of proteasome 
inhibitors for the treatment of pulmonary fibrosis. These data accord well with the established 
concept that the degree of proteasome inhibition in a given cell determines the biological 
outcome ranging from beneficial to cytotoxic effects (Fineschi et al., 2008; Meiners, Ludwig, et 
al., 2008). 
It also has to be considered whether the bleomycin mouse model is an appropriate model for 
IPF-related pulmonary fibrosis and therapeutic testing of drugs such as proteasome inhibitors. 
Bleomycin initially causes acute lung injury and inflammation followed by fibrotic tissue 
remodeling in a very short time of about 7 to 9 days after intratracheal instillation. Within the 
fibrotic phase it resembles some of the histological patterns also seen in IPF such as increased 
expression of collagen and fibronectin and fibrotic remodeling. However, fibrotic remodeling in 
the bleomycin mouse model is reversible and therefore does not fully reflect the slow and 
irreversible progression of fibrosis as seen in IPF (Moeller et al., 2008; Moore et al., 2013; 
Mouratis & Aidinis, 2011). Therapeutic intervention with proteasome inhibitors in the beginning 
of the fibrotic remodeling phase might interfere with normal tissue repair and therefore even 
accelerate the damaging effects of bleomycin in this mouse model. Despite these limitations, 
the bleomycin mouse model remains the best characterized and probably most convenient 
model so far to test novel therapeutic compounds for pulmonary fibrosis (Mouratis & Aidinis, 
2011). 
Together with published data (Fineschi et al., 2008; Mutlu et al., 2012), these results thus 
strongly point towards a very narrow therapeutic window of proteasome inhibitors for the 
treatment of pulmonary fibrosis. The therapeutic window might even be narrower for irreversible 
proteasome inhibitors such as oprozomib. Together with the observation that treatment of 
bleomycin-challenged mice with proteasome inhibitors during the fibrotic remodeling phase 
even aggravated lung damage, it is well feasible that functional proteasomes are even required 
for the fibrotic wound healing response in the lung. This is also supported by previous data on 
elevated proteasome activities in fibrotic lungs. Indeed, activation of the proteasome, to a 
certain point, might also be necessary to promote wound healing during fibrotic remodeling. 
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Therefore irreversible inhibition of 20S CPs might even be detrimental to fibrotic lungs. The 
challenge then would be to specifically target activated proteasome complexes in the fibrotic 
lung to the right degree and at the right time point. 
Therefore, inhibition of the formation of 26S proteasome complexes, as shown by Rpn6 
knockdown, could represent a novel therapeutic approach to interfere with pulmonary 
myofibroblast differentiation and fibrosis, being more specific than the use of catalytic 
proteasome inhibitors that inactivate the proteolytic active sites of the 20S. Indeed, some 
compounds have already been identified to target protein-protein interactions within the 20S and 
26S supercomplex (Gaczynska & Osmulski, 2015). The immunosupressor rapamycin, for 
example, has been identified to compete with the 19S RP for binding sites on the α-ring of the 
20S CP, thereby interfering with 26S formation (Osmulski & Gaczynska, 2013). Treatment of 
bleomycin-induced fibrosis with rapamycin, however, did not show any antifibrotic effects but 
rather reduced lung function and increased weight loss in fibrotic animals. This effect cannot 
solely be explained by rapamycin-mediated impairment of 26S formation as the action of this 
drug is mainly based on antagonizing the mTOR kinase (Ballou & Lin, 2008). 
Targeting of Rpn6 therefore might be a promising approach to selectively inhibit 26S formation 
without direct interaction with other cellular pathways and might in future represent a novel 
alternative for conventional proteasome inhibitors of the 20S CP. 
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4.3 Conclusion and Outlook 
This study identified altered proteasome function as a possible novel trigger of IPF. Activation of 
the proteasome was observed in myofibroblasts, in experimental lung fibrosis, and in human 
IPF lungs. This activation was controlled by the 19S subunit Rpn6, which was required for the 
formation of highly active 26S/30S proteasomes. Rpn6 expression was further induced by 
TGF-β, and Rpn6 knockdown in activated myofibroblasts resulted in reduction of 26S/30S 
proteasomes, profibrotic marker proteins, and proliferation. Rpn6 was significantly elevated in 
fibrotic mouse and human lung tissue. Further, Rpn6 was predominantly expressed in human 
myofibroblasts and hyperplastic basal cells. These cells also showed increased levels of 
polyubiquitinated proteins providing evidence for an overall elevated protein turnover by the 
ubiquitin-proteasome system. 
Rpn6-mediated activation of the proteasome by formation of 26S complexes during 
myofibroblast differentiation in IPF thus might provide a novel mechanism within the 
pathogenesis of IPF.  
However, targeting of the proteasomal 20S CP failed to reduce lung fibrosis in this study. 
Although the novel, chymotrypsin-like site-specific inhibitor oprozomib provided antifibrotic 
effects in pmLF at non-toxic doses, local pulmonary or oral application accelerated bleomycin-
induced lung damage. These findings confirm an overall important role of the proteasome in 
fibrotic lung remodeling. Therefore conventional proteasome inhibitors of the 20S active sites, 
which actually affect all proteasome complexes, might be too toxic for application in lung 
fibrosis. 
Together with the finding that prevention of 26S formation and thereby inhibition of ubiquitin-
dependent protein degradation provides antifibrotic effects without affecting 20S activities, this 
study strongly proposes the development of novel proteasome inhibitors that interfere with the 
assembly of the 19S RP to the 20S CP. Hereby, Rpn6 might serve as a novel drug target to 
impair pathologic formation of 26S/30S proteasomes and therefore ubiquitin-dependent protein 
degradation in IPF. 
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6 APPENDIX 
6.1 Abbreviations 
A   
α1-7 Alpha subunits 1-7 of the 20S proteasome 
αSMA Alpha smooth muscle actin 
AECI Alveolar epithelial cell type I 
AECII Alveolar epithelial cell type II 
ALAT Latin America Thoracic Society  
AMC 7-amino-4-methylcoumarin  
ANOVA Analysis of variance 
APS Ammonium peroxodisulfate 
ATCC American Type Culture Collection 
ATF6 Activating transcription factor 6  
ATI Alveolar type I 
ATII Alveolar type II 
ATP Adenosine triphosphate 
ATS 
 
American Thoracic Society 
 
B 
 
BAL Bronchoalveolar lavage 
BSA Bovine serum albumin 
BZ 
 
Bortezomib 
 
C 
 
°C Degrees Celsius 
C. elegans Caenorhabditis elegans 
CDK Cyclin dependent kinase 
cDNA Complementary DNA 
C-L Caspase-like 
CMC Carboxymethylcellulose 
Coll-I Collagen type I, collagen I 
CP Core particle of the proteasome 
CTGF Connective tissue growth factor 
CT-L 
 
Cymotrypsin-like 
 
D 
 
d Day(s) 
Da Dalton 
DAPI 4',6-diamidino-2-phenylindole 
DMEM Dulbecco's Modified Eagle's Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Desoxy-nucleotide-tri-phosphate 
DTT Dithiothreitol 
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DZL 
 
Deutsches Zentrum für Lungenforschung 
 
E 
 
ECM Extracellular matrix 
ED-A Extra domain A  
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
EGTA Ethylene glycol tetraacetic acid 
EMT Epithelial mesenchymal transition 
ER Endoplasmic reticulum 
ERAD Endoplamic reticulum-associated protein degradation  
ERS European Repiratory Society 
ES cell 
 
Embryonic stem cell 
 
F 
 
FBS Fetal bovine serum 
FDA Food and Drug Administration (USA) 
FGF Fibroblast growth factors 
FITC Fluorescein isothiocyanate  
Fn Fibronectin 
FOXO Forkhead box O  
Fw 
 
Forward 
 
G 
 
g Force 
g Gram  
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase  
GFP Green fluorescent Protein 
Gly  
 
Glycin  
 
H 
 
h Hour(s) 
h Human 
HEPES N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid 
HIF Hypoxia-inducible factors 
HRCT High resolution computer tomography 
HRP 
 
Horseradish peroxidase 
 
I 
 
I Inhibitor 
IAP Inhibitors of apoptosis  
IF Immunofluorescence 
IHC Immunohistochemistry 
IL Interleukin 
INF Interferon 
IPF Idiopathic pulmonary fibrosis 
IRE1 Inositol requiring enzyme 1  
I-SMAD Inhibitory SMAD 
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J  
JRS 
 
Japanese Respiratory Society  
 
K 
 
K Kilo 
kg Kilogram 
KRT5 
 
Cytokeratin-5 
 
L 
 
l Liter 
LOXL2 Lysyl oxidase-like 2 
Luc 
 
Luciferase 
 
M 
 
μ Micro 
m Milli 
M Molar 
mA Milliampere 
mg Milligram 
ml Milliliter 
mM Millimolar 
MMF Medetomidin-Midazolam-Fentanyl 
MMP Matrix metalloproteinase 
mRNA Messenger RNA 
MTT 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide  
MUC5B 
 
Mucin 5B 
 
N 
 
NF Nuclear factor  
NG Native gel 
nm Nanometer 
nM Nanomolar 
NPC Neural progenitor cell 
NTP 
 
Nucleoside triphosphate 
 
O 
 
ODD Oxygen-dependent degradation domain  
OZ 
 
Oprozomib 
 
P 
 
PA Proteasome activator 
PAC Proteasome assembling chaperone 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphatate buffered saline 
PCR Polymerase chain reaction 
PDGFR Platelet-derived growth factor receptor 
PERK Protein kinase RNA-like ER kinase  
PFA Paraformaldehyde 
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phLF Primary human lung fibroblast 
pmATI Primary mouse ATI cell 
pmATII Primary mouse ATII cell 
pmLF Primary mouse lung fibroblast 
PMN Polymorphonuclear leukocytes  
POMP Proteasome maturation protein 
PPAR Peroxisome proliferator-activated receptor  
PVDF 
 
Polyvinylidene difluoride 
 
Q 
 
qRT-PCR 
 
Quantitave real-time Polymerase chain reaction 
 
R 
 
rev Reverse 
RIPA Radio-immunoprecipitation assay 
RNA  Ribonucleic acid  
RP Regulatory Particle 
Rpn Regulatory particle non-ATPase  
Rpt Regulatory particle triple A ATPase 
R-SMAD 
 
Receptor-regulated SMAD 
 
S 
 
SBE SMAD-binding element  
sc Scrambled 
SDS  Sodium dodecyl sulphate  
SFTPC Surfactant protein C 
siRNA 
 
Small interfering RNA 
 
T 
 
TEMED  N,N,N’,N’-Tetramethylendiamin  
TERC  Telomerase RNA component  
TERT  Telomerase reverse transcriptase  
TGF  Transforming growth factor  
TIMP  Tissue inhibitor of metalloproteinase  
T-L Trypsin-like 
TNF  Tumor necrosis factor  
TR Telomerase RNA 
TRIS  Tris(hydroxymethyl)-aminomethane  
TTF1 Thyroid transcription factor 1  
TβRI TGF-β transmembrane type I receptor 
TβRII 
 
TGF-β transmembrane type II receptor 
 
U 
 
Ub/Ubi Ubiquitin 
Ubi-K48 Lys48-Ubiquitin  
UIP  Usual interstitial pneumonia  
UMP Ubiquitin-mediated proteolysis 
UPR Unfolded protein response 
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UPS 
 
Ubiquitin-proteasome system 
 
V 
 
V  Volt  
V  Volume  
VEGFR  Vascular endothelial growth factor receptor  
vWF 
 
Von Willebrand factor  
 
W 
 
WB Western blot 
 
 
 
 
 
120 
APPENDIX 
 
 
 
121 
6.2 Publications 
6.2.1 Original articles 
Semren N, Welk V, Korfei M, Keller IE, Fernandez I, Adler H, Günther A, Eickelberg O, Meiners 
S. Regulation of 26S proteasome activity in pulmonary fibrosis. American Journal of Respiratory 
and Critical Care Medicine, 2015 Nov;192(9):1089-1101. 
Semren N, Habel-Ungewitter NC, Fernandez IE, Königshoff M, Eickelberg O, Stöger T, Meiners 
S. Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of 
Pulmonary Fibrosis. PloS One, 10(9), e0136188. 
Lenz A. G., Stoeger T., Cei D., Schmidmeir M., Semren N., Burgstaller G., Lentner B., 
Eickelberg O., Meiners S., Schmid O. Efficient bioactive delivery of aerosolized drugs to human 
pulmonary epithelial cells cultured in air-liquid interface conditions. American Journal of 
Respiratory Cell and Molecular Biology, 2014 Oct;51(4):526-35 
6.2.2 Review 
Meiners S, Keller IE, Semren N, Caniard A. Regulation of the proteasome: evaluating the lung 
proteasome as a new therapeutic target. Antioxidants & Redox Signaling, 2014 Dec 
10;21(17):2364-82. 
6.2.3 Meeting abstracts 
Welk V, Semren N, Korfei M, Guenther, Eickelberg O, Meiners S. Altered Protein Homeostasis 
in Pulmonary Fibrosis Indicates a Role for Proteasome Activator 200. 
Poster presentation, ATS International Conference, Denver, USA (2015). 
Semren N, Habel-Ungewitter NC, Fernandez IE, Eickelberg O, Stöger T, Meiners S. Validation 
of the 2nd generation proteasome inhibitor oprozomib for local therapy of pulmonary fibrosis. 
Poster presentation, DZL Meeting, Hamburg, Germany (2015). 
Semren N, Welk V, Korfei M, Guenther, Eickelberg O, Meiners S. Altered Protein Homeostasis 
in Pulmonary Fibrosis Indicates a Role for Proteasome Activator 200. 
Poster presentation, ERS International Conference, Munich, Germany (2014). 
Semren N, Korfei M, Fernandez IE, Günther A, Eickelberg O, Meiners S. Proteasome function 
in lung fibrosis. 
Oral presentation, ERS International Conference, Munich, Germany (2014). 
Publications 
 
 
 
122 
Meiners S, Pfister N, Korfei M, Fernandez IE, Günther A, Eickelberg O. Altered proteasome 
function in lung fibrosis. 
Poster presentation, ATS International Conference, San Diego, USA (2014). 
Semren N, Korfei M, Fernandez IE, Günther A, Eickelberg O, Meiners S. Altered proteasome 
function in lung fibrosis. 
Poster presentation, DZL Meeting, Heidelberg, Germany (2014). 
Pfister N, Fernandez IE, Eickelberg O, Meiners S. Proteasome function in lung fibrosis. 
Poster presentation, Munich Lung Conference, Munich, Germany (2013). 
Pfister N, Fernandez IE, Eickelberg O, Meiners S. Regulation of the proteasome in lung 
fibrosis. 
Poster presentation, ERS International Conference, Barcelona, Spain (2013). 
Pfister N, Fernandez IE, Eickelberg O, Meiners S. Regulation of the proteasome in lung 
fibrosis. 
Poster presentation, ATS International Conference, Philadelphia, USA (2013). 
Pfister N, Fernandez IE, Eickelberg O, Meiners S. Proteasome function in lung fibrosis. 
Poster presentation, DZL Meeting, Bad Nauheim, Germany (2013). 
Pfister N, Fernandez IE, Eickelberg O, Meiners S. Regulation of protein degradation by the 
proteasome in lung fibrosis. 
Poster presentation, Air Symposium, Fürstenfeldbruck, Germany (2013). 
Pfister N, Habel NC, Stöger T, Eickelberg O, Meiners S. Evaluation of ONX0912, a novel 
proteasome inhibitor, for treatment of lung fibrosis. 
Poster presentation, Febs Meeting, Kusadasi, Turkey (2012). 
Pfister N, Habel NC, Stöger T, Eickelberg O, Meiners S. Investigation of the novel proteasome 
inhibitor ONX0912 for the treatment of lung fibrosis. 
Poster presentation, Munich Lung Conference, Munich, Germany (2012). 
Pfister N, Habel NC, Stöger T, Eickelberg O, Meiners S. Evaluation of ONX0912, a novel 
proteasome inhibitor, for treatment of lung fibrosis. 
Oral presentation, ERS International Conference, Vienna, Austria (2012). 
 
APPENDIX 
 
 
 
123 
Pfister N, Eickelberg O, Meiners S. Evaluation of ONX0912, a novel proteasome inhibitor, for 
treatment of pulmonary fibrosis.  
Oral presentation, “Herbsttagung der Sektion Zellbiologie und der Sektion Infektiologie und 
Tuberkulose“, Homburg, Germany (2011). 
 
 
 
 
124 
 
APPENDIX 
 
 
 
125 
6.3 Acknowledgements 
Coming to the end of these exiting and memorable years as a PhD student, there are many 
people that need to be acknowledged for their support, guidance and inspiration during this 
time. I could not have done it without you! 
I am very grateful to Prof. Dr. Ernst Wagner for the supervision of my thesis at the LMU, for 
helpful discussions within the student seminars, and for the great support in all administrative 
issues. 
Thanks a lot to Prof. Dr. Oliver Eickelberg for giving me the opportunity to do my PhD at the 
CPC and for providing such an inspiring, international and modern research environment. 
I would like to thank my supervisor PD Dr. Silke Meiners for her great scientific guidance 
throughout this time, for allowing me to create my own ideas and projects, and for sharing the 
enthusiasm for my topic. Thanks a lot for the very exciting, formative, and instructive time in 
your lab! 
For sure I could not have enjoyed the time so much without my wonderful lab-members. 
Therefore a great thanks to Vanessa Welk (thank you so much for your support during the 
paper revisions), Christina Lukas (thanks a lot for your great technical support), Ilona Keller, 
Alessandra Mossina, Dr. Sabine van Rijt, Dr. Anne Caniard, Dr. Oliver Vosyka, Korbinian 
Ballweg, Deniz Bölükbas and Dr. Angela Dann for all your scientific input, contributions of 
ideas, kind support and the fun we had in and outside the lab. 
I further would like to thank Nunja Habel-Ungewitter, David Kutschke, Simon Orth, Isis 
Fernandez, Daniela Dietel and Constanze Heise for the great help with long-day animal 
experiments. Thanks to Dr. Tobias Stöger for helpful advice in animal issues and your scientific 
input on the oprozomib paper. 
I am also very grateful to Dr. Martina Korfei for the great collaboration, extensive email support 
and your invaluable input on the Rpn6 paper. 
As a “non-biologist” I have benefitted a lot from the research school “Lung Biology and 
Disease”, and therefore I would like to thank Dr. Dr. Melanie Königshoff for equipping me with 
useful knowledge about methods and lung biology. I also thank Camille Beunèche and 
Dr. Doreen Franke for their administrative help.  
One highlight during my time at the CPC was the great companion of my PhD fellows. Therefore 
I especially would like to thank Dr. Bettina Oehrle, Dr. Andrea Schamberger, 
Acknowledgements 
 
 
 
126 
Nunja Habel-Ungewitter, Dr. Franziska Uhl, Dr. Barbara Berschneider and Juliane 
Bartmann for making my time at the CPC so memorable for me. 
Special thanks to Alessandra Mossina, Ilona Keller, Dr. Sabine van Rijt and Dr. Anne 
Caniard for the great time we shared together, for many fits of laughter, for your help on all 
aspects of life and your friendship. 
I dearly thank my parents and parents in law for their boundless help and support to rapidly 
continue my thesis after maternal leave, for listening to my worries and for encouraging me.  
My deepest thanks to my husband Daniel for your incredible patience and for being the best 
support one could wish for. Thank you Ella for always cheering me up and for reminding me 
what really counts. 
